Developing an integrated MDT service model for the management of patients with lung cancer by Sridhar, Balasubramanian
Sridhar, Balasubramanian (2013). Developing an integrated MDT service model for the management 
of patients with lung cancer. (Unpublished Doctoral thesis, City University London)
City Research Online
Original citation: Sridhar, Balasubramanian (2013). Developing an integrated MDT service model 
for the management of patients with lung cancer. (Unpublished Doctoral thesis, City University 
London)
Permanent City Research Online URL: http://openaccess.city.ac.uk/3014/
 
Copyright & reuse
City  University  London has developed City  Research Online  so that  its  users  may access the 
research outputs of City University London's staff. Copyright © and Moral Rights for this paper are 
retained by the individual author(s) and/ or other copyright holders.  All material in City Research 
Online is checked for eligibility for copyright before being made available in the live archive. URLs 
from City Research Online may be freely distributed and linked to from other web pages. 
Versions of research
The version in City Research Online may differ from the final published version. Users are advised to 
check the Permanent City Research Online URL above for the status of the paper.
Enquiries
If you have any enquiries about any aspect of City Research Online, or if you wish to make contact  
with the author(s) of this paper, please email the team at publications@city.ac.uk.
 i 
 
 
 
 
 
Developing an Integrated MDT Service 
Model for the Management of Patients with 
Lung Cancer 
A thesis submitted to City University for the Degree of Doctor of Philosophy,  
in the Centre for Health Informatics, of the School of Informatics 
September 2012 
Balasubramanian Neelakantan Sridhar 
 
 
 
  
PhD Thesis         Bala Sridhar 
 
      Page ii 
 
 
 
 
 
 
 
 
 
 
 
 
Bertrand Russell wrote in the  
Philosophy of Logical Atomism 
 
 
 
“The point of philosophy is to start something so 
simple as not to seem worth starting and to end with 
something so paradoxical that no one will believe it” 
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ABSTRACT 
The motivation for this research was the publication in 1995 of the Calman-Hine report. 
This provided a strategic framework for the delivery of cancer care by creating a 
network of cancer care centres in England and Wales to enable patients to receive a 
uniformly high standard of care. The report acknowledged the fact that although the 
evidence on optimal cancer care used to prepare the report was based on two key 
sources (i) medical literature and (ii) audit data provided by UK cancer registries, they 
did not lend themselves to controlled experiments as most information came from 
retrospective analyses; hence they were subject to a number of possible flaws and 
biases. 
 
Yet the report recommended some key structural changes to be implemented. The 
focus of the research described in this thesis was centred on the recommendation of a 
multidisciplinary team (MDT) review of patients prior to a treatment decision, both in 
general cancer units as well as in specialised cancer centres. Given the mandate to 
implement these recommendations, the research questions addressed were “can the 
current configuration support this recommendation?”, “what evidence was there to 
support the effectiveness of the MDT?” and “was there a model of care to support the 
service delivery of cancer care?” A literature review established that there was no 
existing template upon which MDT services could be set up. This research therefore 
set out to develop an MDT model to support operational delivery of care in the setting 
of a cancer centre. The clinical specialty in which this research was undertaken was 
that of lung cancer. 
 
The research successfully developed a conceptual model. However, in the process, a 
number of operational and practical constraints were identified within the revised 
service configuration designed to deliver high quality cancer care through the 
incorporation of the MDT service, and this ultimately limited the extent to which the 
model could be deployed in the particular clinical setting. Nevertheless, the modelling 
process did enable a range of core issues to be identified, enabling design solutions to 
be formulated and tested, thereby confirming the effectiveness of the MDT model. In 
particular, the adoption of a soft modelling approach was shown to be beneficial in 
addressing operational problems. By engaging clinical and other end-users right from 
the start in the modelling process, the models did become operationally accepted, 
allowing resistance to change to be overcome and the solution to be integrated into the 
business process. 
 
MDT services are now well established, both in cancer units and cancer centres and 
published data on their effectiveness in the treatment of lung cancer, although not 
conclusive; demonstrate an increase in resection rates. However, assessing the long-
term impact of MDTs on lung cancer outcomes remains a topic for future research.  
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1 INTRODUCTION AND PURPOSE 
1.1 Background and Motivation 
The World Health Organisation has forecast that cancer will be the major global health 
problem within the next two decade. The expectation is that by the year 2020 the 
number of cancer cases will have soared from its current 10 million a year to 20 million. 
In Britain, it is predicted that one in two people will develop the disease, compared with 
the one in three today1. Substantial changes introduced in UK, Australia and other 
European countries were triggered following the introduction of the 1971 National 
Cancer Act in the USA that led to the creation of the National Cancer Institute (NCI) 
and Cancer Centres Programme.  
 
In the UK there have been over a dozen reports on cancer services since 1970; most 
central DoH guidance dating from that decade. A number of regional reviews were also 
undertaken and published in the late 1980s. In the early 1990s more comprehensive 
reviews were instigated following the publication of population based systematic 
comparisons of survival between European countries, which reported that outcomes 
were worse in the UK for most types of cancer than in other countries2. The reviews 
were undertaken by the ten Regional Health Authorities. Almost all of these reports 
identified the broad principles of cancer services that were acknowledged by the 
Steering Group that was appointed to review specialist services in London.  
 
The Report of the Cancer Services Review submitted to the London Implementation 
Groups by an Independent Steering Group reinforced most of the recommendations, 
such as equitable access to cancer services for the local population, improving the 
accuracy  of registration data, ensuring continuous education for GPs and nurses on 
the diagnosis of cancer, the setting of minimum standards of care, standards for 
content and speed of communication between hospitals, GPs and community nursing 
teams, review of palliative care, and the establishment of Specialist Cancer Centres to 
coordinate local services.   
In April 1995 the Report by the Expert Advisory Group on Cancer to The Chief Medical 
Officers of England and Wales Dr. Kenneth Calman and Dr. Deirdre Hine titled, A 
Policy Framework for Commissioning Cancer Services3 was published. The 
Calman-Hine Report, as it was called, after the two chief medical officers who led its 
development, proposed a network of Specialised Cancer Centres and a network of 
Cancer Units [the latter not at every District General Hospital (DGH)] to be designated 
by 1997. In March 1996 further guidance was issued on the implementation of the 
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Calman-Hine Report recommendations in the Executive Letter EL(96)15. This was the 
first national policy for the delivery of cancer services in the UK. 
 
The Calman-Hine Report outlined general criteria for high-quality Cancer Centres and 
Cancer Units within a ‘hub and spoke’ model of cancer care. These criteria cover all 
aspects of cancer care concerning organisational, staffing, clinical and audit 
arrangements focusing on the key message that better quality cancer care is delivered 
by multi-disciplinary teams via specialisation, concentration of expertise/skills and 
integration of the contributions of the key cancer disciplines. 
 
The report whilst highlighting the achievements in cancer care provision (England & 
Wales), recommended the following salient points: 
 a new structure for cancer services, 
 equity of access and outcomes, 
 equity, efficiency, accessibility, effectiveness and appropriateness to achieve a 
uniformly high quality of cancer service provision. 
 
The Advisory Group proposed a new structure that involved three levels of care:  
1. Primary Care Teams. 
2. Designated Cancer Units. 
3. Designated Cancer Centres. 
 
The report attached great importance to the integration of 
i) The three levels of care with each other and with non-cancer related services thus 
providing a comprehensive cancer service, 
ii) Work at cancer centres and units.   
 
The Calman-Hine Report offered a clear framework for the delivery of good cancer 
care, addressing longstanding problems of optimal service configuration, delineating 
the respective clinical roles of the local units and specialised centres whist defining the 
necessary scale of activity for the delivery of patient-centred care in an effective and 
efficient manner. 
 
Although the report recommended the concept of cross boundary working via networks 
across primary, secondary, tertiary and community services, it offered no partial advice 
on organisational structure, hence it was left to the local services to define the state of 
the cancer services provided prior to the implementation of the recommendations and 
service configuration. 
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In response to the Calman-Hine Report, Enfield and Haringey Heath Authority set up a 
multi-agency team to review local cancer service provision in Enfield and Haringey. 
This review highlighted many key issues pertinent to cancer service delivery, quality of 
cancer care and access to information along the cancer journey for both the patient 
and the multidisciplinary teams. 
 
The local service review helped to develop an epidemiological profile of cancer, define 
existing service provision, review guidance and literature, define optimal Calman 
cancer services, match existing to optimal service provision and agree 
recommendations for implementing changes. 
 
As this review cut across the boundaries of primary, secondary, tertiary and community 
care sectors, it highlighted the key issues inherent in each sector and also those that 
crossed boundaries. It conducted Focus Group and one to one interviews with health 
care professionals, using the questionnaire attached in Appendix A; to seek their views 
on local cancer service provision. Patients were interviewed to seek their attitudes to 
local cancer service provision. Cancer patients who participated in the interview 
included those with breast, bowel, bladder, lung and pancreatic cancers.  
 
Patients and health care professions (GPs, hospital consultants, nursing staff, staff 
from professions allied to medicine i.e. physiotherapist, psychological medicine, etc.) all 
identified a range of issues such as: 
 Time it took for the GPs to refer to specialist, see Fig B.7 (Appendix B). 
 Patients not taking their symptoms seriously. Fig 1.1 
 Communication of diagnosis by the GPs. 
 Referral time Fig B.7 (Appendix B). 
 Waiting time to obtain a hospital appointment. 
 Waiting to be seen by a specialist. 
 The number of visits to the hospital for tests to confirm diagnosis, then for 
treatment and subsequent tests (see Fig B.10 Appendix B). 
 Not understanding all the information provided by the oncologist, nursing staff 
and other health care professionals (see Fig B.11 Appendix B). 
 Communication between primary and secondary care professional staff. 
 Communication between secondary and tertiary care. 
 Communication between hospitals and hospices. 
 Quality of terminal care not being highly regarded. 
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Fig 1.1 Time taken for patients’ with symptoms seeking medical help. 
These issues themes were identified following the analysis of the questionnaire. 
Appendix B presents the summary the key findings and a detailed survey report. 
Coming face to face with these issues and the state of local cancer services provide 
the motivation to undertake a closer study of the vision of the Calman–Hine Report, of 
patient-centred care, delivered by coordinated services, which have genuine 
partnerships with each other. There is the integration of other providers to offer 
support, to meet psychological and non-clinical needs. There is access to palliative 
care when required, from diagnosis onwards, and not just in the terminal stage. 
Effective communications and networks are the keys to making this vision a reality.  
 
Motivation was also provided by an awareness of the strategy being developed for the 
local health services to achieve the Calman-Hine Report recommendations, at the 
same time becoming increasingly aware of the conflicts, effort and resources called on 
from the local health economy to effect these changes. The short and medium impact 
of the changes to be introduced on services during the period of transition was also 
intriguing. The local epidemiology review revealed that the local incidence of lung 
cancer was exceptionally high. The 1992 Thames Cancer Registry data revealed that 
there were 287 registrations of lung cancer for the residents of Enfield and Haringey 
Health Authority: 183 for men, an age standardised rate of 55.4 per 100,000 and 104 
for women, an age standardised rate of 42.9 per 100,000. In 1993 there were 217 
deaths from lung cancer, 150 men and 67 women. This was attributed to a combination 
of socio-economic factors, life-style, poor housing etc. 
How soon did patients' consult their GP? 
n= 83
3
4
8
9
14
17
10
7
11
0 2 4 6 8 10 12 14 16 18
0 - 5 days
6-15 days
16- 30 days
31 - 45 days
46 - 60 days
61-75 days
76- 90 days
91 - 105 days
>105 days
No of Patients
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The key challenge faced by the service has been improving the cancer survival rate, 
this always being one of the important outcome indicators. The report also identified 
quality of life as the other important outcome measure. Lung cancer is the commonest 
cancer in the UK causing 1 in 4 deaths and 6% of all deaths (32,000 deaths/ year, 
8.4% of male deaths and 3.7% of female deaths). It is the most common cause of 
cancer in men and the second most common cause in women after breast cancer4. It is 
responsible for considerable morbidity and has a poor prognosis5. Internationally, lung 
cancer is the commonest cancer in the developed world, responsible for an estimated 
896,000 new cases (incidence) in 1985 or 1 in 8 new cases, the vast majority of which 
are fatal. In the United States, each year about 178,000 people are diagnosed with 
lung cancer and about 160,000 die of the disease, making it the leading cause of 
cancer related mortality6. There are about 1.3 million new cancer cases and about 
840,000 deaths from cancer annually in the European Union7.  
 
In 2010 there were 268,758 newly diagnosed cases of malignant cancer registered in 
England. Of this total, 136,372 cancers were in males and 132,386 in females, 
representing an increase of 1.3 per cent (1,736 cases) in males and 1.8 per cent 
(2,343) in females, compared with 2009.The age-standardised incidence rate of all 
cancers is 423 males and 370 females per 100,000 population, compared with 424 
males and 367 females per 100,000 population in 2009. The four most common sites 
for new cancer registrations are breast, prostate, lung and colorectal, accounting for 
around 53 per cent of the 268,758 new cases of malignant cancer. The three most 
common cancers for men are prostate, lung and colorectal. There were 33,779 new 
lung cancer cases registered in 20108 in England. Lung cancer accounts for around 14 
per cent of all cancers in males and 11 per cent of all cancers in females. The age-
standardised rate of lung cancer in males and females is 56 and 38 respectively per 
100,000 population. In the UK, around 91 per cent of lung cancer in men and more 
than 86 per cent in women are linked to lifestyle and environmental factors9.  Table 1.1 
below provides a summary of the number of new cases registered in England in 2010, 
broken down by gender.  
 Males Females Total 
Description number % number % number % 
Lung 18738 14 15041 11 33,779 13 
Colorectal 18590 14 14628 11 33,218 12 
Prostrate 34892 26 NA NA 34,892 13 
Breast NA NA 41259 31 41,259 15. 
All other sites 64152 47 61458 46 125,610 47 
Total 136,372 100% 132,386 100% 268,758 100% 
Table 1.1 All new cancer registration, England, 2010. 
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The five-year survival in non-small cell carcinoma is as follows:  
 Stage 1 (Early operable lung cancer) survival approximately 60% 
 Stage 2 (Operable lung cancer) survived approximately 45% 
 Stage 3  (Border line operable lung cancer) survived approximately 15% 
 Stage 4  ( Inoperable lung cancer ) survived <2% 
1.2 Research Hypothesis 
The primary research question of this study was “Can the current service configuration 
support the recommendation of the Calman-Hine Report and subsequent documents 
such as NHS Cancer Plan, Cancer Strategies, policies and other reports published 
recommending that all patients must be reviewed by a multidisciplinary team (MDT) 
prior to treatment decision?”  
The research hypothesis was to question the practicality of this recommendation within 
current service configuration and if by reviewing patients at the MDT meeting prior to 
treatment decision will this: 
1. Have an impact on recorded outcomes of treatment of lung cancer. 
2. Improve survival rate facilitated by early detection, early referral, early 
diagnosis and early treatment. 
3. Improve access to cancer services, 
4. Facilitate effective multi-professional communication, and 
5. Improve quality of care provided. 
1.3 Aim  
The aim of the study was to test the hypothesis by developing and evaluating an 
integrated multidisciplinary service delivery model for lung cancer.  
1.4 Objectives and Methodology 
The key objectives were as follows: 
 Critically review published evidence for an existing or in-development 
integrated multidisciplinary service delivery model for lung cancer. 
Methodology: Carried out extensive literature review and review of national 
research register to investigate if similar work had been or being undertaken 
within the cancer care service development sector. 
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 To critically review published evidence to see if there are similar models 
developed within other health disciplines or other sectors/ industries.  
Methodology: Carried out extensive and thorough literature review and 
review of national research register to investigate if similar work had been or 
being undertaken within other health care (clinical disciplines) and/or other 
industries. 
 To undertake thorough review of published models and their application.  
Methodology: Carried out detailed review of published models to investigate 
availability of similar or near similar (conceptual or established) models 
supporting multidisciplinary team within cancer care service /health care 
(other clinical disciplines) / biomedical / pharmaceutical and/or other 
industries. 
 To review current service configuration and identify the key issues, the 
bottlenecks along the cancer journey. 
Methodology: Performed one to one interviews and focus group studies 
across the local health economy and cross referenced this with other 
national service review reports and publications.  
 To review supportive evidence by performing data collection and analysis. 
Methodology: Undertook multiple audits, surveys, review of existing 
databases, hospital medical case notes to understand and establish the 
quantitative and qualitative evidence of current service baselines. 
 Understand the data collection process and requirements to support MDT 
meetings. 
Methodology: Employed Soft System Methodology to deconstruct the 
patient journey and performed detailed local end to end of cancer patient 
journey across the local health economy and cross referenced this with other 
national work programmes to understand requirements, current issues and 
bottlenecks and barriers.  
 To develop a MDT model that will enable the service to review patients 
efficiently and is integrated into the service model.   
Methodology: Used Soft System Methodology (SSM) to frame the root 
definition prior to developing the conceptual model.  
 To develop a pathway to facilitate rapid, safe, efficient, effective referral 
communication and data capture system. 
Methodology: Using Lean methodology (value stream mapping) and SSM 
methodology mapped the various interconnected pathways and identified 
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number of multiple, repetitive steps and processes.  These then were 
reflected in the revised conceptual model. 
 To validate the MDT model, by undertaking model based experiments.  
Methodology: the conceptual model was presented to various teams and on 
gaining approval performed number of proof of concept studies to evaluate 
the robustness, performance whilst identifying new issues and risks of the 
model  
 To integrate the MDT model into operational workflow. 
Methodology: Following model validation and approval of the proof of 
concept. the model as to be deploys across the local health economy, but for 
a number of operational issues, legislative barriers the deployment was 
restricted to a single Trust. 
1.5 Organisation of the Thesis 
The thesis covers three areas of study, namely the background to the problem, a 
review of the literature and the presentation of the author’s efforts. 
Chapter one has established the background and motivation for this study, providing a 
fairly comprehensive overview of the local situation and evolution of this research. This 
chapter has aimed to clarify the context and provide a rationale for proceeding with this 
research. With the background and reasons for the study covered, the chapter then 
went on to state the research hypothesis, aim and objectives. 
Chapter two provides an overview on the aetiology and nature of the disease itself, 
providing an insight into the epidemiology, aetiology, clinical presentations and 
symptoms, diagnostic process, staging and diagnosis, treatment and supportive care. 
Chapter three provides a review of the existing body of knowledge, where the author’s 
quest was to discover whether similar problems had been solved in other disciplines/ 
specialties of healthcare or in the commercial and industrial sectors. 
Chapter four details the work involved in understanding the current operational 
process that helped in defining current service provision, provides an overview and the 
motivations for selecting the modelling methodology adopted to understand the 
problem situation.  A series of workflows were undertaken, charting both the patient’s 
journey and data flow along the care pathway. This work also enabled identification to 
be made of the various issues, bottlenecks, process issues, and constraints, external 
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and internal pressure points that acted on the system. This work helped the various 
departments involved to reflect on the process that was in place, often asking, “Why do 
we do what we do?” - thus enabling an opportunity to review possible solution and 
overhaul inefficient processes.  
Chapter five provides a comprehensive overview of the methodology used to extract, 
collect, and analyse the data, obtained during various stages of the research in a 
number of organisations. Data that helped to define the base line, service performance 
prior to the introduction of Multi-disciplinary Teams (MDT) and service data following 
the introduction of MDTs are presented. This chapter also details the gaps in the data 
that are not routinely available to the service. Also considered are the limitations posed 
by the missing data and what is being done to address these issues. The year on year 
data provided the basis for charting out both the current state and the future state of 
service development. 
Chapter six provides an overview of the proposed model and the practical limitations 
of model validation. The core concept for the model was based on the directives issued 
by the DoH, following a comprehensive service review of cancer services in England 
and Wales. However, developing and implementing the model was left to local 
healthcare professionals. This provided the opportunity to test the various principles of 
service modelling that could be integrated into service delivery to reform and refine, the 
existing service delivery, helping to address the bottlenecks and constraints that had 
been identified. 
Chapter seven explains the difference between model validation and verification 
highlighting how the model was validated including the implementation pilot studies 
conducted to test the model and service delivery concepts, conceived as part of this 
research, whilst integrating some of the national directives to meet the timescale and 
targets set by the DoH. This chapter also explains the pace of change of cancer 
service management, resulting in some aspects of the model being implemented 
earlier than planned, whilst others had to be modified to accommodate the changes 
dictated by various directives. Details as to how some aspects of the model could not 
be implemented as planned are discussed. This situation arose as a result of other 
teams working on national schemes arriving at similar solutions that took precedence 
as these solutions had undergone formal pilot approval and were deemed successful, 
hence being implemented as good practice by all other service providers.  
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Chapter eight details how various aspects of the model were integrated into 
operational processes using technology as an enabler to help address the current 
bottlenecks, to improve communication and to enhance the quality of data captured at 
source. This chapter also discusses the ability of the system to adapt and evolve, 
providing opportunities for review and modification, thereby enabling benefits to be 
reaped in terms of improved service outcomes. 
Chapter nine provides a review and discussion of the main findings of the study and 
provides insights into the author’s perspective on the various aspects of the service 
including contributions to knowledge made. 
Chapter ten concludes the work undertaken, the outcomes of this study, 
demonstrating the extent to which objectives had been met, and summarises the key 
contributions to knowledge made. It also makes suggestions regarding future research 
that could be undertaken to support service development. Anniversary    
1.6 Definitions 
The term lung cancer includes all malignancies arising in the epithelium of the airways 
below the larynx as shown in Fig 1.2 and excludes mesothelioma (i.e.bronchogenic 
carcinoma). 
 
Fig 1.2  Profile of Lung cancer sites (CancerHelp UK)10 
The hospital specialties mainly involved in the treatment of cancer of the lung include: 
general and chest medicine, geriatric medicine, oncology, radiotherapy, thoracic 
surgery and palliative medicine (including pain clinics). 
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Improving Outcomes Guidance series 11,12 states the significance and the value of  the 
Multi-Disciplinary Team (MDT) approach13,14,15,16 which now is a dimension of 
contemporary medicine and is becoming more and more important in everyday clinical 
practice, particularly in cancer care. It is at the centre of the new methods of 
management of cancer patients and is fundamental to delivering effective care due to 
the increasing number of tumours requiring multimodal approaches. The multi-
disciplinary approach to clinical management aims to: 
 deliver clinical care in a seamless and efficient manner 
 patients can receive consistent information about the available 
treatment options and their consequences 
 treatment planning design is a collaborative effort   
 bring patients into contact with the relevant specialist with specific expertise 
available when and where it is required 
Multi-Disciplinary Teams (MDTs) are teams made up of various healthcare 
professionals who work together to discuss individual cases and decide on how best to 
manage and streamline the principal procedures for treatment and care. The team 
includes lung physicians, thoracic surgeons, medical and clinical oncologists, 
supported by dedicated radiologists, pathologists, and specialist nurses, 
physiotherapists, occupational therapists, psychologists, dieticians and any other 
healthcare professionals or specialists who are involved in the care pathway.  
1.7 Delimitations of scope and key assumptions 
Major shifts in service configuration and patterns of service delivery are usually 
complicated, often facing professional and organisational resistance whist placing a 
huge demand on the local economies for various resources. 
 Changes recommended by the Calman-Hine Report need to be backed with adequate 
and appropriate funding, but these are not clearly defined and will be considered as 
external factors. Major resources are in short supply, though identified as being 
necessary for developing specialist cancer services. This research will highlight these 
issues, but as these are external factors, they are deemed out of scope of this study. 
Only part of the model will be deployed in the clinical base chosen for this research; 
aspects of the model that straddle organisational boundaries are out of scope. 
Scalability testing of the model was not achieved owing to the dependencies, resource, 
organisation structure, and/or local service configuration.  
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2 EPIDEMIOLOGY, DISEASE PROCESS AND THE CLINICAL SETTING 
2.1 Introduction 
This chapter details the work undertaken to primarily understand the International, 
National and Regional epidemiology of cancer as a disease group before focusing on 
lung cancer. This was followed by studying the epidemiology of the local population 
where this research was conducted. This involved defining the local disease pattern 
and frequency of the disease; and defining the number of individual cancers, to help 
determine the nature of the services required for the catchment population. Cancer is 
not one disease by many. Hence it was very important to review the epidemiology of 
the disease collectively for all cancers to help establish the depth and spread of the 
problem before the focus was shifted lung cancer. This was an essential pre-requisite 
prior to the implementation of the Calman-Hine recommendations. The local health 
service providers wanted answers to significant questions that would help define the 
level of investment required to build the local cancer services along the Calman-Hine 
framework. 
2.2 Cancer Epidemiology and definitions 
Cancer is a major public health concern. It is estimated that one in three people will 
develop cancer at some point in their lifetime. Around one quarter of the population will 
die from this disease. To understand the global burden of cancer has been quite 
challenging. Understanding the burden of disease is fundamental to defining and 
developing appropriate systems and services.  
To quantify the burden of any disease is a complex task. No single measure can 
effectively capture the many different dimensions of varying concerns and their 
relevance to the individual, to the health care system and to society17,18. In theory, 
incidence rates provide the clearest measure of the burden of carcinogenic exposure(s) 
at the population level. Incidence is defined as the number of new cases of cancer 
occurring during a given time period in a specified population. Compared with mortality 
rate, incidence rates allow, in theory, a more meaningful comparison between 
population, ethnic groups, countries and time period. 
This reflects the dependence of mortality rates on prognosis and, hence, treatment 
effectiveness. In addition, survival rates for many cancers depend on their stage of 
presentation, a function of both public and professional awareness, as well as access 
to health care and quality of care available at the point of delivery. Reliable incidence 
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data are only available for a small fraction of the global population. This fraction was 
estimated to 18% of the world population in 199018. In 1996, the International Agency 
for research on cancer (IATC, World Health Organisation) compiled incidence data, 
meeting acceptable standards in a series of informative volumes named “Cancer 
Incidence in Five Continents”. The key reasons for limited availability of reliable 
incidence data are due to the dependence on reliable census of the entire population, 
by age, gender, access to adequate diagnostic facilities, histological confirmation, and 
complete as well as timely notification of all new diagnose s to appropriate cancer 
registries. 
Cumulative incidence provides a measure that indicates the burden of new disease, 
yet, unlike incidence rates, it is a more interpretable and intuitive measure of disease 
frequency. It is defined as the proportion of people among those at risk over a specific 
period of time who develop disease, i.e. the probability or risk that an individual will 
develop disease during that time period. A number of assumptions are necessary for 
cumulative incidence to be a valid measure, such as there being no loss to follow-up, 
the entire population at risk being followed for the same time period. These 
assumptions make cumulative incidence unrealistic, making incidence rates a more 
appropriate and valid measure of the disease.  
Cancer prevalence data is another significant measure. Cancer prevalence is defined 
as the number of people in a given population, at a specified time who have been 
diagnosed with cancer. Many of these individuals may have been cured. In contrast, 
this provides information useful for the planning of healthcare resources, in particular 
outpatient care, regular check-ups, and the treatment of long-term complications since 
resources for terminal care depend critically on the number of persons in the population 
with a history of cancer. 
Even if incidence rates are stable, prevalence may increase as a consequence of 
improved prognosis. Advancement of the time of diagnosis, following an increase in 
screening, may further increase the prevalence of cancer. Irrespective of its 
significance, prevalence is difficult to capture through population surveys, as 
willingness to participate may differ between individuals. Hence to obtain reliable 
prevalence requires linkage between long-term cancer registration and survival 
databases, as well as updated population registers. To the affected patients, clinicians 
and health care planners, the probability of survival is of paramount interest. Survival 
rate is defined as the proportion of cancer patients surviving a specified time after 
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diagnosis. Despite their intuitive appeal as a measure of prognosis and therapeutic 
efficacy, survival data have numerous determinants, limitations and pitfalls.  It requires 
the long-term follow-up of a large number of patients and spurious patterns may arise 
due to lead-time bias, influenced by diagnostic intensity; sometimes it is difficult to 
classify causes of death correctly. 
Mortality rate is considered the single most important set of indicators of the burden of 
cancer as it is measured at population level, being the risk of dying from specific 
cancers or from all cancers. Mortality rate is defined as the number of cancer deaths, 
described in terms of numbers (often per 105 person-years, or absolute number of 
deaths per year) or as a rate. It is also the preferred measure for evaluating secondary 
prevention programmes. However, individuals who are cured do not appear in the 
mortality statistics, thereby reducing the utility of mortality as a measure of the overall 
burden of cancer. Nevertheless, reduction in mortality is the standard target for 
improvement in cancer control. 
Two different standardised measures are commonly used a) Standardised Mortality 
Ratio (SMR) – a measure of how much more or less likely a person is to die in the 
group being studied, compared to someone of the same age and sex in England and 
Wales and b) Age Standardised Mortality Rate, a measure of how many people 
would die in a standard population, if they had the same mortality experience as the 
group being studied. The standardised mortality rate is expressed as a death rate per 
100,000 population. 
Another significant measure introduced relatively recently and not used widely is the 
Years of Life Lost (YLL) and is defined as the number of years lost between age at 
death and expected (in the absence of this disease) age at death. This measure 
accommodates the fundamental differences between dying from cancer in childhood 
versus dying from cancer later in life. Ranking cancers by YLL can dramatically 
influence the apparent impact of a specific form of cancer. 
Another measure that helps to measure the combined impact of cancer on both quality 
of life and survival is the Disability-Adjusted Life Years (DALY), where 1 DALY 
equals 1 lost year of health life. Two key parameters required to measure DALYS in a 
population are the total number of life years lost due to the disease of interest and the 
number of these years lived with a disability of known severity. Assigning quantitative 
scores to disability is difficult or arbitrary and also the values involved in determining 
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these scores may differ both within and between populations.  Despite these limitations 
DALYS are a valuable measure that provides an indicator for both quality and quantity. 
2.3 Worldwide Profile of Cancer 
The latest figures published19 in 2011 reported that 2.7 million new cancer cases (6.6 
million cases in men and 6. million in women) and 7.6 million cancer deaths were 
registered worldwide. The same report also stated that the number of new cancer 
cases is expected to increase to 21 million by 2030. 
Lung cancer was the most common cancer worldwide with13% of the total number of 
new cases, followed by breast cancer (women only) 11% and by colorectal cancer as 
the third most common cancer with 10% of all new cases in 2008 (see Fig 2.1). 
Lung cancer is the leading cancer site in males, comprising 12.7% of the total new 
cancer cases and 23% of the total cancer deaths. In 2001 WHO report20 stated that 7 
million deaths (12% of all deaths) both in developed and developing countries was 
caused by lung cancer, being the third leading cause behind, ischaemic heart disease 
and cerebrovascular disease.  Fig 2.2 show a comparison of the top 50 countries with 
the highest overall cancer rates in the world. 
 
Fig 2.1  New cancer cases diagnosed in 200821 
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Fig 2.2  50 countries with the  highest overall cancer rates in the world22.  
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Among men, lung cancer is the most common cancer and the leading cause of death 
and among women breast cancer is the most frequently diagnosed cancer and the 
leading cause of cancer death among females, accounting for 23% of the total cancer 
cases and 14% of the cancer deaths. Although breast cancer is the most common 
cancer with the highest incidence and leading cause of death, fewer than 50% of 
women with breast cancer die from this disease. Even though advances made in 
treatment and disease management has had an effect on the mortality, progress has 
been slow as shown in Fig 2.3. There is considerable variation in the fatality of cancer, 
depending on the cancer site, histological type, and clinical stage23. The comparison 
between mortality and incidence rates allows a crude assessment of the fatality of type 
of cancers see Fig 2.4 for the worldwide age standardised incidence and mortality data 
for men and women. Mortality rates offer a good approximation of incidence rates for 
lung cancer, but not for breast cancer. 
 
 
Fig 2.3 Trends in age-specific death rates (log scale) for all cancers combined, 1970–2006 
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Fig 2.4 Age Standardised Incidence & Mortality in Men  and Women (2008)24 
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age standardised incidence and mortality for males and females residents of United 
Kingdom. 
 
Source: Office for National Statistics 2010. 
FIG 2.5 New cancers diagnosed in males and females, England, 201026 
 
 
Fig 2.6a Major cancers: age-standardised incidence by sex (Males), 2007-0927  
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Fig 2.6b Major cancers: age-standardised incidence by sex (Females), 2007-0927 
 
 
Fig 2.7 Major cancers: age-standardised mortality by sex, United Kingdom 2007-0927 
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and women; 13% for men and 16% for the women in the United States. Fig 2.8 
provides a comparison of five-year cancer survival rates for the women in the United 
Kingdom for all cancers, with 79% in breast but only 6% for lung cancer. 
 
Fig 2.8  Comparative 5 year survival for all cancers in the UK – Women28 
Fig 2.9 provides a comparison of five-year cancer survival rate for men in the United 
Kingdom for all cancers, with 61% in prostate but only 6% for lung cancer. 
 
Fig 2.9  Comparative 5 year survival for all cancers in the UK – Men28 
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2.5 Regional Profile of Cancer 
Mortality from cancer is higher in the North West compared to England and Wales 
overall in all age groups except people less than 35 years. In the period 1997 – 1999 
the standardised mortality rate for all cancers in the North West was 261 per 100,000 
for men and 180 per 100,000 for women. In the same period, the standardised 
mortality rate for England and Wales was 237 per 100,000 for men and 164 per 
100,000 for women29 . The incidence of cancer amongst residents of the North West 
Region is higher than in England and Wales as a whole. Fig 2.10 shows cancer to be 
the leading cause of death among the residents of the North West. A closer look at the 
deaths caused by cancer among the residents of the North West shows lung cancer 
(29%) to be the leading cause of death in men (Fig 2.11) and the second leading cause 
(20%) in women (Fig 2.12).  
Cancer is a chronic, progressive disease, and long term surveillance is needed to 
access the effectiveness of efforts to control it. Clinical treatment and care of the 
individual cancer patient is designed to eradicate malignant disease, or to achieve 
permanent remission with minimal loss of function or to provide palliation of symptoms. 
 
 
 Fig 2.10 Main Cause of Deaths to residence of the North West Region 200930 
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Fig 2.11Cancer Deaths in Men – North West Region 200930  
 
Fig 2.12 Cancer Deaths in Women – North West Region 200930  
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2.6 Epidemiology of Lung Cancer 
A hundred years ago, lung cancer was a reportable disease and it is now the 
commonest cause of death from cancer, both in men and women in the developed 
world.  Adler in 191231 reported all cases of lung cancer in the published literature, and 
worldwide there were only 374 cases. Today, lung cancer is one of the commonest 
cancers worldwide and its incidence is rising, especially in the developing countries32. 
In the UK in 2003 the crude incidence rate was 62.3 cases per 100,000, this amounting 
to 37,127 new cases each year – 1 in 7 of all new cancer cases in the country33. Fig 
2.13 shows the age-standardised incidence and mortality with 95 per cent confidence 
intervals by sex and country, for lung cancer in 2007. Incidence rates for developed 
countries are about 100 per 100,000 per year for men, and 45 for women. The male to 
female ratio is about 3 to 1 after adjustment for age.  Geographic and gender patterns 
reflect the stage of that epidemic. Although the incidence of lung cancer has been 
falling overall in recent years in this country, there has been very little improvement in 
the overall survival.  Table 2.1 provides an international comparison of historic five-year 
relative survival in adult men (aged 15-99 at diagnosis) in England and Wales (adults 
diagnosed 1986-90), Europe (1985-89) and the USA (1986-90). 
 
Fig 2.13 Age Standardised Incidence and Mortality for Lung Cancer in the UK 200733  
 
 
58.0 
63.7 
81.2 
65.1 
37.4 39.8 
58.4 
37.1 
0
10
20
30
40
50
60
70
80
90
England Wales Scotland N Ireland
R
at
e
 p
e
r 
1
0
0
,0
0
0
 p
o
p
u
la
ti
o
n
 
males females
1. Lung cancer is coded as C34 in the International Classification of Diseases, Tenth 
Revision (ICD-10). 
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 National average - 
England & Wales 
Affluent group –  
England & Wales 
Highest region – 
 England & Wales 
Scotland2 Europe2 USA3 
Lung- Men 6 % 6% 8 % 6% 10% 13% 
Footnotes 
1  Average survival rate for England and Wales; survival rate for affluent group (England and Wales); and 
highest survival rate among NHS Regions (all deprivation groups combined) 
2  Data from EUROCARE II study. Average rate for European countries (incl. Scotland) and regions (incl. 
parts of England and Wales) covered by EUROCARE II study. 
3  Average survival rate for US states covered by SEER programme  
Table 2.1 International comparison of Lung cancer survival – men 
 
Similarly Table 2.2 provides an international comparison of historic five-year relative 
survival in adult women (aged 15-99 at diagnosis) in England and Wales (adults 
diagnosed 1986-90), Europe (1985-89) and the USA (1986-90). 
 National average 
–England & Wales 
Affluent group - 
England & Wales 
Highest region – 
 England & Wales 
Scotland2 Europe2 USA3 
Lung- Women 6 % 7% 9 % 7% 11% 16% 
Footnotes 
1 Average survival rate for England and Wales; survival rate for affluent group (England and Wales); and 
highest survival rate among NHS Regions (all deprivation groups combined) 
2 Data from EUROCARE II study. Average rate for European countries (incl. Scotland) and regions (incl. parts 
of England and Wales) covered by EUROCARE II study. 
3 Average survival rate for US states covered by SEER programme  
Table 2.2  International comparison of Lung cancer survival –women 
 
Review of regional epidemiological data published by the North West Cancer 
Intelligence Service (NWCIS) shows that the incidence of lung cancer increases with 
age, peaking in the over 85’s for men and 75-79 year olds for women (fig 2.14). 
Incidence rates were consistently higher in men in all age groups. Regional 
epidemiological profile for lung mortality closely mirrored the national and international 
trends. Lung cancer mortality by age shows a similar pattern to that of incidence; with 
men in oldest age group 80 to 84 and 85 plus having the highest age specific mortality 
rate and those in 75-79 years for women. 
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Fig 2.14 Age Standardised Incidence of Lung Cancer in the North West 2003-200534  
 
 
Fig 2.15 Age Standardised Mortality of Lung Cancer in the North West 2003-200534  
 
Overall trend over the past twenty years lung mortality in men has decreased and been 
stable in women across the North West Region. 
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2.7 Aetiology and Risk factors 
Cancer is a diverse family of diseases, consisting of over 100 forms that spawn from 
almost every cell type in the body. Each cell type gives rise to distinct forms of cancer, 
and the diversity is greatly increased by the fact that multiple forms of cancer can be 
developed from each cell type, depending both on the location of the cell and the 
genetic aberration. 
Despite the broad diversity, several features are common to all cancers. These include 
unrestricted cellular proliferation, circumvention of cell cycle control, growth without 
appropriate signals, escape from programmed cell death, altered interaction between 
cells and surrounding environments, evasion of immune-mediated eradication and the 
invasiveness into normal tissue35.  
Cancer manifests itself as either a solid tumour or a non-solid leukaemia in the 
circulatory system. The term tumour is non-specific for a lump or swelling, that is 
characterised as either benign or malignant. The hallmark of malignancy is the 
invasiveness of tumour cells into the surrounding normal tissue. Several categories are 
used to determine the degree of tumour malignancy, including rate of growth, degree of 
differentiation, extent of invasiveness and metastatic potential (Table 2.3). In most 
cases, metastasis characterises the highest degree of tumour malignancy and is 
usually the cause of death in cancer patients. 
Cancer progresses in distinct stages, often over long periods of time, whereby a 
respective cancer cell progressively accumulates genetic aberrations resulting in 
increasing tumour malignancy36. 
 Benign Tumour Malignant Tumour 
Invasiveness Non-invasive, often encapsulated Invasive 
Rate of growth Slow often static Rapid 
Differentiation Well differentiated, often resembles 
tissue of origin 
Undifferentiated 
Metastasis Never Often metastatic 
Table 2.3 Comparison of Benign and Malignant Tumour 
Metastasis is defined as the migration of tumour cells from a primary mass to distant 
sites in the body, where the migrating cells take residence and eventually develop into 
secondary tumour mass. Tumours can metastasise to multiple regions of the same 
organ or to different organs, making eradication of metastatic cancers extremely 
difficult. In almost 50% of patients, surgical excision of the primary tumour does not 
cure the disease, as metastasis has already occurred37,38. As they disrupt many organ 
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systems, metastasis is considered the most severe and common life-threatening 
complication of cancer. 
2.8 Lung Cancer 
Cancer of the lung includes a number of malignant diseases (mainly carcinomas) 
affecting the lung and associated structures. Malignancy is subdivided into a number of 
cell types (histological types). The characteristics of the diseases, aetiology, prognosis, 
and amenability to treatment differ between them. The major distinction is between 
small cell (oat cell) and non-small cell tumours because they require different types of 
treatment. The classification proposed by the World Health Organisation (WHO) is the 
most widely accepted histological classification. The major histological lung cancers 
are squamous cell carcinoma (30-50%), small cell lung carcinoma (10-30%) large cell 
carcinoma (5-15%) and the increasingly common adenocarcinoma (10-30%).  
 
Lung cancers are epithelial tumours occurring in the major airways but they can also 
develop in the lung parenchyma. As a result of exposure to inhaled carcinogens the 
cells in the surface epithelium undergo a series of genetic mutations which result 
initially in cellular abnormality, before developing into carcinoma-in-situ and finally 
invasive carcinoma. The main cell types with their approximate frequency are listed in 
Table 2.4. Tumours are grouped for most clinical purposes into ‘non-small-cell lung 
cancer’ (NSCLC) and ‘small-cell lung cancer’ (SCLC). Over recent years the incidence 
of adenocarcinomas has been increasing and that of SCLC decreasing. 
Cell type  Approximate frequency (%) 
Small-cell carcinoma  15  
Non-small-cell carcinomas  
Squamous cell carcinoma 
Adenocarcinoma  
Large cell carcinoma  
Bronchoalveolar cell carcinoma 
Adenosquamous carcinoma  
Carcinoid tumours (atypical)  
 
40  
35  
5  
1  
1  
1  
Table 2.4  Pathological classifications of the major types of invasive lung cancer 
Small-cell lung cancer usually arises in the larger airways and has the most rapid 
doubling time of all lung cancers. In at least three-quarters of patients, metastatic 
spread has occurred by the time of diagnosis.  
Squamous cell carcinoma usually arises in the central air-ways and has a propensity 
to form large solid tumours, which sometimes cavitate.  
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Adenocarcinoma is less strongly associated with smoking, is more common in 
women, and can have a significantly slower doubling time than other lung carcinomas. 
It often develops from a peripheral nodule.  
Bronchoalveolar cell carcinoma is relatively rare, is very weakly associated with 
smoking and characteristically (though not exclusively) occurs in older female patients. 
It is a form of adenocarcinoma that spreads along the lining of alveolar spaces and 
small airways and usually presents as ill-defined peripheral consolidation, often initially 
misdiagnosed as infection. 
 
Lung cancers have a very high rate of spread with local invasion into the adjacent 
spaces such as the pleura, and organs such as the heart and great vessels. The 
circulatory system aids the spread to distant organs such as the liver, other lobes of the 
lung, brain, bone, adrenal glands and the skin.  The overall prognosis for lung cancer is 
poor, with around 50% of patients not surviving beyond 6 months of diagnosis and only 
20–25% being alive at one year The reason for such poor outcome is because patients 
remain asymptomatic for a long time, and by the time they present to the specialist the 
majority have locally advanced, inoperable or metastatic disease. 
2.9 Presentation 
Fig 2.16 provides an overview of the updated clinical pathway39 recommended by the 
National Collaborating Centre for Cancer for NICE. This is a good reference point to 
start to summarise the cancer patient journey. 
2.9.1 Symptoms  
As mentioned before, most patients with lung cancer are asymptomatic during the 
earlier stages of the disease, with a significant proportion of stage I and II tumours 
being detected when investigations are carried out for other purposes, such as chest X-
rays. The symptoms of lung cancer are summarised in Table 2.5.  
Symptoms of Lung Cancer 
Primary tumour 
 Cough  
 Dyspnoea  
 Wheezing/stridor (large airway narrowing)  
 Haemoptysis  
 Chest pain  
 Fatigue/lethargy  
 Fever/malaise (post-obstructive pneumonia)  
 Weight loss  
Regional spread  
 Facial swelling (superior vena caval obstruction)  
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Symptoms of Lung Cancer 
 Hoarseness (left recurrent laryngeal nerve palsy)  
 Dyspnoea (pleural effusion; phrenic nerve palsy)  
 Dysphagia (mediastinal node enlargement)  
Distant metastases  
 Bone pain  
 CNS symptoms (confusion, seizures)  
 Abdominal pain (liver capsule)  
Table 2.5 Symptoms of lung cancer  
 
2.9.2 Multidisciplinary teams (MDTs)   
Improving Outcomes Guidance clearly states that the multidisciplinary team (MDT) 
meeting lies at the centre of the new methods of management for cancer patients and 
is fundamental in achieving the improved outcomes. The multidisciplinary teams have 
been endorsed40 as the principal mechanism for ensuring that all the relevant 
disciplines and professional groups contribute to and participate in decisions on the 
clinical management of patients. The development of multidisciplinary working systems 
has simplified some of the referral processes between professionals and has improved 
communication to all relevant parties. 
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Fig 2.16 Clinical Pathway as recommended by the National Collaborating Centre for Cancer39  
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2.10 Treatment 
Review of data of patients diagnosed with lung cancer as part of the research identified 
patients received treatment using a combination of modalities i.e. surgery, 
chemotherapy, radiotherapy etc., also a high number of patients were recorded as not 
receiving treatment. This reason was due to the co-morbidities especially chronic 
obstructive pulmonary disease41.  The main options for treatment were Surgery only, 
radiotherapy only, chemotherapy only, or combination of surgery with chemotherapy 
and/or chemotherapy, radiotherapy and chemotherapy, other treatments such as 
hormone therapy, immunotherapy etc. Fig 2.17 summarises the treatments received, 
by modality, by patients diagnosed with lung cancer across North West Region in 
2003-0534. 
 
Fig 2.17  Lung cancer treatment by cancer network in the North West Region 2003-0534 
GMCCN: Greater Manchester Cheshire Cancer Network; LSCCN: Lancashire and South Cumbria Cancer 
Network and MCCN: Merseyside and Cheshire Cancer Network 
 
2.10.1 Small-cell lung cancer 
 
It is estimated that 75% of patients with small-cell lung cancer have extensive disease 
at the time of diagnosis. The principal treatment is chemotherapy combined with 
radiotherapy for patients with a favourable prognosis. SCLC is a highly chemo-
sensitive tumour, with response rates of approaching 90% using modern combination 
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platinum-based chemotherapy. The most common combination first-line treatment is 
cisplatin with etopside given in 4 to 6 cycles at three-weekly intervals. In patients with 
limited disease this is given in combination with thoracic radiotherapy.  
 
Cerebral metastases are common, so patients who respond well to first-line treatment 
are offered prophylactic cranial irradiation. Patients with extensive disease of 
Performance Status (PS) 0–2 are usually managed with combination chemotherapy 
alone.  Treatment of SCLC results in good symptomatic relief in the majority of patients 
and there are significant medium-term improvements in survival (Table 2.6). 
Unfortunately, relapse is common and, overall, less than 5% of patients survive beyond 
2 years.  
Stage Untreated 
median survival 
Treated median survival 5 year survival 
(%) 
Limited disease 3 months 14–20 months 10–20 
extensive 
disease 
6 weeks 8–12 months 3–5 
Table 2.6 Survival in small-cell lung cancer by stage and treatment 
 
2.10.2 Non-small-cell lung cancer 
 
Treatment of non-small-cell lung cancer (NSCLC) is primarily dependent on stage, with 
fitness and co-morbidity being factors in a proportion of patients. At least 60% of 
patients with NSCLC have metastatic disease at the time of presentation and in the UK 
no more than 20% have operable or resectable disease.  
 Stage I – IIIA Non-small-cell lung cancer  
Surgery is the first choice for treatment in those with stage I and II disease who are fit 
to undergo such treatment and a small proportion of those with stage IIIA tumours are 
also considered eligible. Lobectomy is the optimum surgical procedure, preserving lung 
function and being associated with better survival than simple wedge resection of the 
tumour mass. Occasionally pneumonectomy is required, but this is associated with 
higher morbidity and perioperative mortality, especially in older patients. In patients 
with impaired lung function a variety of other options are considered. The five-year 
survival rate of patients after surgery is shown in Table 2.7 below.  
Stage Survival at 5 yrs (%) 
Stage Ia 84 
Stage IB 68 
Stage IIa 47 
Stage IIB– chest wall invasion 56 
Stage IIB – mediastinal invasion 29 
Stage III (n0 disease) 34 
Table 2.7 Five-year survival in non-small-cell lung cancer after surgical resection  
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 Postoperative chemotherapy has been shown to improve absolute five-year 
survival by up to 10% in patients with stage II and IIIA NSCLC.  
 Postoperative radiotherapy has been demonstrated to be of little value. 
 Radical radiotherapy is of proven value in patients with stage I and II NSCLC 
who are medically unfit for surgery, although the five-year survival rates are less 
than half those seen with surgery. Continuous hyperfractionated accelerated 
radiotherapy (CHART) has been shown to be superior to conventional 
radiotherapy42.  
 Pancoast tumours arise in the superior sulcus of the thorax and are most often 
squamous cell carcinomas. They are classically associated with brachial plexus 
involvement, which can lead to severe nerve root pain and Horner’s syndrome. 
There are usually treated with a combination of chemo-radiotherapy followed by 
surgical resection if feasible 
 Stage IIIB – IV Non-small-cell lung cancer 
The vast majority of patients with stage IIIB NSCLC are considered inoperable, but 
there is a small proportion who may benefit from surgery. The NICE Guidelines43 state 
that in good performance status patients with stage IIIB NSCLC where the tumour can 
be covered in a radiotherapy field, there is good evidence that a combination of 
chemotherapy and radiotherapy is associated with a significant improvement in 
medium-term survival with a small proportion of long-term survivors. For those with 
stage IIIB disease too extensive for such radical therapy and those with stage IV 
(metastatic) disease, combination chemotherapy is now established as the first-line 
treatment in fitter patients. Cisplatin or carboplatin are most commonly combined with 
vinorelbine, gemcitabine or paclitaxel and given for up to four cycles at three-weekly 
intervals. NSCLC is less chemosensitive than SCLC with response rates between 50 
and 60% using modern platinum-based regimes. Many studies have confirmed a 
modest improvement in median survival of around 10–12 weeks on such 
chemotherapy, and the proportion of patients who remain alive at one year is almost 
doubled on treatment. There is often significant symptomatic improvement and careful 
studies have shown no overall detriment to quality of life with chemotherapy44.  
2.10.3 Palliative radiotherapy  
Palliative radiotherapy is of value in the management of multiple symptoms in all 
patients with lung cancer at any stage of their illness. It may be of particular value in 
the following situations:  
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 pain – from bone metastases or chest wall involvement. 
 large airway obstruction – particularly when there is extrinsic compression.  
 persistent cough.  
 persistent haemoptysis.  
 spinal cord compression.  
 superior vena caval obstruction.  
 symptomatic cerebral metastases. 
2.11 Palliative care  
Lung cancer is a disease where patients often experience a very high frequency of 
discomfort and pain with the duration of survival in the majority of patients being 
measured in months rather than years. Although it is important to offer patients radical 
therapy, it is equally imperative that these patients have access to high-quality 
supportive and palliative care that should include both the patient and their carers and 
encompass a variety of elements including:  
 quality of life.  
 symptom control.  
 support with adjustment to loss.  
 support and guidance regarding the completion of unfinished business.  
 dignified death in the patient’s place of choice.  
 prevention of problems in bereavement. 
The following are the most common symptoms to cause distress in the final months 
and weeks of life. 
 Difficult or laboured breathing or shortness of breath (Dyspnoea) is a sign of 
serious disease of the airway, lungs, or heart. There is good evidence that 
specialist breathlessness clinics are of benefit for some patients. Opioids can 
be of value in terminal dyspnoea and are best administered orally. 
 Pain is particularly a problem when there is chest wall involvement or bony 
metastases. Pain management plays a crucial role for these patients. Palliative 
radiotherapy is an important component of pain management in some patients.  
 Excess fluids between the two membranes that envelop the lungs (Pleural 
effusions) are another common feature and are best dealt with in specialist 
respiratory units. 
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 Cough can be difficult to manage but palliative radiotherapy is often useful or 
managed with oral opioids and sometimes nebulised. 
 Fatigue is common and often as the result of anaemia. 
 Physical wasting with loss of weight and muscle mass caused by disease 
(Cachexia) is almost a common feature of the later stages of the disease and 
oral corticosteroids offer good, if short-term, relief in many patients.  
 Depression is also poorly recognised and put down to a ‘normal response’ to a 
patient’s illness. Antidepressants are of great value in some patients.  
2.12 Specialist nursing 
The emergence of the lung cancer nurse specialist (LCNS) has been one of the most 
important elements in improving the care of lung cancer patients in the last 10 years or 
so. With the emergence of the MDT, patients are often seen by a variety of doctors, 
commonly in more than one hospital. The LCNS is seen as the single point of contact 
for the patient and carers from the start of their ‘journey’ at the time of the diagnosis. 
They are in the ideal position to form an on-going supportive relationship with the 
patient and their carers and provide a stable ‘thread’ as the patients move along the 
care pathway. They are an invaluable source of information and advice and are of 
proven benefit in the follow-up of many patients. 
2.13 Service provision 
Cancer services in the UK have developed and improved greatly since the Calman–
Hine report of 1995 and the National Cancer Plan of 2001. The key elements for lung 
cancer service should include:  
 clear referral pathways to a specialist team with identification of all abnormal 
chest X-rays  
 the availability of a rapid-access lung cancer clinic  
 all patients being managed by a specialist MDT comprising representatives of 
all the key disciplines  
 all patients having access to a lung cancer nurse specialist  
 every service regularly auditing its activity, performance and outcomes 
2.14 Risk Factors 
2.14.1 Smoking 
There have been several breakthroughs during the 20th century, but none more 
significant than Sir Richard Doll and Austin Hill’s remarkable landmark article published 
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in 1950 in the British Medical Journal that confirmed the suspicion that lung cancer was 
associated with cigarette smoking
45
. The incidence of the disease is higher in men than 
among women due to the earlier spread of the smoking habit among men. The male-
female ratio has changed significantly over recent years being around 3:1 in the late 
1970s but only 1.5:1 in 2005
46
. This is because the incidence has been falling in males 
since the 1970s but continuing to rise slowly in females. These changes in incidence 
parallel the changes in smoking rates but with some 20–25 years delay. Around 85% of 
cases occur in individuals over the age of 60 years with the median age at diagnosis 
being 72 years (see Fig 2.18). It is rare below the age of 40 years. The incidence of this 
disease in men in the UK has been the highest in the world, but rates have been falling 
by 7-10% every five years since the mid -1970s. At the same time, incidence among 
UK women has been increasing by 10% every five years since the mid 1970s, and in 
1990 lung cancer overtook breast cancer in Glasgow as the most common cancer in 
women47. 
 
Fig 2.18 Age distribution of Lung cancer cases in England and Wales, 2009 
 
The rate of increase in women slowed down by the end of the 1980s. These incidences 
tend to mirror earlier trends in tobacco smoking, which causes 90% of lung cancer. 
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Lung cancer mortality tends to mimic the figures for incidence, because survival has 
been poor for decades. 
Cigarette smoking is attributed to be the most significant contributory factor for 90% of 
cases in males and 80–85% in females48.  Approximately 1 in 6 lifelong smokers will 
develop lung cancer, the risk being more strongly related to the duration of smoking 
than the number of cigarettes smoked per day. Smoking cessation at almost any age 
significantly reduces the risk of developing lung cancer, causing the risk to stabilise, 
and stopping before the age of 50 results in a fairly low risk of developing lung cancer. 
Even stopping smoking at the age of 60 delays the risk of developing the disease by 
more than 10 years and significantly reduces the overall risk (see Fig 2.19)49. 
 
2.14.2 Other Contributory Factors 
There are, however, other contributory factors that are associated with lung cancer, 
such as involuntary or passive smoking that may increase the lung cancer risk by 20 
per cent50. It is estimated that around 4000 people who never smoked die of lung 
cancer in the UK each 
 
Fig 2.19 Effects of stopping smoking at various ages on the cumulative risk (%) of death 
from lung cancer up to age of 75 years 
 
year, 20% of these deaths being attributed to passive smoking. Occupational factors 
such as exposure to asbestos51  and radon52 cause between 3 and 17% of lung cancer 
cases.  The other risk factor is the presence of chronic airflow obstruction that has 
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been variously estimated to increase the risk by as between two-and six-fold53. A 
history of lung cancer in a first-degree relative, i.e. a family member who shares about 
50 percent of their genes with a particular individual in a family, is associated with an 
approximate doubling of risk, independent of the smoking history. This relative risk is 
as high as five-fold where the cancers develop under the age of 60 years54.  
2.15 Summary 
This chapter has provided an account of the epidemiology and disease processes 
associated with lung cancer and the clinical settings in which it is treated. Lung cancers 
are classified into two main categories: small-cell lung cancers (SCLC), which account 
for about 20% of cases, and non-small-cell lung cancers (NSCLC), which account for 
the other 80%. Non-small-cell lung cancers include squamous cell carcinomas (35% of 
all lung cancers), adenocarcinomas (27%) and large cell carcinomas (10%). The next 
chapter will go on to review the literature in the field that is relevant to the proposed 
research investigations. 
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3 LITERATURE REVIEW 
3.1 Introduction  
Prior to starting this research it was important to understand the background that 
initiated the Calman-Hine Report and the context in which these recommendations had 
been made. Table 3.1 summaries the list of key documents in the order of year in 
which they were published following the review of NHS performance and service 
outcomes. These publications sought to define a bold and ambitious future for NHS 
service delivery by setting clear objectives and directions. 
Document Title Year 
Published 
The Health of the Nation - A Strategy for Health in England55. 1992 
The Health of the Nation Key Area Handbook-Cancers56. 1993 
Variations in Health, what can the Department of Health and NHS do? 
The Health of the Nation57. 
1995 
The new NHS. Command Papers58. 1997 
A First Class Service – Quality in the NHS59. 1998 
Our Healthier Nation – Green Paper60. 1998 
Securing Good Health for the Whole Population: Population Health 
Trends61. 
2003 
Table 3.1 List Department Health documents that shaped the future of NHS 
 
This was followed by reviewing key policy documents that defined the shape of Cancer 
Care services in England and Wales. Table 3.2 summarises the key documents that 
were reviewed to seek answers to some preliminary questions in order to evaluate the 
rationale for this study before embarking on the research. 
Title Year 
Pubished 
Cancer Care and Treatment Services: Advice for Purchases and 
Providers62. 
1991 
Management of Non – Surgical Cancer Services in Scotland63. 1992 
Protocol in Investment Health Gain – Pain, Discomfort and Palliative 
Care64. 
1992 
Reducing delays in Cancer Treatment: Some Targets65. 1993 
Information for effective purchasing Getting better with Health66. 1993 
Report of the Cancer Services Review to The London Implementation 
Group67. 
1993 
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Title Year 
Pubished 
Calman K, Hine D.  A Policy Framework for Commissioning Cancer 
Services  
1995 
Guidance on the Structure and Function of Cancer Centres68. 1996 
Patient – Centred Cancer Services? – What Patients Say?69. 1996 
Public Health in Europe, European Commission Report 19977. 1997 
Improving outcomes in lung cancer. National Cancer Guidance70. 1998 
Referral Guidelines for Suspected Cancer71. 2000 
Cancer Information Strategy72. 2000 
Manual of Cancer Services Standards73. 2000 
National Cancer Performance Indicators74.  2000 
The NHS National Cancer Plan40. 2001 
Service Improvement Guide Lung Cancer75. 2001 
Cancer National Survey of patients: National Overview 1999/200076. 2002 
Improving Cancer Services77. 2005 
Cancer Reform Strategy78. 2007 
Table 3.2 List Department Health documents published to reform cancer services  
3.2 Search Summary 
All pertinent theories, policies, protocols and guidelines79,80,81,82 and all seminal, 
Department of Health documents relating to cancer services and directives were 
reviewed and are appropriately referenced.  The principal document that instigated this 
study was the Calman–Hine Report of 1995. The primary objective of the literature 
review was to investigate whether:  
 similar work has been or is being carried out elsewhere; 
 there is either a conceptual, theoretical or working model for the  
multidisciplinary team, as recommended by the Calman-Hine Report;  
 similar service configurations have been adopted in other clinical specialities; 
 there is any high-quality evidence that MDTs directly improved treatment 
outcome and improved survival of patients with lung cancer as compared with 
the traditional model of care; and  
 available published studies also demonstrated other research outcomes such 
as improved communication, early detection, diagnosis, treatment, and quality 
of care. 
 
In addition to the above objectives, the literature review also focused on understanding:  
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 the extent to which models were employed to resolve or develop operational 
pathways in a complex system such as health care; 
 what evidence was available to support the specific modelling approach 
adopted by the author in health care and review what other approaches had 
been successfully undertaken by other researchers working in the health 
care domain; and 
 the level of integration achieved by the solutions generated as a result of 
modelling especially within health care. 
 
Some of the key sources used for the literature search are as follows: National 
Research Register 1998, 1999 and 2000- 09, MEDLINE, BIDS, CURRENT 
CONTENTS, Cancer Net, INSPEC, OVID Biomedical, EMBASE, JOURNAL WATCH, 
CRSP/CRSB - (Computer Retrieval of information on Scientific Projects), KINGS FUND 
LIBRARY database, ANBAR and ASSIA (Social Science& Humanities for part of 
management science research) and PHIN - (Pharmaceutical and Healthcare industry 
New). 
 
3.2.1 Related Work 
The literature review confirmed that there was no published evidence of similar work 
being carried out to that proposed in this research. Although a number of organisations 
and newly formed cancer networks were working on various initiatives aimed at 
evaluating concepts or conducting feasibility study funded by the Cancer Collaborative, 
most of these studies did not follow any rigorous scientific methodology. Most of the 
studies were proof of concept pilots testing service reconfigurations if they were fit for 
purpose and scalable by trial and error.  
 
3.2.2 Models of MDT Teams 
The literature review confirmed that there was no published record of a comprehensive 
integrated multidisciplinary team model as defined by the Calman- Hine Report. While 
many papers83,84,85,86,87were found on the approach of multidisciplinary team working 
and on the benefits of a multidisciplinary clinic88 there is no clear evidence to suggest a 
formal integrated service model for cancer services being recommended or published.  
 
Extensive searches revealed one paper published in 199889 that provided evidence for 
a patient-centred multidisciplinary management model. Although the concept and 
approach of this model seemed similar to that recommended by the Calman-Hine 
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Report, on closer examination this paper advocated the merits of an MDT and 
advocated MDT management of patients rather than providing a template for an MDT 
model. Also this paper did not demonstrate that this model was deployed to manage 
patients beyond the confines of the reported organisation. 
 
3.2.3 Comparable Service Configurations  
A literature search revealed that a similar approach is being tried in other specialties90, 
but has yet to become a standard practice. Oncology is pioneering the development of 
the MDT. The paper90 states that “no study to date of multidisciplinary care of heart 
failure has shown the benefits to be independent of optimal medical care” proving  the 
fact that MDT practice is still to be established in this speciality. 
 
3.2.4 Impact of MDTs on Treatment Outcome and Survival Rates 
Although evidence indicated the acceptance of the MDT as a concept within the clinical 
domain and belief in its effectiveness to improve the management of treatments 
received by patients, there was very little published evidence to substantiate this view. 
An initial literature review preformed prior to the start of this research provided no clear 
evidence. However, a recent review identified a few papers published supporting the 
effectiveness of MDT91. In 2005 a group 92 from the Royal Infirmary Glasgow, claim 
their study to be the first to examine the impact of the introduction of MDT on the 
survival of patients with inoperable non-small-cell lung cancer, presenting to a single 
centre. They concluded that the introduction of MDT is associated with an increase in 
the proportion of patients presenting with stage IIIb disease being staged and receiving 
chemotherapy and that was associated with doubling of survival in patients with stage 
IIIb disease.  Similar studies by other researchers93, indicate a statistically significant 
increase in radical radiotherapy from 3% to12% (p=0.004) following the introduction of 
MDT.  Another study94 indicates that resection rate for non-small-cell lung cancer 
increased from 4.7% to 27% in favour of MDTs. At the same time other researchers 
referenced above86 have reported that their systematic review of publications between 
1984 and July 2007 shows limited evidence linking MDTs with improved survival, but 
stress that this result does not mean that MDTs are ineffective, only that there is limited 
evidence of this. 
  
3.2.5 Other Research Outcomes 
Studies mentioned in the above section indicated that MDT was not only influential in 
changing patient management, but they also facilitated optimal inter-communication 
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among attending specialists16. Although clinical management teams are by nature 
multidisciplinary and interdisciplinary, the MDTs have provided a structural framework 
for the professionals to work from. Patients surveyed have indicated that the changes 
to the management of patients’ treatment brought about by the MDTs have significantly 
increased patient satisfaction along with the quality of care they received. Accurate 
published data are not available to support this claim. 
3.2.6 Models to Resolve or Develop Operational Pathways 
The application of modelling to resolve real life operational problems in healthcare95,96 
provides a reliable methodology for understanding and evaluating the consequence of 
possible actions prior to deployment. The use of modelling and simulation 
methodology97,98 as a problem-solving tool99 has been well received and accepted as a 
suitable approach to long standing but dynamic issues such as bed occupancy100, 
length of stay, managing waiting lists, patient flow, estimation of throughput etc. This is 
especially true when there is a requirement to deploy unproven and untested solutions 
into the operational domain with high risk attached. It also applies in safety critical 
domains when deploying solutions that are required to be operationally risk free, are 
very expensive, resource intensive and time consuming; and in trying to establish proof 
of concept as demonstrated by some researchers101,102.  
 
3.2.7 Evidence to Support a Specific Modelling Approach 
A model can be regarded as a representation of reality103. However, whilst true, this is 
a somewhat simplistic viewpoint and a great depth of understanding is needed. 
Literature review of the application of modelling in healthcare was carried out to see 
whether there was a body of published work that helped to understand, evaluate, 
change, manage and control complex systems by incorporating both explicit extrinsic 
and intrinsic variables. This search and study helped to gain good insight into the 
various approaches to modelling i.e. qualitative (soft and hard) interpretive models104, 
and mathematical and logical models105,106,107 with particular relevance to published 
work in this discipline.  
 
Clinicians have also been looking toward mathematics to gain further understanding of 
mechanics108, in tumour biology109,110 for gaining increased quantitative understanding 
and predicting the behaviour of tumours for well over forty years111. This is important as 
the rate of growth of a tumour is a defining factor in disease progression and 
management. The combination of mathematics and theoretical biology gave rise to an 
interdisciplinary research field usually referred to as Mathematical biology or 
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biomathematics, with four major subfields, biological mathematical modelling112,113, 
complex system biology, bioinformatics114 and computational bio-modelling/bio-
computing. Models have similarly found applications115,116,117 in service management. 
Other examples of modelling approaches that were found included solutions developed 
using a comparative application of parametric and non-parametric models118 for 
hospital cost efficiency and productivity, qualitative dynamic models119 in medical 
diagnosis and discrete choice modelling developing applications for clinical service 
development. Literature review revealed the use of soft methodology such as Soft 
Systems Methodology (SSM) a Problem Structuring Method (PSM) used to identify 
problem situation and formulate appropriate solutions e.g.  SSM deployed at King’s 
College Hospital in London for their change management programme “Transforming 
Healthcare Delivery”, established in 1994.  
There are a few studies reported in the literature that combine PSMs with other 
methods such as Discrete Event Simulation (DES)  Almost all of these use 
SSM120,121,122,123,124, although125 some use cause-and-effect diagrams. Of the few 
studies that combine PSMs with DES, all the known examples are in health care. SSM 
is the most popular approach because it can be used to structure the process of 
understanding in a rigorous and transparent fashion, which cannot be achieved to the 
same degree when using cause–and-effect diagrams. Although it has been argued that 
the soft (SSM) and hard (DES) paradigms are incommensurable126,127show that the two 
are compatible and can be used in combination in operational research/management 
science studies. 
As mentioned earlier, the guidelines for managing lung patients recommend that all 
patients should be managed by a specialist MDT comprising representatives of all the 
key disciplines. This brings together relevant health care workers with specialised 
knowledge of particular aspects of lung cancer diagnosis or treatment. In several 
countries, clinical practice guidelines for lung cancer recommend that MDTs should be 
used to plan the management of all lung cancer patients  
 
Many aspects of the multidisciplinary clinic, in particular the scheduling of patients128, 
clinical inter- and intra- communication, team working, and criteria for data collection, 
have been picked up in a series of informatics projects129,130 and initiatives 
(modernisation programmes) both in the healthcare sector and in other commercial 
environments. The National Research Register revealed that most of the on-going 
projects on cancer services (dealing with non-clinical issues) are focused on assessing 
outcomes, effectiveness (health economics) and addressing resource shortfall.  
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3.3 Summary 
In this chapter, a critical review has been undertaken of literature that is relevant to the 
current research investigation with its focus on the management of patients with lung 
cancer. The literature review established that no work similar to that proposed in this 
thesis was being carried at out at the beginning of this research. It also demonstrated 
that there are organisations in the health care domain that are prepared to examine 
alternative ways to understanding, identifying and finding creative solutions demand of 
the system arising from the reforms introduced by the Department of Health. It was in 
the gap between the real world and the ideal world of models that the true potential for 
creativity and ingenuity lies. 
The next chapter will describe the current services configuration for the management of 
lung cancer. 
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4 CURRENT SERVICE CONFIGURATION  
The publication of the Calman-Hine Report required every cancer service provider to 
review their cancer service provision and establish a baseline, defining how close or far 
they were from the recommendations and the model of care and to devise a local 
service plan to phase in the recommendations. Hence it provided an excellent 
opportunity to participate, to understand and assimilate the findings in order to develop 
the future state model, having established what work had been published in relation to 
the development of a multi-disciplinary care model. 
This chapter focuses on the preliminary work done to establish the current (baseline) 
state and to provide an understanding of the service provision. It also served to chart a 
map of the operational patient pathway pattern, i.e. how does a cancer patient journey 
from primary care to secondary care to tertiary care and what is the nature of the 
interaction with palliative and community care? It was important to study both the intra- 
and inter-sectorial pathways and their interaction with each other and other care 
providers i.e., hospice, social services, private care etc. The initial review focused 
primarily on the view points of the service providers, but also provided opportunities to 
involve patients so as to ascertain their experiences.  
4.1 Calman-Hine Service Review Report 
The report published by the DoH in April 1995, written by the Expert Advisory Group on 
Cancer, titled “A Policy Framework for Commissioning Cancer Services3  triggered the 
cancer care service providers to undertake a comprehensive service review against the 
criteria defined in the report. The proforma used to carry out the baseline assessment 
is presented in Appendix C. The background and motivation for the original review and 
subsequent reports was the: 
 heavy burden of disease on the community – one in three people will get the 
disease and one in four will die from it; 
 potential for reducing deaths from cancer by prevention, screening and by early 
clinical diagnosis and management at first presentation; 
 huge economic consequences resulting from cancer. The cost of cancer care to 
the NHS is estimated to be as much as 6% (over £1 billion) of NHS hospital 
expenditure and there are substantial broader financial burdens; 
 apparent variations in recorded outcome of treatment; and 
 overall increase in the incidence of cancer. 
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The Policy Framework Report helped to recognise the size and complexity of the 
subject of cancer and also the advancing and changing nature of treatments. The 
report set out a number of general principles which it considered should govern the 
provision of cancer care. These are: 
Local treatment service: a network of services which might operate across the sector 
to provide maximum benefit to the local population. All patients should have access to 
a uniformly high quality of care in the community or hospital. 
Chemotherapy: local provision of chemotherapy seen as a major element in improving 
cancer care; care to be provided as close to the patient’s home as is compatible with 
high quality, safe and effective treatment. 
Public and professional education: to help early recognition of symptoms of cancer 
and the availability of national screening programmes. 
Patient Support: clear information provided to patients, families and carers, to help 
understand treatment options and outcomes at all stages of treatment.  
Communication: cancer service development to be patient-centred, with good 
communication between professionals and patients. Effective communication between 
the health sectors i.e. primary care, secondary care etc.; imperative in achieving the 
best possible care. 
Service Development  
Multidisciplinary management and consultation needs surgical and oncology experts to 
work together i.e. medical and/or clinical oncologist working along with the surgical 
oncologist. Site specialisation – clinicians should specialise in the particular cancers 
they treat. 
The Lung Cancer Team should include medical and nursing staff with specialised 
knowledge of diagnosis and treatment, both curative and palliative, of lung cancer. A 
lead clinician- normally a respiratory physician – should be managerially responsible for 
the service as a whole. The core members of lung cancer multidisciplinary team are: 
 Respiratory/Chest physician with special interest in lung cancer 
 Clinical Oncologist 
 Medical Oncologist  
 Radiologist(s) with thoracic expertise (including interventional radiologist) 
 Pathologists (Cytologist and histopathologist) 
 Clinical Nurse specialist 
 Palliative care specialist. 
 Thoracic surgeon 
 MDT Coordinator 
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 Research nurse/coordinator 
In addition to this the following staff would have close links to the MDT  
 Other specialist nurses (chemotherapy specialist) 
 Palliative care nurse specialist 
 Psychologist/psychiatrist 
 Social worker 
 Chaplain/pastoral care worker 
 Bereavement care worker 
 The primary health care team 
 Dietician  
 Physiotherapist 
 Occupational therapist 
 Speech and language therapist 
 Complementary therapist 
 Benefit advisors 
 Counsellors 
Establishment of Cancer Centres and Cancer Units, with cancer centres serving a 
population of at least 1,000,000 (though this was under review at the time of publishing 
the report) 
Research: obligation on all clinicians to assist in properly organised multi-centre 
research. 
Routine Data Collection: systems and procedures in place to record and capture 
cancer data contributing to local, regional and national data analysis. 
This report was focused at quite a high level and not intended to provide the granularity 
to enable local services to define their requirements. Nevertheless it formed the 
backbone of this research and triggered a number of interesting questions and 
challenged the ethos of the current service configuration.  
4.2 Establishing Current Baseline 
Having reviewed all the key DoH policy documents, reports, health circulars and 
executive summaries as detailed in Chapter 3, further work was undertaken, reviewing 
regional and district cancer service review documents131,132,133,134,135 along with 
additional lung cancer and service specific guidelines that are summarised in Table 
4.1. 
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Document Title Year 
Published 
Palliative Care Pathway(1998); NHS Executive136. 1998 
Service Improvement Guide Chemotherapy137.  2001 
Service Improvement Guide Lung Cancer138.  2001 
Service Improvement Guide Multidisciplinary team working139. 2001 
Service Improvement Guide Palliative Care140. 2001 
Service Improvement Guide Pathology141. 2001 
Service Improvement Guide Patient Information142. 2001 
Service Improvement Guide Primary Care143. 2001 
Service Improvement Guide Radiotherapy144. 2001 
Cancer Services Collaborative – Twelve months on145. 2001 
Table 4.1 List of lung cancer and service specific guidelines  
 
In addition to these, some key documents listed in Table 4.2, defining the information 
strategy and data requirements specific to support and deliver the objectives set in the 
cancer plan, were reviewed. 
Document Title Year 
Published 
Framework for Information Systems: The Next Steps. Working for 
Patients146. 
1990 
Handbook for IM&T specialist Getting better with Information147. 1992 
Information requirements revisited CASPE research report to Information 
Management Group148. 
1990 
Information for Health. An information strategy for the modern NHS 1998 - 
2005149. 
1998 
Cancer Dataset Project150. 2000 
Data Set Change Notification 34/2001 Monitoring the 2001 cancer waiting 
time151 target of one month from urgent GP referral to treatment.  
2001 
Table 4.2 List of key information and data documents 
 
4.2.1 Reason and Overview of the selected Methodology  
While the literature review provided an excellent overview of the national 
recommendations and requirements, a series of local process mappings helped to 
understand the local service configuration. This combined knowledge helped to narrow 
down the options of the most suitable modelling methodology, although the original 
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intention was to construct a mathematical model. Review of local service configuration 
presented a complex, messy operational problem situation. There was quite a 
substantial body of evidence suggesting, as discussed in Chapter 3 the use of Soft 
System Methodology (SSM), a Problem Structuring Method (PSM) that has been 
successfully used in healthcare120-123 and in a few cases combined with Discrete Event 
Simulation (DES)221.  
The ‘soft’ SSM methodology was developed an as alternative to using ‘hard’ system 
engineering methodology, where the nature of the problem is ill-defined, messy, 
changing and complex152.  The principal element of the methodology involves the 
following: 
 ascertain the problem situation; 
 devise/create relevant purposeful activity models; 
 deliberate upon/ reassess the situation using the models, to help identify/ 
establish systemically desirable and culturally feasible changes, 
accommodating conflicting interests in order that action-to-improve to be taken; 
 taking action to improve the problem situation. 
Hence the process starts with a real-world situation that is perceived to be problematic 
by one or more people, which calls for exploration, selecting, naming and modelling 
relevant human activity systems. To explore the problem situations SSM uses Rich 
Pictures (RP) to help in expressing the multiplicity of relationships and communicating 
about the real world problem situation. This also helps to identity the purposeful activity 
systems that facilitates the construction of clear definitions called Root Definitions of 
the system to be modelled. The Root definition expresses the core or essence of the 
perception to be modelled and contains the transformation process T that transforms 
an input entity into an output entity. The root definition should state/include: do P (what 
to do) by Q (how to do it) contributing to achieve R (why to do it) identifying the 
Customer, Actors, Transformation process, Weltanschauung, Owner, Environmental 
constraints (CATWOE) elements addressing the three Es (Efficacy Efficiency and 
Effectiveness).  
 
This contributes to the construction of conceptual models that are relevant to the 
purposeful activity systems. The steps that follow model development are the real 
strength of SSM, as the primary purpose of building models of purposeful activity 
systems is to coherently interrogate the actual problem situation with the users of the 
system as active participants. This facilitates the comparison of the conceptual model 
with the real-world problem situation and defining/ implementing desirable and feasible 
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changes. Hence SSM is a learning system and has the flexibility to accommodate 
different views and constraints, and has the ability to be scaled up or down as the 
situation demands. This was the motivation for selecting SSM as the methodology for 
this research. Also in SSM the representation of the problem situation is assembled by 
engaging the system users. On the one hand this is very beneficial, but on the other 
can be challenging in a group situation. It is challenging because, for the group to 
represent the ‘system’ in which they are engaged, including seeing what they may see 
and agree as being problematic, it is based on their individual or collective exposure 
and experience.  
SSM as a methodology helps to negate these issues by allowing different starting 
points for the representatives in the groups, accommodating group dynamics to yield 
‘many world’ or ‘multiple perspectives’. The Rich Picture (RP) facilitates the capture / 
assembling of the individual perspectives along with the collective stream. This 
provides a means of exploring the motives (do something), and acts as a presentation 
device. As such it helps communicate ideas for others to understand and as a means 
to raise matters that are difficult to express conventionally.  The use of the Rich Picture 
to encapsulate the real-situation constructed in a participatory manner allows the 
various representatives in the group to contribute their individual process components 
that then merge/ converge into the larger picture. This visualisation of the process 
evokes creative thinking, enables arcane and at times cryptic issues to surface, thereby 
contributing to exemplify those issues that are difficult to express as words, but easier 
as pictures. 
 
4.2.2 Study Approach 
Although it was possible to follow and map the work flow process specific to MDT, it 
became apparent that doing so would not lend itself to developing a detailed and 
robust MDT model. Hence, it was essential to map the cancer journey right from 
primary care to a clinical outcome. This was a big challenge as various professional, 
clinical and data pathways criss-crossed. At times the pathway boundaries became 
blurred such that they almost seemed like one. Following a pathway failed almost all 
the time or became so complex that it could not be studied on its own. The literature 
review had established that Soft Systems Methodology had been deployed 
successfully in health care settings153 such as King’s College Hospital. 
The study model was developed along the seven stages Soft Systems Methodology154 
(see Fig 4.1).  
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The seven stages are:  
 SSM 1 -  Problem situation considered problematic  
 SSM 2 -  Problematic situation expressed  
 SSM 3 -  Root definitions of relevant purposeful activity systems,  
 SSM 4 -  Conceptual models of the systems (holons) named in the root  
definitions 
 SSM 5 -  Comparison of models and real world  
 SSM 6 -  Changes: systemically desirable culturally feasible  
 SSM 7-  Action to improve the problem situation  
 
For this study prior to “defining the problem situation” it was necessary to understand 
the current service design. This was done by investigating the services, 
compartmentalising the constituent parts of the cancer journey to allow the tracking of a 
patient from primary care through secondary care and beyond, before the issues with 
MDT could be distilled. However, in doing so it also required an understanding of the 
pathways within each organisation. The aim was not to deconstruct the service, but to 
develop each element as a continuum so that they could all be brought back together 
or converged into the whole. A similar approach was taken while expressing the 
problem, to ensure retention and differentiation of the issues across the multiple 
pathways; the knowledge acquired was then distilled to address the research question. 
It needs to be stated that the aim of the research was not to review the system as a 
whole. 
 
 Rather it was to define the problem situation it was necessary to undertake such an 
exercise as there were no documented process maps either within an organisation i.e. 
at the District General Hospital (DGH) from the time a referral is received through to the 
patient being discharged, transferred to another unit or certified dead, or across the 
health community. There were department-specific process maps, but they were not up 
to date. This thesis does not intend to document the details of the work undertaken to 
build this picture, but will provide an overview and demonstrate how the findings from 
this review helped not only to develop the MDT model, but also identify all the 
supportive systems that the MDT service model is dependent on. This introspective 
approach also allowed questioning some of the established local standard operating 
procedures (SoPs), protocols, processes, challenging the practice, and getting the 
service providers thinking about alternative approaches. It also enabled the definition of 
the range and nature of (mix of high level) issues, bottlenecks, concerns, and risks 
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associated with each of the segments and the interrelationship between some or all of 
them. 
It especially identified those that were peculiar to that segment or segments, hidden 
(unknown to the organisation) observed but not reported, and avoidable but not 
progressed due to resource scarcity. To deconstruct the service, a service review 
model (Fig 4.2) was developed, identifying the essential parameters and the inter-
relationships between them. Information on the current service provision and 
configuration framework was limited and often incomplete. Collation and analysis of 
these parameters helped to establish the state of the current service provision. The 
service review model also supported historic data analysis and was base-lined against 
the new Hub and Spoke model recommended, Fig 4.3, by the Calman-Hine Report. 
 
The service review model helped to establish the basic building blocks of the how the 
review should proceed, by defining the key stages of the review and breaking each 
stage into manageable blocks, keeping related tasks as close as possible to allow 
seamless transition of the work stream. Finally, it brought together all the work streams 
by converging all the relevant work streams, data and recommendations to provide the 
reviewers the opportunity to see the complete picture of current service provision. In 
turn this allowed further detailed analysis of process and data to be undertaken and the 
knowledge base consolidated to help develop the MDT model. 
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Fig 4.1 Conventional seven-stage model of SSM. 
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Fig 4.2 Service Review Model.
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Cancer Centre
Serving a population of >1 
million
Hub and Spoke Model for the Delivery of Cancer Care
Cancer Unit
Community 
care/ Palliative 
care
Primary Care/ GP 
Surgery
Private Hospital 
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 The service model also helped to prioritise the category of data required to establish 
service baselines by providing the structure for collecting, collating, and analysing the 
data.  
  
4.2.3 Defining the problem situation SSM1 for the MDT Model 
To help define, understand and objectively state the problem situation in relation to the 
MDT service, it was essential to establish the baseline of the multidisciplinary team 
working by conducting a systemic review of all the preceding processes and activity 
leading up to the patient case review at the MDT meeting. This includes following the 
patient, data, paper, and information workflow as shown in Fig H.1-H.9 in Appendix H. 
The challenges facing the service could be categorised as logistics, scheduling and co-
ordination of all the relevant representatives of the MDT, and all this before addressing 
the issue of access to and/or availability of critical data. It became clear that the MDTs 
were not formed of teams as one would define ‘teams’ from an organisational structure, 
but rather a loose consortium of professionals with special interest and appropriate 
skills as defined in the Guidance document “Improving Outcomes in Lung Cancer”155.  
 
This had usually led to representatives making time to attend these meetings, reflecting 
their professional commitment to their patients, but if their clinics overrun or they have 
conflicting meetings, attendance at MDTs suffered. Equally important was the minimum 
infrastructure required to run such a session. For each patient the consultant 
responsible for the patient presented the case history detailing the patient’s diagnosis 
and prognosis. The Pathologist reviewed the appropriate histological slides and 
reviewed the reports. These could be the ones they had verified and signed off or on 
some occasions review reports that were generated by a referring hospital or unit. The 
Radiologist does the same and the team review all the information they have to hand 
and discuss the most appropriate treatment option for the patient. These meetings 
provided a free and frank exchange of opinions and review of treatment management 
practice enabling a decision to be reached that is usually agreed by all, or at least by 
most of the representatives.  
 
For this to happen the Pathologist needs access to microscopes that are attached to 
display screens to review the slides with the rest of the team and similarly the 
Radiologist needs access to a display screen as almost all of the Radiology 
Departments in the country now operate a digital service as they have Picture 
Archiving and Communication Systems (PACS) that have made films redundant. 
Organisations were not structurally ready to accommodate a multitude of MDTs, at 
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least one for each tumour group. MDT meeting rooms became a bottleneck, even if the 
specialist could accommodate the MDT schedule. The scale of investment required to 
enable an organisation to handle all MDTs operationally has not been published; 
something not really identified in most of the policy documents. Most organisations 
have evolved the infrastructure over the years; again there exists a huge variation as 
the minimum requirements for MDTs are open to interpretation and most often must 
compete with all other prevailing funding initiatives and demands. 
 
This in turn impacts on the demand versus capacity issue as the organisations are 
performance monitored on the uptake of MDT reviews. The infrastructure requirement 
was classed as an external factor, something neither this research nor the model could 
not resolve, but identified as a major dependency. The focus was then shifted to data, 
in their many forms i.e. availability, quality, relevance, usefulness, access, mode of 
transmission, reliability and validity, associated risks and most importantly, timeliness. 
To summarise, some of the issues that MDTs aimed to resolve were: 
 Non-uniform access to specialist care 
 Reporting of inadequacies in cancer services 
 Disjointed referral system 
 Large variation in frequency of individual treatments used, treating doctors’ 
caseload and patient survival 
 
4.2.4 Expressing the problem SSM2 for the MDT Model 
This phase focused on reviewing and consolidating the information gathered during 
SSM1 – defining the problem situation along with the requirements and work 
undertaken to establish the current state, including the information gained from the 
literature review. Fig 4.4 summarises the approach taken to illustrate and to sequence 
all the interrelated pathways, the interrelationships and interdependencies that exist 
between primary, secondary and tertiary sectors. In addition to this, illustrations also 
helped to define boundaries within which this research can be undertaken.  The upper 
section of this diagram represents the real word and the lower section the system 
world. The real world has five key players  
P – the patient  
A - representing primary care  
B – representing secondary care 
C - representing tertiary care and  
D - representing palliative care; this included hospices.  
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As mentioned, the primary objective of this was to identify a) the interactions between 
A, B, C & D and b) how P interacts with the service. It is important to stress that the 
research site was confined only to C for the development of the MDT model. 
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The problem situation was expressed using Rich Picture. Rich pictures, such as those 
represented in Fig 4.5 and Fig 4.6 were developed for defining the problems across the 
patient's care pathways (whole system). The idea of using drawings or pictures to think 
about issues is common to several problem solving or creative thinking methods 
(including therapy) because our intuitive consciousness communicates more easily in 
impressions and symbols than in words156. Drawings can both evoke and record insight 
into a situation, and different visualization techniques such as visual brainstorming, 
imagery manipulation and creative dreaming have been developed emphasising one of 
these two purposes over the other157,158,159,160. 
 
Fig 4.5 Photograph of the Rich Picture developed during the first workshop. 
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Fig 4. 6  Rich Picture:  presenting the problem. 
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Rich pictures are drawn at the pre-analysis stage, before it was clearly known which 
parts of the situation should best be regarded as process and which as structure. This 
was developed to help crystallize the process, the issues and activities within each, so 
as to piece together the current service configuration as described by the staff who 
delivered the service. This then helped to formulate the models to drive the 
methodology and framework that helped in turn to assess the business processes of 
the current cancer services, objectively develop problem definition, and establish the 
baseline.  
 
The Rich Picture presented in Fig 4.6 helped in defining the problem situation from the 
beginning to the end of the patient's journey, asking What, Why, Where, When and 
How for each segment that supported the patient's journey by service providers and 
established what data were available or were not available (missing or lacking). This 
assisted in understanding, supporting and substantiating the MDT service 
requirements, whilst highlighting gaps in the data collection. The exercise of mapping 
the pathway also helped to gain insight into the multi-professional perspective and to 
define issues, bottlenecks, constraints both external and internal to the care delivery 
system and also from other sectors e.g. pharmaceutical. All these could have either a 
direct or indirect impact on service delivery and on the perception of the service from 
the viewpoint of patients and external suppliers. Fig 4.7 is a schematic representation 
of this MDT mapping exercise. Although the focus of this research is circumscribed to 
developing an MDT model, the data required for this model are generated, handled and 
communicated from the wider operations; hence any mapping exercise involved a 
whole system approach.  
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Fig 4.7 Schematic defining the problem situation within the MDT workflow.  
 
4.2.5 Development of Root Definition SSM3  
Proceeding with the methodology in order to formulate the Root Definition, it is 
necessary to define a number of ingredients which are identified by the CATWOE 
mnemonic, namely Customers (who would be the victims or beneficiaries of this 
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system?); Actors (who would perform the activities?); Transformations (what input is 
transformed into what output?); Weltanshauung (what view of the world makes this 
system meaningful?); Owner (who could abolish this system?); Environmental 
Constraints (what in its environment does this system take as given?). 
 
By focusing on one specific problem (situation), one often stops looking for other 
problems, that is, when there is a risk of missing something that is potentially more 
fundamental than the problem being focused on. CATWOE helps avoid making serious 
mistakes by providing a simple checklist that when used appropriately stimulates open 
thoughts. In this specific context we have: 
 Customer   Patients   
 Actors Health care staff  
 Transformation 
process 
Modernisation programme 
 ‘Weltanschauung’ 
(world view) 
NHS Cancer Plan/ Calman-Hine  Report/Patients and 
Staff experiences 
 Owners Health care staff / commissioners and Patients 
 Environmental 
constraints 
DoH directives, Skill availability, Funding/ 
Organisational boundaries/ technical deficiencies 
The root definition for the MDT model  
“A system that facilitates improving consistency, continuity, co-ordination, 
communication and cost-effectiveness of managing patient data which in turn 
will contribute to improved clinical outcomes, survival, quality of life, patient 
satisfaction, enabling the service to become patient-centric, by establishing a 
process to replace the current paper driven system, by a semi electronic system 
that will aid the delivery of data/information required for treatment decision and 
recording of MDT outcomes whilst addressing the key issues of professional 
communication and access to specialist care.” 
The guidelines and directives provided a rich source that detailed the ideal state for 
cancer service delivery. The aspiration should be that given the availability of all 
variables and resources in the required measures, the system should be able to deliver 
effective, efficient, timely, and high quality cancer care to all its patients. These 
provided the ingredients for constructing a theoretical service model, but it was 
imperative that prior to any model development, an understanding of the real world 
configuration should be achieved.  
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4.2.6 Conceptual service models of the systems SSM 4 
A conceptual MDT model was developed from the Rich Picture created in stage 2. 
This, combined with the root definition defined in stage 3, helped to identify issues. The 
ideal world was defined using the documented evidence such as National Guidelines 
and what the services users aspired to, to deliver high quality care in a centre of 
excellence. This ideal world is referred in this thesis as What Good Looks Like (WGLL) 
see Fig 4.8. The conceptual model development took into account of these aspirations 
and along with appropriate enablers aimed to facilitate the transformation from the 
current to the intended state. 
 
Fig 4. 8  Photograph of the wall chart summarising the issues (in Pink) and appropriate 
enablers. 
The Rich Picture played a significant role in the development of the conceptual MDT 
model. It was pertinent that the MDT model, while addressing the critical issues of 
access to information, delays, communication and scheduling, does not over 
complicate the proposed solution.  The most significant, complex component of this 
model was defining the interdependence of many external organisations contributing all 
relevant patient specific data into a robust data repository. The other important 
component was to enable the system to schedule cases for review, to enhance and 
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provide a transparent and clear communication with greater visibility to all the relevant 
multidisciplinary teams. Chapter 6 provides a detailed account of model development. 
Following the presentation of the Rich Picture developed during the first workshop; the 
users were presented with an ideal scenario without the defined problem situation. 
Using the same techniques used to compile the Rich Pictures, user comments, 
suggestions, queries, concerns were captured along with the possible way forward to 
resolve or eliminate the problem situations using different coloured post-it notes (Fig 
4.9).  Yellow post-it notes were used to define the optimal state (vision), pink post-it  for 
defining issues/problems/concerns; and green for enablers-processes or new 
functionality required to resolve the issues identified as the problem.  
 
Fig 4. 9  Defining the ideal state by summarising the issues (in Pink) and appropriate 
enablers. 
 
The primary purpose of the conceptual service model was to define the interaction 
between the components and the role of MDTs within the system. This development 
phase highlighted the fact that it was impossible to change one or two components of 
the system without influencing other parts/components. Focusing on fixing one or two 
broken components and failing to consider the big picture could result in unintended 
consequences.   
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4.2.7 Comparison of model and real world SSM 5 
The conceptual MDT model was initially presented to the relevant MDT teams along 
with the Rich Pictures and the wall chart (Fig 4.9) that summarised the ideal/optimal 
future state. Established during the initial phase, this was used to provide a high-level 
comparison of the conceptual model against the real world to the multi-professional 
stakeholders. The users provided valuable feedback, which provided a significant 
opportunity to expand and enhance some component parts of the MDT problem 
situation, by reviewing the model against the Rich Picture so that critical design flaws, 
limitations, external and internal constraints could be identified, reviewed and analysed. 
The conceptual MDT model was subsequently fine-tuned and underwent a significant 
data modelling simulation exercise. This took place before the design and specification 
were signed off and was followed by preliminary testing of data exchange routine and 
customisation of the use interface to enable easy identification to help health 
professional review and prepare the cases prior to the meeting.  Chapter 7 provides a 
detailed account of MDT model validation. 
4.2.8 MDT Model based experiments SSM6  
The next stage focused on developing the proof of concept application in multiple 
settings, internal testing and fine tuning of the model, resolving issues, managing risks 
and capturing the future work flow and obtaining pre-deployment clinical sign off. 
Chapter 8 provides details of the Model Based Experiments. 
4.2.9 MDT Model deployment SSM7  
The proof of concept highlighted numerous operational inter-/intra- organisational 
deployment constraints that were not model-dependent, but might potentially affect 
model deployment across the patient's journey.  Hence, the decision was made to use 
the basic principle of the concept and scale down to deployment such as to meet the 
requirements of a single organisation. Chapter 9 details the deployment approach. 
4.3 Summary of Work flow Conducted to Assess the Cancer Patient Journey 
To understand the issues, bottlenecks and constraints that affected effective and 
efficient delivery of cancer services and to gauge the opinion of patients who received 
care from the local health care providers and to define any associated problems, it was 
critical to track the end-to-end patient journey through Primary, Secondary, and 
Tertiary, Community / Palliative and Hospice care. This involved starting from the point 
when a patient reports to their General Practitioner or to A&E up until the time when the 
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patient is either discharged from the hospital, to a hospice or back to the community 
and /or dies. Fig 4.10a provides a schematic of the compartmentalised patient pathway 
breaking the journey into various stages  
To facilitate this study a randomised, all-inclusive sample (not just patients who were 
later diagnosed to have lung cancer) was established. The purpose was to identify the 
similarities and differences between lung and other tumour groups. The work flow 
review looked at process, data and information pathways as shown in Fig 4.10b, 
paying particular attention to the practice of multidisciplinary clinics, team meetings and 
decision making. 
 
Fig. 4.10a Schematic of Patient pathway. 
 
It was important to gain a perspective of the users’ experiences and what their opinions 
and expectations were from the service. 
A detailed questionnaire (Appendix A) was used to collect qualitative data through 
structured interviews. Retrospective audits were conducted to substantiate the 
experiences of both staff as service providers and patients as users 
The mapping of the patient's journey audit  using structured forms, E.1,- E.3 shown in 
Appendix E, was repeated every time the clinical base was changed owing to career 
progression of the author, from North Middlesex Hospital, Edmonton, London, to 
Whiston Hospital, Prescot, Merseyside and then to the Christie Hospital, Manchester. 
This was necessitated by the differing service configurations in the three organisations 
and the period during which these reviews were conducted. During the time spent at 
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North Middlesex Hospital, a DGH providing acute care, the organisation was bidding to 
become a Cancer Centre, rather than being a Unit and was in the early phase of 
implementing the Calman-Hine recommendations.  
 
On the other hand Whiston Hospital, was a designated Cancer Unit, with a differing 
catchment population, different epidemiological profile, higher deprivation score and 
local social conditions and just further along in the implementation of the 
recommendations. Christie Hospital is a single speciality tertiary care Cancer Centre 
hospital, providing cancer care across geographical boundaries with a catchment area 
of over three million people. Irrespective of the differences, it was possible to review 
the service provision using the same framework and retain the Root Definition. As 
described in Chapter 2, patients usually see their general practitioner with symptoms, 
such as cough, chest pain, haemoptosis (coughing of blood), shortness of breath, 
symptoms of hypercalcaemia, malaise and anorexia. In smokers this may raise the 
suspicion of malignancy and the GP would either request a chest x-ray or refer the 
patient direct to a chest physician. Patients might alternatively go to the Accident & 
Emergency (A&E) Department where they would then be referred to a chest physician. 
 
A chest physician then carries out further investigations including taking a history, 
examining the patient, chest x-ray, bronchoscopy, CT scan, sputum cytology and 
occasionally percutaneous biopsy. At this point the patient will have a diagnosis of lung 
cancer and it should be possible from the investigations performed to have an accurate 
assessment of the extent of the disease and hence the appropriate treatment. 
Management of lung cancer is complicated and depends upon many factors including 
the stage of the disease, histology, age of the patient and other underlying conditions. 
The treatment modalities, as mentioned in section 2.10 (Fig 2.17), for lung cancer are: 
 Chemotherapy 
 Radiotherapy  
 Surgery  
 Radiotherapy & Chemotherapy 
 Surgery & Chemotherapy 
 Surgery & Radiotherapy 
 All three modalities 
 Palliative Measures 
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Fig 4.10b Schematic representation of Cancer Patient’s Journey. 
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Breaking the process down into its constituent stages allowed each to be examined in 
turn. 
Retrospective audits were undertaken (Appendix F) to quantify the timeline within the 
secondary care setting following referral. This study substantiated the views of those 
staff who had participated in the focus group discussions, suggesting that there were 
process and policy, as well as management, clinical, financial and technological issues 
that impacted upon the delivery of cancer services. Many of the external issues, such 
as lack of skilled radiographers, capacity in thoracic surgery, number of CT machines, 
linear accelerators, etc. were well recognised and documented161,31,162 with the local 
management having little control over these. However, some of the other issues played 
a significant role. These include: inter-professional, inter-sector communication, 
administrative processes, lack of robust management of local processes and staffing 
issues, lack of proactive monitoring and management of appointment 
systems163,164,165,166,167,168. Other factors were poorly designed IT systems, including 
impact of other numerous DoH and local initiatives and reporting requirements, often 
involving the same staffing group who are tasked with delivering operational 
efficiencies and service provision.  
 
A detailed review of the current operational processes was undertaken, using 
combinations of methodologies. This yielded an understanding of the reasons for 
adherence to all aspects of standard operating procedures (SoPs), policies, and 
protocols that govern the current service configuration. It also identified what worked 
well and what needed improving/ revising across the treatment pathway. The principal 
techniques employed included process mapping, action research involving focus 
groups, service questionnaires and soft systems methodology for a whole system 
approach. Other techniques that complemented the modelling methodology such as 
LEAN (Toyota Production System), Total Quality Management/ Continuous Quality 
Assessment (TQM/CQA) and Clinical Audit (snapshot review focused on addressing 
specific issues), were used to study specific pathways/ components and/or processes. 
The whole programme of work was managed deploying the PRINCE2 Project 
Management methodology for managing the programme of work. Techniques such as 
LEAN169,170 also referred as the Toyota Production system, is a management system 
refined by Eiji Totoda of Toyota Motor company, for problem solving, leadership, 
focused on improving production (efficiency by eliminating waste), operations, supplier 
collaboration, product and process development  and customer support.  
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This work also helped to develop the future state model consolidating knowledge on 
the interaction of process, data, and information. It enabled assessment to be made of 
demand versus capacity factors, appointments, booking and waiting list processes and 
issues, patient handovers, clinical practice of diagnostic testing, prescribing, data 
sharing and data quality. The value of information technology as a vital tool supporting 
operational processes was assessed, together with inconsistencies of systems, 
interfaces between various clinical systems, lack of electronic integration and data 
sharing issues between primary, secondary, tertiary, palliative, hospice and social 
services.  
4.4 Issues, Bottlenecks and Limitations 
The review highlighted that to a large extent the local health care services delivered 
good quality cancer care to the local population, whilst facing numerous operational 
difficulties, some acting on the system, others acting from within the system. There 
were some common issues and constraints observed in all three clinical bases and 
supported by the data analysis. It should be emphasised that issues such as shortage 
of staffing, equipment and funding were known constraints among various authorities, 
professional groups like the Royal Colleges, who have published interim guidelines to 
deal with these issues171,172,173,174,175 that are well documented and acknowledged by 
the service providers.  
 
4.4.1 Service planning 
The key observation made during the charting of the patient journey was that there 
were areas where the lack of a clear operational service plan contributed to the service 
being reactive; then there were delays caused by both extrinsic and intrinsic demand 
on the system. External factors impacted on the optimal service provision i.e. access to 
thoracic surgery and surgeons176, and the availability of thoracic surgeons at MDT 
meetings177 The provision of CT scanners improved following the National Cancer Plan 
(NCP), but with growing demand access to CT remained problematic. The shortfall of 
highly-skilled staff as documented in the Wanless Report178  directly affects operational 
services. In addition to all these the service as a whole is constantly dealing with new 
policies from the Department of Health (DoH) aimed at service improvements, 
standards, guidelines and targets as summarised in Fig 4.11. 
This led to managing services on the margins, often putting enormous pressure on the 
various professional teams. The intrinsic issues identified are inherent to the current 
configuration where care is delivered as a series of interventions, with multiple 
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professional referrals, appointments and visits to radiology, pathology and 
radiotherapy. Patients are often under the care of multiple consultants, nursing and 
allied health professionals, with no one person or team responsible for the patients 
from start to finish. 
 
Source: Are we choosing Health? Audit Commission report, July 2008.  
Fig 4.11 Key policies with impact on the health of the population 1997 – 2007.  
 
This traditional, segmented pathway led to each department being responsible for its 
management and meeting its responsibilities. Thus the outpatient department 
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concentrates on managing referrals, waiting times and making sure every patient 
meets the two weeks’ target. Diagnostic departments such as pathology (Fig F.103 & 
F.105 in Appendix F) and radiology are focused on the turnaround time, managing 
urgent and routine referrals. The pharmacy focuses on the monitoring of prescribing 
patterns of the oncologist for high cost chemotherapy drugs, turnaround time (Appendix 
I) etc. All this resulted in a management system lacking reciprocal operation within 
specific departments and with other service providers. Overall, this current system is 
management-centric and not patient-centric. As a result, the study identified a number 
of operational issues.  
 
4.4.2 Communication 
Communication179,180 between professionals and within sectors was another 
contributing factor affecting the system. The issue was that professionals were 
frequently not receiving the information that was useful in relation to the provision of 
care. This was a known issue, with numerous reports emphasising the need for good 
clinical communication. These ranged from the “Tunbridge Report on Medical 
Records181” in 1965 to more recently “Improving communication, the exchange of 
information and patient care: suggested guidelines for secondary care doctors and 
GPs182.  
Various programmes and initiatives, instigated over the years, have improved 
communication and collaboration between the professional staff, defining and 
designing data collection forms and proformas, simplifying and streamlining channels 
of communication and making better use of appropriate technology i.e. fax, electronic 
systems etc. However, this has not resolved the issue of effective communication 
across the health boundaries i.e. primary /secondary/tertiary and between 
professionals, ranging from inadequate handovers to sharing relevant critical clinical 
information. 
Poor communication between the primary and secondary care sectors acknowledged 
in the Lung Cancer Service Improvement Guide is an issue often attributed to 
inefficient systems that require repeated data entry and capture of basic administrative 
and clinical data exchanged between the sectors. This causes unnecessary delays in 
routing the referral to the right person, absorbing valuable time of administrative and 
clinical staff and patients.  
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Communication issues between health care professionals and patients were not just an 
issue within the NHS; the literature review also identifying examples from United States 
of America183.  The national reports and publications from the National Audit Office184 
have all stressed this to be a key issue. 
4.4.3 Scheduling 
Scheduling patients for various appointments across multiple departments was another 
instance of services not being joined up, requiring departments to operate individual 
booking/appointment systems. This resulted in patients needing to wait for 
appointments from different departments, prior to the confirmation of the diagnosis and 
while on a treatment, revisiting the hospital many times on different days for a series of 
diagnostic tests. The audit revealed instances where patients had received two 
appointments for two different services within the Radiology Department on the same 
date and at the same time, resulting in the patient having to cancel one and then 
needing to revisit the hospital for the cancelled appointment; or when patients were 
given appointments by two different departments at the same time on the same day.  
The clinical culture of repeating some of the diagnostic tests, for tests carried out in the 
earlier units, introduced additional delays. In some diagnostic departments the lack of 
skilled staff had an impact on the department being able to operate at full capacity. 
Result reporting and the availability of results in a timely manner was an issue on a 
day-to-day basis in the outpatient clinics. This is more so in oncology as the patients 
need to undergo routine blood tests in order to assess their fitness to receive 
chemotherapy. 
The common bottlenecks for lung care patients were: 
 waiting for imaging- CT/MRI/PET scanning (although CT access has improved 
in many areas)  
 availability of radiotherapy – time to radical RT; problems implementing 
CHART185. Although a number of new linear accelerators have been installed 
over the last seven years the National Radiotherapy Advisory Group (NRAG)186 
report calls for a significant increase in radiotherapy capacity 
 access to thoracic surgery 
 provision of surgical expertise 
 referral time, waiting time for investigations, 
 willingness of medical professionals to refer appropriately to colleagues 
 availability of chemotherapy 
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 availability of palliative care 
In short the three key issues to be addressed in the delivery of care for lung cancer 
patients were: 
 the provision of a rapid, efficient and effective service to deliver the appropriate 
medical or surgical management in each case; 
 the investigation of important medical and scientific issues in order to improve 
management of cancer patients; and 
 identification and implementation of appropriate preventative measures. 
4.5 Summary 
This chapter has summarised the work undertaken to define, understand and 
objectively identify the baseline required to establish a multidisciplinary team model. 
The detailed process review involved following the patient, data, paper, and information 
work flows. This work has highlighted what data were available that helped to 
understand, support and substantiate service review, whilst highlighting the gaps in 
data collection. The next chapter will go on to consider the issues associated with data 
collection. 
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5 DATA COLLECTION 
5.1 Introduction 
Data collection was driven by the need to assess and establish a baseline for, and to 
substantiate, the current service performance as described by service providers; to 
define the service patterns, clinical outcomes, survival, and types of data collected, 
gaps and quality of the data. It is important to state the issues experienced in obtaining 
data. The author started this research with the intention of developing a tool-kit, a 
mathematical model to enable NHS managers to define, design and evaluate a service 
model for oncology. This would then enable them to deploy a service model that they 
knew would work or at least give managers great visibility as to the issues, gaps and 
changes required.  
As soon as data collection and the investigation for data sources was started, two key 
issues became apparent.  
 Access to data from various organisations  
The significant issue was gaining access to data from the organisations along the 
patient's pathway. The major constraint was surrounding the data sharing 
arrangements between the various organisations within the NHS (secondary care 
Trusts, PCTs {GP Practices}) and between the NHS and social services. This was 
predominantly because individual organisations claimed ownership or felt that they 
were the custodians of the patients data; patients who were seen or treated under their 
care. Access to original data sources proved extremely difficult even with the approval 
of local Ethics Committee. Access to anonymised data was provided but this did not 
have the complete data set required for this research, hence access to individual 
medical/case notes was vital which was denied. 
 All existing data repository systems in the organisations approached were 
largely designed to collect administrative data with only a small sub-set of 
clinical data (Table 5.1).  
As mentioned earlier, anonymised data laws were largely composed for administrative 
data and as such were very limited, providing data on organisation code, disease, 
referral, appointment, treatment, procedural date, etc. Some had date of diagnosis but 
the time line was restricted to that particular organisation; there was no visibility of data 
continuum i.e. from primary to secondary care. The third issue was that where access 
to medical notes was provided it became apparent that either data had not been 
collected or else the recording of data was inconsistent. So on some records the 
relevant clinical data items were recorded or could be gleaned from reading the 
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annotations, letters, results etc, but in other instances these were not recorded. The 
practice depended on who was recording the data.  
Data 
Required 
MDT Data set 
Data Source 
Available 
from 
anonymised 
data set 
Available 
from Data 
Source 
NHS Number  A NA  
Hospital number  B/C   
Organisation Code  A/B/C   
MDT Tumour group  B/C   
Surname  A NA  
Forenames  A NA  
Patient address at diagnosis  A NA  
Postcode of address at diag(Area lives now-MDT)  A   
Sex  A   
Birth date  A   
Diagnosis date
 
A
 ( when 
recorded)
 ( when 
recorded) 
Primary diagnosis
 
B
 ( when 
recorded)
 (when 
recorded) 
Tumour laterality  B   
Histology / Type of cancer  B    
MDT Discussion indicator  B/C   
MDT Discussion date  B   
Care plan agreed date  B/C   
Recurrence Indicator  B/C   
Cancer care plan intent  C   
No cancer treatment reason  C   
Co-morbidity indicator description  A/B/C   
Co-morbidity indicator value  A/B/C   
Performance status  B/C   
Stage T or relevant classification
 
B
  (when 
recorded) 
Stage N or relevant classification
 
B
  (when 
recorded) 
Stage M or relevant classification
 
B
  (when 
recorded) 
Stage - site specific staging classification
 
B
  (when 
recorded) 
Grade of differentiation  B   
Cancer vascular or lymphatic invasion  B   
Excision margin  B   
Nodes examined number  B   
Nodes positive number  B   
Consultant  B/C   
1st appointment date  B/C   
Key worker  B/C   
Hospital (MDT use referring Hospital)  B   
Pre / Post treatment  B/C   
DecisionToTreat date - days remaining  B/C   
View referral symptoms  B/C   
Investigations  B/C   
Treatment - date of surgery (link to op note)  B/C   
Treatment - procedure  B/C   
Treatment - treatment intent  B/C   
Clinical Trial status  B/C   
Pathology - report date  B   
Photographs obtained  B/C   
Table 5.1 MDT data set and organisation generating the data187 
A= Primary Care, B= Secondary care (cancer Units) and C= Tertiary (Cancer Centre) Hospitals 
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Such variations did not facilitate retrospective analysis of data to establish trends or 
even to develop a baseline. Hence developing a mathematical model to address 
clinical workflow, without clinical data, proved challenging and had to be abandoned. 
As stated above access to data from other NHS organisations was not straight 
forward188, especially for anonymised clinical data requested from non-clinical NHS 
staff. Tracking patients across primary, secondary and tertiary care required contacting 
numerous GP practices where the patients for the required sample size were 
registered. The procedure to obtain data from secondary care, i.e. District General 
Hospitals, was quite complicated. Secondly, when successful, the data made available 
were limited, with no clinical data that could as they stood be used in modelling. For 
example, data were required in order to undertake:  
i) Discrete-event simulation, where the dependent variables are actors in, or are 
developed by, the system. In health care systems these can include patients, 
providers, carers, administrators, inventory, capital equipment, etc. The independent 
variable is time. In this type of simulation, it is expected that events takes place at 
discrete points in time (e.g. the arrival of two patients at the reception, one at time t1, 
the second at a later time t2). A key aspect of a discrete-event simulation is the 
system-state description, which includes values for all of the variables in the system. If 
any variable changes, it changes the system state. In a simulation, the dynamic 
behaviour of the system can be observed as entries (e.g. patients, staff inventory) as 
they move through the nodes and activities (e.g. Reception desk, nurse review, clinical 
consultation, laboratory test, etc.) and are identified in the model. The rules governing 
the motion of the entities and the paths they follow are peculiar to the specific model 
and are specified by the modeller. Describing systems that involve human interactions 
requires the use of mathematics based on probability theory and statistics, which can 
describe the variability and discrete nature of the event.  
Data play a vital role in understanding system behaviour and its ability to meet future 
demands. Large databases can provide the basis for addressing system-wide issues in 
health care. Information in databases can reveal relationships that are not obvious from 
an examination of a smaller number of instances, by using data mining techniques. 
Four kinds of information can be extracted from databases:  
 Classification data: characteristics that suggest a high probability that a 
patient will develop lung cancer by a given age 
 Estimation data: if the rate of change in potassium exceeds a defined limit, 
the patient may be at increased risk for arrthymias 
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 Variability data: identification of variations in the prescribing habits of 
clinicians or sutures used by surgeons 
 Predictive data:  the likely number of deaths from a given illness or condition 
Once a set of independent variables are identified the analysis can then continue to 
determine the relationship to a dependent variable: 
 Is a patient with symptoms X and Y likely to develop symptom Z? 
 What is the effectiveness of an X-ray for the screening of lung cancer 
symptoms? 
 Is there evidence that patients taking a given combination therapy regimen A 
and B are more likely to have a given side effect? 
 Is there a predisposition for a particular age group to have specific 
conditions? 
The main focus of this research started with identifying data requirements for 
developing the MDT Model.  As the MDT model depended on efficient operational 
processes, the data gathering and review processes used the service review model 
(Fig 4.2), described in Chapter 4. This allowed definition and identification of the type of 
data, the source where the data were held and the availability of existing data that 
would establish current service provision, access, the quality of the service, 
measurement of basic metrics and profile outcomes. 
Data were categorised into: 
Epidemiological data – that helped to assess incidence, prevalence, mortality, 
survival and co-morbidity associated with cancer.  
Operational Data – those that provided factual details on the number of patients 
treated by various organisations, identified patterns, geographic catchment, trend 
analysis, measures of demand, and capacity.  
Service Quality – data that help in reviewing the quality of service provided to 
individuals and groups of patients and commissioners. 
Clinical Outcome – data that help individual clinical staff or teams to review their 
performance, highlighting strengths, weaknesses and opportunities. 
Organisational performance – targets and overall performance data such as HES 
Data and Dr Foster189. 
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 Having defined the data requirement, the next stage defined the data sources, 
mapped the flow of data, and the various data exchange points across organisations 
and between the various legacy systems. 
5.2 Data Source and Methodology 
Data for this research were originally planned to be collected from primary, secondary, 
tertiary, community, private, and social services. In the end data were collected only 
from secondary and tertiary sources as the other agencies declined to participate due 
to the nature of the service configuration. The Cancer Registry provided data on the 
local epidemiology that was detailed in Chapter 2. It was essential to collate data from 
each sector and organisation in each sector, but due the organisational boundaries, 
operational data were considered to be confidential and sensitive; hence limiting 
access to historical data. 
Data for this research were obtained mainly from secondary care service providers, 
Cancer Registries, the audit department, and from personal data collection using 
questionnaires and proformas (see Appendix E). Epidemiological data were gathered 
from various annual reports obtained from the Cancer Registries190,191,192,193 public 
health reports194 and World Health Organisation reports. Operational/service data were 
mainly obtained from acute hospital information departments and/or from departments 
e.g. radiotherapy staff provided significant clinical data that information departments 
were not collecting. Clinical trials provided basic data on patients, who were enrolled in 
trials, but as most of the trials were active, data were locked; hence only limited data 
were made available. The audit departments shared valuable data on service quality 
and good practice. These proved to be very valuable as they provided a snapshot of 
service quality. As there were year-on-year audit data on some data such as 
chemotherapy drug wastage, both structured and semi-structured questionnaires were 
developed to review workflow and feedback from user experience. These formed the 
other significant data source. To summarise, the following were the sources: 
 Information departments and audit departments in secondary care units, 
 Service department e.g. radiotherapy,  
 Thames Cancer Registry, 
 North West Cancer Intelligence Service (formerly North West Cancer Registry), 
 Office of Population Census and Survey (OPCS), 
 Hospital Episode Statistics, England, and 
 Dr Fosters. 
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5.3 The Nature of Available Data 
Considerable effort is invested in capturing large quantities of data within primary, 
secondary, and tertiary care, although it is difficult to ascertain the minimum core data 
needed to make service planning decisions195. Primary care services were unable to 
provide either administrative data, data that helped to define the patient demographics 
(i.e. age, sex, post code, occupation, social factors etc), or clinical data (i.e. onset of 
illness, co-morbidities conditions, lifestyle factors e.g. smoker etc.) either due to 
confidentiality or lack of local informatics provision and organisational boundaries.  
Hence primary care data were collected, where available, from referral information and 
to some extent from the Cancer Registry. As the exchange of referral information 
between primary and secondary care was paper-based, it depended on the data clerk 
in the receiving organisation transcribing these data accurately onto the host system. 
Referral data forms from GP surgeries were often incomplete; hence data were not 
available for secondary or tertiary units to populate this information. 
Often owing to the operational pressure at the secondary/tertiary level, only the 
mandatory data were recorded on the hospital Patient Administrative Systems (PAS). 
Moreover some PAS systems did not have the relevant fields for recording clinical 
information that were populated in the GP referral forms. Within the secondary care 
systems, data were held in disparate systems often in stand-alone databases 
developed for a specific purpose. These database structures and data entries did not 
adhere to, or conform to, standards prescribed by the information department and data 
standard authorities. Analysis of data from these stand-alone systems often required 
data cleaning and triangulation to obtain meaningful information. Predominantly the 
systems in secondary care systems were set up to capture administrative data, 
although there were clinical systems that had the ability to capture clinical data.  
By and large the focus of the information departments was analysis of administrative 
data, geared to meeting reporting requirements, requested by the DoH, such as the 
Common (Minimum) Data Set (CDS). Over the last few years the needs to provide 
cancer data sets to the Cancer Registries saw the advent of dedicated databases 
being set up, such as the British Association of Surgical Oncologists (BASO) database 
for breast cancer, Data for Head and Neck Oncology (DHANO), Lung Cancer Audit 
Data (LUCADA) etc. to capture site-specific tumour data. These are reported on an 
annual basis to the Cancer Registries.  Large pockets of clinical data lie hidden in 
paper records and of late are being captured in an electronic format, generally to be 
used for audit and/or research purposes. Aspects of clinical data are being analysed to 
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feed into service/ financial decisions such as high cost chemotherapy drugs and 
radiotherapy activity, including treatment details, i.e. number of fractions, exposure 
duration etc. These two key elements go toward informing the commissioners of the 
level of funding they will require for their local population based on the incidence and 
prevalence, generally termed as Burden of Disease. 
5.4 Data Collection 
Epidemiology data for national, regional and local populations were collected by 
accessing the respective Cancer Registry annual reports (referenced earlier) and the 
international cancer statistics databases such as Globocan196. As mentioned earlier, 
the primary focus of the data collection was to define and understand current service 
provision, to enable a new MDT service model to be formulated by estimating current 
demand, quantifying trends, quality of service and efficiency. Data for establishing the 
Burden of Disease, along with the underlying mortality and morbidity scale, were 
collected to help establish the likelihood of future demand for cancer services in the 
local population.  
It was also possible to evaluate whether the current service provision could and would 
cope with current and future demand. In addition to reviewing available data, the 
missing data items were collected by undertaking multiple snap-shot audits such as to 
learn about the referral routes, time-scales, appropriateness and delays etc. from 
primary to secondary care units. This followed tracking the patient journey within the 
secondary care facility, with a view to establish type, duration, unit cost and cumulative 
cost per episode of care. It became quite apparent that administrative data such as 
FCEs (Finished Consultant Episode) were used to assess activity, length of stay/ bed 
occupancy and thus were used to define throughput. No data were available on clinical 
outcomes, tumour stages at first presentation, etc.  
 
A preliminary review of the data extracted from various information systems revealed 
numerous gaps and /or lack of data in relation to some part of the pathway. This was 
especially true for measuring the time taken for a patient to move from one stage of the 
journey to the next. This was purely because, as mentioned above, historically the 
information systems were designed to record and report on administrative data such as 
CDS (Common Data Set), HES (Hospital Episode Statistics) etc. to the DoH.   
 
Review of the site-specific databases i.e. BASO for Breast cancer; DHANO for Head 
and Neck; LUCADO for Lung etc. demonstrated that both in secondary and tertiary 
care the data sets were often incomplete for most patients. Data flow from primary care 
to secondary care was marginally better when compared to the completeness of 
PhD Thesis         Bala Sridhar 
 
Page 84 
 
primary care data in tertiary care. The quality of data from secondary to tertiary care 
was also very limited with major gaps in recording key data items such as date of 
diagnosis, confirmation of diagnosis and staging; vital in order to follow patients’ 
progress along the cancer journey. Table 5.2 below illustrates the quality of treatment 
modality data that were recorded, revealing the problems within routine data capture 
process. In 22% of the samples there were no records of treatment within the case 
notes, one cannot assume this was because of co-morbidities especially Chronic 
Obstructive Pulmonary Disease (COPD).as there was no entry of this in the notes.  
Local re-audit revealed similar result (see Fig F.40, F.48 Appendix F). 
Treatment Modalities Patients % 
Chemotherapy 20 7% 
Radiotherapy 75 26% 
Surgery 14 5% 
Radiotherapy and Chemotherapy 23 8% 
Surgery and Chemotherapy 0 0% 
Surgery and Radiotherapy 4 1% 
All three modalities 1 0% 
No treatment recorded 63 22% 
Death Certificate Only 91 31% 
TOTAL 291 100% 
Table 5.2 Lung cancer- Distribution of treatment modalities, 1992 
The issue with recording data is further substantiated by published work in 2007 see 
Table 5.3 that highlighted the number of records without no treatment recorded 58.1%. 
Treatment Modalities Patients % 
Chemotherapy 1472 9.8% 
Radiotherapy 1999 13.3% 
Surgery 968 6.5% 
Radiotherapy and Chemotherapy 1501 10.0% 
Surgery and any other therapy 291 1.9% 
Other Treatment 52 0.3% 
No treatment recorded 8705 58.1% 
TOTAL 14988 100% 
Table 5.3 Treatment of Lung cancer patients, North West 2003-200534  
 
Data from palliative services and hospices were virtually unobtainable. Cancer 
Registries were the only source, but the quality of data was very limiting as most of the 
organisations’ data submission reflected the established data capture procedures and 
processes. Snap-shot audits substantiated the presence of the issues, the scale of the 
issues and their likely impact to be established. 
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5.5 Data Flow 
To obtain a better understanding on how data moved along the patient journey, 
between the various sectors, a separate data flow mapping was undertaken (Fig 5.1).  
Fig 5.1 is a schematic representation of the data flow pathway incorporating both paper 
and electronic records. The aim of this schema was to capture data flow irrespective of 
the format. This schema also helped to identify who did what, where, when, why and 
how. Some organisations had a different data/information pathway (Fig 5.2). The 
significant difference with this workflow was that the data collection system had clearly 
identified the responsible staff to ensure data were captured at source. 
The study focused on differentiating between administrative and clinically important 
minimum data between the various professionals to identify the movement of clinical 
data/information across the various health sectors and between professionals. The 
data exchange was base-lined using the lung cancer minimum data set. This 
highlighted issues such as poor data recording practice, lack of a simple and easy to 
use data recording systems, clear role definitions with responsibility for data recording, 
constraints, bottlenecks in the current service framework. It also highlighted problems 
posed by the lack vital clinical data at the point of care along the patient journey and 
their impact on service provision.   
The data flow within the secondary care system with multiple data capture systems, 
some integrated and others stand-alone systems, required repeated data entry and the 
transcribing of data from paper and proformas, by a range of interdisciplinary staff. 
5.6 Data Analysis 
5.6.1 Background  
The Christie Hospital NHS Trust is a tertiary cancer centre, based in Manchester 
serving 3.2 million people across Greater Manchester and Cheshire. The local health 
economy includes 11 primary care trusts (PCTs) and 15 other acute and mental health 
trusts. The PCTs are mainly co-terminous with city and borough council boundaries 
across the Greater Manchester and Cheshire Cancer Network. The local health 
economy is part of the North West Strategic Health Authority which serves the health 
needs of 6.7 million people.  
The NHS North West has three tertiary cancer centres: Clatterbridge Oncology Centre 
on the Wirral, the Rosemere Centre in Preston and the Christie Hospital, which is the 
largest. There is also a radiotherapy unit in Carlisle, run by the North Cumbria Acute 
Hospitals NHS Trust. Based on the estimated number of new cancers each year, the 
Christie's share of the potential market is currently 77% of all new patients within the 
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network, 43% of all new patients across the North West, and 5% of new patients 
nationally. 
5.6.2 Current Activity (Operational data) 
Based on 2005/06 data Christie treated 9,830 new patients, provided 79,878 
radiotherapy fractions (measured doses), 32,756 chemotherapy treatments and carried 
out 2,938 surgical operations.  85% of new patients were from within the Greater 
Manchester and Cheshire Cancer Network, 11% were from outside the network but 
within the North West and 4% were from other parts of the country and abroad. In the 
same year, Christie treated patients from 224 primary care trusts across the UK. The 
main local commissioners were the 11 primary care trusts in Greater Manchester and 
the eastern part of Cheshire. 
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Fig 5.2 Data collection model incorporating inter-professional workflow 
 
In addition to this, significant contracts are held with primary care trusts in other parts of 
Cheshire, Merseyside, Cumbria and Lancashire.  Christie also holds a contract with 
Healthcare Commission Wales. Christie has 257 beds including six critical care beds 
and 49 patient chairs for inpatient, day case and outpatient treatments. There are 
seven wards and one day ward, three surgical theatres and one radiotherapy theatre. 
This includes a specialist adult leukaemia unit and young oncology unit, which is one of 
only eight dedicated teenage cancer units in the country.  Christie provides services in 
three main categories: 
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 Radiotherapy – the use of fractions (measured doses) of radiation. Treatment is 
usually several small doses over a specified period of days or weeks, but can 
also be given in a single treatment. Treatment covers both radical (curative) and 
palliative radiotherapy. 
 Chemotherapy – the use of drugs to treat cancer, usually delivered as several 
treatments over a number of weeks.  
 Surgery – highly complex surgical procedures, with a range of specialties 
covering colorectal, upper gastro intestinal, ear, nose and throat, 
urological/pelvic and gynaecological cancers, together with plastic and 
reconstructive surgery.  
Clinical support services is provided by a radiology department with three CT and two 
MR scanners and pharmacy, pathology, psychological medicine and rehabilitation 
services. Christies also provide specialist endocrinology services and private patients. 
Christies currently have 1,177 patients entered into 368 clinical trials 
Treatment 
modality 
Inpatient 
spells 
Day 
case 
spells 
Outpatients 
treatments 
Outpatients 
new 
Outpatients 
follow ups 
Chemotherapy 4,664 1,711 24,497     
Radiotherapy 1,463 779 67,527     
Oncology / 
supportive 
work 
5,169 4,128   6,796 42,055 
Transplants 97         
Total 
oncology 
11,393 6,618 92,024 6,796 42,055 
Surgery and 
critical care 
1,432 1,210   2,070 7,816 
Endocrinology 75 1,136   809 2,997 
Clinical 
genetics and  
mental health 
      399 647 
Grand total 12,900 8,964 92,024 10,074 53,515 
Table 5.4 Actual and projected patient activity  
 
Please refer to Appendix G for the detailed analysis of the operational/service data. 
5.6.3 Review of cancer pathway and MDT data  
There were no operational data readily available to assess the average time it took for 
patients diagnosed with lung cancer from referral to discharge or death. The lung 
pathway audit carried out soon after the publication of Calman-Hine Report in 1996 
was taken to be the baseline at the start of the research. This audit was carried out by 
the author when employed at New River Health Authority (1995 -1997) as part of the 
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local Calman-Hine Review Team. A total of 135 patients were eligible, but it was only 
possible to track 93 patients’ case notes; of these 67% related to males and 33% 
females; 47% of patients were referred by their GP, 10% were seen at A&E and then 
referred to oncologists, 9% were from other hospitals. However, 20% were internal 
referrals primarily referred by a GP to a chest physician and/or other consultants, 
hence were deemed as inappropriate referrals. For 14% of the sample relevant data 
were not available. Specialists saw 47% of patients within two weeks; for 20% of the 
patients data were recorded in the case notes. 32% patients were seen outside the 
recommended time scale of two weeks. Following the first review, only 18 % of the 
patients received a treatment decision within two weeks; 39% of patients did not have 
these data items recorded in their case notes.  The overall timeline is summarised in 
Fig.5.3. Detailed analysis is attached in Appendix F.  
 
Fig 5.3 Baseline patients’ cancer journey timeline. 
A similar audit was conducted again in 1998 and re-audited in1999. This audit was 
objectively measured against the guidelines, both in 1998 and in 1999. The 1998 audit 
identified a number of shortcomings. An action was pulled together along with an 
implementation timescale. The audit was repeated in 12 months, which showed that 
the actions implemented were effective by and large except in some aspects showed 
the actions implemented were effective by and large except in some aspects of the 
referral pathway. This was attributed to short staffing. This stage of the implementation 
of the Calman-Hine recommendation was having significant impact on the service197. 
Amongst the significant observations established by this audit was that healthcare 
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professionals were not recording relevant decision points, thus hindering objective 
assessment of performance. A good example of this is when the decision-to-treat time 
line was reviewed. 
 
Fig 5.4  Operational audit of patients’ cancer journey timeline 
 
It was not possible to establish the timescale from first visit to treatment for 36 patients 
(38%) as there was no record in the case notes.  
 
5.6.4 Audit of result review and acknowledgement 
Similarly, another audit of case notes (n=309) to establish the availability of diagnostic 
results revealed that only 123 (39%) had CT reports filed (not in date order) in the 
notes, of which less than 10% were signed by clinical staff. Equally less than 10% of 
the full blood count (haematology test) results were found in the case notes with 1.75% 
signed by clinical staff. The reason for not filing reports in cases was attributed to two 
key factors. The first was that results were available in electronic format from the lab 
system, although multiple paper copies were still printed and distributed to all 
clinicians. The second was the non-availability of filing clerks, re-assigned to other 
roles following the introduction of electronic results. However patients were seen by the 
clinical team in peripheral sites/clinics with no access to the hospital information 
system and hence totally reliant on the paper case notes. This disjointed approach to 
service configuration highlights the risk of implementing service improvement initiatives 
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without proper consideration of the overall system and the fact that some projects and 
programmes are still effectively working in silos. 
 
 
5.6.5 MDT Audit. 
An audit carried out to assess the role of MDTs and their impact on clinical 
management of lung cancer patients revealed that although only 48% of the patients 
had been discussed at the MDT meeting (the target was 95%), there was a notable 
change to the number of patients routed for surgery with resection rates going up; 
similarly for chemotherapy. Also some vital clinical status information were 
captured/updated (Fig F.39 Appendix F) Published studies have also reported an 
increase in resection rates post introduction of MDTs198 from 4% per MDT to 18% for 
all patients and 24% for Non-Small Cell Lung Cancer (NSCLC) patients post the 
introduction of the MDT.  Data presented at the First National Lung Cancer 
Workshop,16-17th April 2002199, indicated that in Leicester surgical resection rate pre-
MDT (1996) was 5.8% and post-MDT (2001) was >16% (Fig 5.5). Similarly the 
percentage of NSCLC patients receiving chemotherapy increased from less than 5% to 
approximately 30% over this same 5 year period. To ensure that this was not an 
anomaly, a review of published audit reports was performed. There were three relevant 
audits published:  
i)  the first in July 2004 titled “Tracking” of New South Manchester 
University Hospital Trust Lung Cancer Patients: Problems and 
Challenges; 
ii)  the second  also during July 2004 titled “North West Regional Audit of 
the Treatment of Lung Cancer by Thoracic Surgeons” July 2004, 
presented at Regional meeting; and 
iii)  the third titled “Non-surgical treatment of lung cancer” reported in 2007 
at the Christie  
All three audits were reviewing the management of lung cancer across the Greater 
Manchester Cancer network. It was surprising too that only one had mentioned MDT 
meeting data as a criterion, but no data were presented, although all three reviewed 
the treatment decision and treatment pathway. This was even though regional 
performance data published indicated that most patients were being discussed at the 
MDT. Reports from the North West Cancer Registry revealed absence of data from 
many local organisations (Appendix J).  
This was mainly attributed to poor data collection and recording processes, 
compounded by lack of staff and systems to capture MDT data at the secondary units. 
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Centres like the Christie are reliant on Cancer Unite to provide these data. A report 
published by the National Audit Commission200 in 2002 identified a number gap, 
although the review focused only on non-clinical data. It was thought that this would be 
straight forward, but it was found that some trusts could not demonstrate even the 
administrative data to be reliable.  
Limitations: owing to the sensitivity of sharing confidential and vital business data, 
some sectors declined access to, and use of, their data for general analysis. This was 
particularly true for GP surgeries and PCTs, hence many of the data, where available, 
were gleaned from secondary sources. 
 
Fig 5.5   The impact of MDT on clinical practice. 
MDT data flow added another dimension to the data flow as the first/ presenting MDT 
meetings for some tumour groups were hosted in the cancer units. Medical and clinical 
oncologists, radiologists and surgeons from the cancer centre attended these meetings 
at the cancer units. Most of these patients are then seen at the cancer centres. Data 
flow was segmented as quite often the data recorded during the first/presenting MDT 
meetings were held locally at the District General Hospitals (DGH). Subsequent review 
MDT meetings took place at the cancer centre, following patient referral to tertiary care, 
fragmenting the data even further. There was no routine, guaranteed exchange of data 
recorded during the MDT meetings between the cancer unit(s) and cancer centre. 
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Source: Greater Manchester and Cheshire Cancer Network Report 2010. 
Fig 5.6   Patients discussed at MDT meeting across the Greater Manchester Cancer Network201  
 
The current operational MDT configuration provided maximum flexibility and ensured 
some degree of continuity of care for the patients, but lack of a supportive data 
collection system led to clinical staff relying on the use of the existing data collection 
framework. These systems were not designed to share data across organisations as 
the primary focus was to serve the local organisation. 
 
The NHS Information Authority was set up in 1999. It convened a working group to take 
forward the work already undertaken by specialist groups and Cancer Registries and 
was tasked with defining and developing a generic national cancer dataset template. 
The template was to enable service providers capture details of care provided to each 
patient along the cancer pathway. Individual organisations were mandated to submit 
data (Appendix I) in the prescribed format on the care provided to their respective 
Cancer Registry. The Cancer Registry collated, reviewed, cleansed and created a 
single patient incident202. However, as the reports demonstrate, organisations were not 
adhering to the format prescribed, thus failing the quality check. As shown in Table 5.5, 
organisations in general have established support only for peer reviewed MDTs as they 
were part of the target used to assess an organisation’s performance.  The non-peer 
group MDTs are not well supported within organisations. Cancer units host peer review 
MDTs for common cancers, whilst cancer centres do so for the rarer cancers.   
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MDT Meeting Day Time Frequency MDT Cover
Colorectal / PMP Monday 8am W 8 n/a Yes
Tuesday 8.15am W 8 No max Yes
Lymphoma - Radiology Tuesday 8.15am M 6 n/a No
Joint Endocrine 9.30am Q ? ? No
Palliative Care Tuesday 12.30pm W n/a n/a Yes
ALU Tuesday 12.30pm W ? ? No
Neurology Tuesday 1pm W 5 n/a No
Endocrine Tuesday 1.15pm 1 every 2m 5 n/a No
Melanoma Tuesday 4pm M 5 5 No
GU Weds 8.15am F 6 ? No
GU Weds 12.30pm W 6 ? Yes
Haematology Weds 3pm W n/a No max Yes
GIST Weds 4pm Q 3 No
Thurs 8am W 8 + 8 No max Yes
Breast Thurs 8.15am F No
Gynae Thurs 12.30pm W 7 No max Yes
Lymphoma - Pathology Thurs 1pm F n/a ? No
Thyroid Thurs 5pm F n/a No max Yes
GI Friday 8am F 8 n/a No
Lung Friday 8.15am F 5 ? No
Endocrine Friday 8.15am 1 every 2m 5 n/a No
Surgical Pathology Friday 1pm M n/a 6 Yes
Anal Friday 1pm Q 8 No max Yes
Lymphoma Friday 2pm W 10 No max Yes
Sarcoma Weds 3.30pm 3 p/m From MRI
Young oncology run downs Mon 8.30am F ? ? No
Young oncology run downs Weds 8.30am W ? ? No
Max for 
Radiolo
gy
Max for 
Pathology
Head & Neck (South 
Manchester Hospital)
Tuesday / Weds 
(alternate)
Head & Neck (Central 
Manchester)
 
Table 5.5 Schedule of the MDTs (peer review and other MDTs) held at Christie Hospital. 
5.7 Summary 
This chapter has focused on the access, availability, type, quality, and issues 
surrounding data collection, recording and management. The data collection process 
demonstrated the fragmented nature of the data within various NHS organisations. 
Some were held in departmental legacy systems, with a few being held in stand-alone 
databases such as in medical statistics departments and clinical audit departments that 
are rich in clinical data and the rest in networked systems. This fragmentation of data 
restricts the ability of the organisation to make the best use of their information and at 
times fails to see this as a significant resource. The next chapter will demonstrate the 
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role of some of these data and the lessons learnt from this experience in developing an 
integrated MDT model. 
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6 MODEL DEVELOPMENT 
6.1 Introduction 
Having established the baseline for the current service configuration and MDT service 
model as described in Chapters 4 and 5, this chapter will detail how the data and 
information gathered were presented back to the stakeholders for defining and 
understanding the problem situation before the information was utilised to develop 
service models. The issue experienced, detailed in chapter 5, especially with access to 
multi-organisational data, forced the author to re-evaluate the modelling approach.  It 
became clear that problem definition for this research was not straight forward, but in 
itself problematic, in that those different professional groups had different perceptions 
of the issues and requirements and there were differences within the same 
professional group in defining the problems. Hence Soft Systems Methodology (SSM) 
was chosen to help define the problem prior to model development.  
 
This approach does not take the organisations for granted, always assuming that staff 
working in these organisations have differing views and perceptions rather than 
subscribing to some overarching objectives and priorities. It supported the different 
starting points for the various groups/ stakeholders catering to the composition and 
dynamics that yielded ‘many worlds’. This approach allowed the author to capture the 
creativity and fill the knowledge gaps. As discussed in Chapter 4, Rich Pictures have a 
long but under-documented track record of generating illustrations with a participatory 
context, exploiting the use of diagrams as a means to aid thinking process203,204. 
Whatever model was to be developed, it had to take into consideration the wider Hub 
and Spoke Model (Fig 4.3) for the delivery of cancer service recommended by the 
Calman-Hine Report. 
 
Although the report proposed this model, the local service providers were delegated 
the responsibility of identifying, approving and establishing the Cancer Centres and 
Cancer Units after completing in-depth service reviews and following evaluation of the 
business case submitted by prospective providers for Cancer Centre status. The report 
did not suggest or specify a model for developing a multidisciplinary service, although it 
did recommend that all patients should be reviewed by an MDT. The National Institute 
for Clinical Excellence (NICE) national guidance for lung cancer205 recommended that 
patients should be reviewed by an MDT representative as a minimum. However, it 
would not be possible to achieve this without having the right framework and all 
requisite resources in place. The emphasis of the study, as described in this thesis, 
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was twofold. Firstly, to enable the researcher to understand, evaluate and to test the 
hypothesis. Secondly to help the clinical sites address some of the short, medium and 
long-term operational issues relating to cancer service delivery. In doing this there was 
the need to incorporate all the recommendations made by the Calman Hine Report, as 
well as the NHS Cancer Plan, Cancer Reform Strategy, Cancer Waiting Time and other 
performance targets.  
 
Development of the conceptual model followed on from the exploratory study described 
in Chapter 4, and from the data collection and data analysis phase described in 
Chapter 5. Model construction involved consolidating the acquired knowledge and 
evidence and reviewing this against the problem definition. The analysis of data helped 
to objectively assess and quantify the magnitude, complexity and interdependencies of 
the issues. This process also made it possible to establish the variance between the 
ideal pathway, as recommended by the British Thoracic Society, against the 
operational pathway, the degree of expected change, the resources required and the 
time scale for implementing these recommendations.  
6.2 Model development 
 The process started off by re-presenting the Rich Picture (RP) developed at the SSM1 
(pre-analysis) stage with the stakeholders, about the complex situation as situation 
summaries. This was done primarily to ensure that all the complexities were 
encapsulated, to avoid any misrepresentation and/or misinterpretation. Fig 6.1 is an 
example of the situation summaries. This exercise also enabled the revisiting of the 
themes captured during the development of the pre-analysis RP, i.e. in the example 
provided (Fig 6.1). Each themes were summarised and these are shown in Appendix 
H.  At these workshops the stakeholders also had the opportunity to review the 
enablers that would facilitate improvement or resolution of the issues. 
These situation summaries were then utilised to review the current issues embedded 
within the system and by involving the stakeholders developed the ideal world 
scenario, an expression of the system performing optimally given that all the required 
variables work in harmony and are in equilibrium. This was presented to the 
stakeholders as (What Good Looks Like- WGLL), Fig 6.2 in operational terms for 
presenting the ideal world.  The stakeholders agreed that this did represent the ideal 
world, then, using their expertise of service delivery, appropriate enablers were 
identified to bridge the gap between the ideal and real world that would then allow the   
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Fig.6.2 Summary of problem situation and appropriate enablers.  
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organisation achieve its business objectives and in the process eliminate or at least 
minimise the issues identified during the pre-analysis stage. Following the definition of 
problem situations and having gained a good insight into the current operational 
configuration along with the requirements and recommendations of the Calman-Hine, 
BTS and NICE guidelines, it was possible to develop the root definitions for the MDT 
Service model. As discussed in Chapter 4, it was necessary to develop a conceptual 
model of the service as a whole before the conceptual MDT model could be developed.  
 
6.2.1 Development of Root Definition for Service Model  
To formulate the Root Definition, it is necessary to define a number of ingredients 
which are identified by the CATWOE mnemonic, namely Customers (who would be the 
victims or beneficiaries of this system?); Actors (who would perform the activities?); 
Transformations (what input is transformed into what output?); Weltanshauung (what 
view of the world makes this system meaningful?); Owners (who could abolish this 
system?); Environmental Constraints (what in its environment does this system take as 
given?). In this specific context we have: 
 
 Customers   Patients   
 Actors Health care staff  
 Transformation process Modernisation programme 
 ‘Weltanschauung’ NHS Cancer Plan/ Calman-Hine  Report/Patients and 
Staff experiences 
 Owners Health care staff / commissioners and Patients 
 Environmental constraints DoH directives, Skill availability, Funding/ 
Organisational boundaries/ technical deficiencies 
 
The root definition of the required system that emerged from this analysis was: “A 
health care system (primary, secondary, tertiary, palliative, community) 
specialised in the delivery of Cancer Care, staffed by clinical, administrative, 
scientific, and technologically - experienced professionals, collaborating and 
working together to transform the service from staff/service centric provision to 
a patient-centric service in line with the modernisation programme to improve 
and  deliver highly specialised cancer care  in the form of therapeutic, 
diagnostic, medical, surgical, radiation and palliative treatment for all patients 
diagnosed with cancer.” 
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6.2.2 Development of Root Definition for the MDT Model  
Similarly, to formulate the Root Definition for the MDT model, it is necessary to define 
the ingredients which are identified by the CATWOE mnemonic, namely Customers 
(who would be the victims or beneficiaries of this system?); Actors (who would perform 
the activities?); Transformations (what input is transformed into what output?); 
Weltanshauung (what view of the world makes this system meaningful?); Owners (who 
could abolish this system?); Environmental Constraints (what in its environment does 
this system take as given?). In this specific context we have: 
 Customers   Patients   
 Actors Health care staff  
 Transformation process Decision to patient’s treatment pathway. 
 ‘Weltanschauung’ NHS Cancer Plan/ Calman-Hine Report/Patients and 
Staff experiences 
 Owners Health care staff / commissioners and Patients 
 Environmental constraints DoH directives, Infrastructure/ funding/ staff/ Skill 
availability (thoracic surgeons)/ implementation, 
system and/or technical deficiencies 
 
The root definition for the MDT model  
“A system that facilitates improving consistency, continuity, co-ordination, 
communication, cost-effectiveness of managing patient data which in turn will 
contribute to improved clinical outcomes, survival, quality of life, patient 
satisfaction, enabling the service to become patient-centric, by establishing a 
process to replace the current paper driven system, by a semi electronic system 
that will aid the delivery of data/information required for treatment decision and 
recording of MDT outcomes whilst addressing the key issues of professional 
communication and access to specialist care.” 
6.2.3 Modelling approach 
The modelling approach was influenced by the methodology detailed by Carson et al206 
which is depicted in Fig 6.3 This approach helped to structure the thought process and 
systematically review all aspects of the study. 
6.2.4 Developing a Service Model 
Developing an alternative representation of the pathway presented in Fig 4.9a and b to 
elucidate the treatment options that patients faced following diagnosis and review by 
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the multidisciplinary team helped to pick on some of the key issues experienced by 
care providers across the cancer journey. This cancer journey assessment established 
the baseline for the delays experienced by patients along the pathway. The DoH set 
minimum and maximum duration for patients to be seen by their GP, to getting an 
appointment at the hospital and to be reviewed by representatives of the MDT 
representative, and to starting the treatment.  
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 Fig.6.3 Modelling methodology206. 
These various key milestones are used as checkpoints to assess service performance. 
These were grouped under Cancer Waiting Time targets (CWT)207. The key points are 
for the patient to be seen by a cancer specialist within two weeks of referral and a 
decision to treat made within 31 days, provided all required tests are carried out in the 
diagnostic phase as shown in Fig 6.4. The two week, 31 and 62 day targets were used 
to assess, monitor and award performance ratings for Trusts and PCTs, with 2 % of 
clinical exceptions being permitted for the31 day target, and 5% for the 62 day target. 
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Cancer Waits records the first treatment of all newly diagnosed cancer patients being 
treated under the NHS in England. This also includes patients who receive palliative 
care only.  Patients who are not reported include 
 Patients who refuse all treatment 
 Patients who die before any treatment is given (e.g. diagnosed at post 
mortem) 
 Patients that have private treatment 
For lung cancer in 2003/4 only 37% of the known incidence was being recorded on the 
Cancer Waits database. This position has improved such that 57% of known incidence 
was being recorded in 2005 (Data: 4,600 patients treated April-June 2005).The 
corresponding figures for other major tumour sites are: Breast (90%), Urology (80%), 
Gynae (76%), Lower GI (75%), Upper GI (59%) 
 
Fig.6.4 Cancer Waiting Time assessment milestones. 
The primary focus of the proposed service model was to be patient-centric, addressing 
the fundamental issues affecting the current service, namely 1) data 
recording/collection, 2) data sharing and 3) inherent system delays, utilising existing 
resources to the full potential and layering additional resources over a period or as and 
when they become available. It was evident from the outset that the model to be 
developed had to have a robust data collection and communication tool, to ensure safe 
and timely management of lung cancer patients. The key issue with the current service 
62 days for all cancers 
from urgent GP referral. 
31 days for all cancers 
GP referral for  
suspected cancer 
First seen for  
suspected cancers 
Diagnostic phase (CT, 
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etc) and MDT 
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First Treatment 
14 days 
PhD Thesis         Bala Sridhar 
 
Page 105 
 
configuration was that the appointment system and processes set in place, which is 
designed to be equitable to all people who access the system, as far as the system 
would allow. Processes within the healthcare care system by and large are designed to 
manage the critically ill. Published studies confirm this fact stating that patients with 
limited disease have to wait significantly longer for treatment than those with advanced 
disease208.   
This often led to early stage patients being pushed back to accommodate the more 
clinically ill patients. This criterion in itself creates a bottle neck effect, in addition to the 
other process-led bottlenecks, such as a splintered appointment system, and a waiting 
list based on clinical and administrative criteria. This is further compounded by external 
factors such as shortage of specialist, skilled staff, and limited, outdated and/ or poorly 
designed infrastructure, limiting installation of vital medical equipment such as PET 
scanner, linear accelerators etc., and the limited funds.  The unit cost of health care is 
growing exponentially, limiting service growth. 
 A handful of studies have reported on the effect of treatment delays209,210 with varying 
findings when it comes to the effect of both hospital delay and symptom to treatment 
delays (Fig 6.5), as these do not seem to impact on survival rate, but referral delays 
seem to have an impact on survival, based on statistical assessment. However waiting 
times have an impact on tumour growth211,212 with one study indicating a rapid doubling 
time of tumour volume, thereby indirectly affecting treatment outcome. If the patients 
who are initially classified as being potentially curable (curative) and fit for surgical 
resection are fast tracked, such patients will have an impact on the overall treatment 
outcome for this group of patients. Delay in diagnosis and treatment has deleterious 
consequences for patients awaiting clarification of their disease213.  
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Fig.6.5 Categorisation of delays213 
Following this review and analysis of the issues and bottlenecks, the Conceptual 
Service Model (Fig 6.6) was proposed as an alternative to the current operational 
service configuration based on the problem statement. This model was developed as a 
consequence of conducting the whole system review to help identify all the relevant 
pathways that interacted with and/ or contributed to the MDT service, with a view to 
improving patient care. The model proposed was designed to provide a service for 
patients who are defined by clinical priorities, i.e. those who are in most need of clinical 
care. Fig 6.6 presents the conceptual, stage one model, encompassing this concept. 
The primary focus was aimed at defining an effective and efficient patient pathway, 
irrespective of whether the final solution was to be paper or electronic-based or a 
combination of the two. The decision was to make the process work for both care 
receivers and care providers. 
 
The modelling solution had to be capable of addressing ethical dilemmas such as 
whether fast tracking patients would result in a two tier system of care. To summarise, 
the model is designed taking into account the published evidence that, as a norm, the 
majority of lung cancer patients come into contact with health care services at a late 
stage. This is as a result of their symptoms often mimicking those of other common 
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illnesses. Screening for lung cancer has been limited,214, 215 with the results obtained 
indicating that side effects and cost outweigh the benefits.  
 
Without having a routine screening, either for sputum cytology or low dose x-ray 
process available for at risk patients, the model proposed that the service should be 
realigned to accommodate an easy one step referral process. This should be followed 
by a single appointment schedule whereby the patient is seen by the specialist at the 
hospital and all necessary diagnostic tests performed (provided the patient is fit enough 
to undergo these tests) on the same day. The service should be able to incorporate 
capacity within its operational diagnostic departments for dedicated slots for new 
referrals. The results of these tests, where possible, should be reviewed and notified to 
the specialist on the same day.  
 
For those who have been diagnosed with early stage cancer (i.e. stages 1 and 2), 
these patients should be reviewed in a fast track MDT,  a dedicated team of specialists, 
with purpose-built review rooms to enable a treatment decision to be made. As 
indicated earlier there is a growing body of published evidence investigating the effects 
of delays, from patient delay, i.e. these are when patients do216 not access the health 
care early on, to referral delays, hospital delays and symptom to treatment delay. 
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Fig.6.6 Conceptual Patient-centric Service Model for the management of lung cancer patients. 
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Formal MDTs have influenced traditional treatment pathways by challenging single-
handed treatment decisions. This was made possible by accessing, sharing and 
reviewing valuable clinical data by the multi-professional team at crucial decision 
points. The underlying issue that impacts strongly upon the delivery of good quality, 
safe clinical care is access to relevant clinical information at the point of care delivery. 
This issue needs to be addressed to enable the service to deliver high class health 
care as advocated by the Government and the Department of Health. 
  
6.2.5 Developing a Multidisciplinary Model 
Review of the work flow informed the research that servicing the MDT meeting is a 
highly effort-driven activity, often not meeting the purpose these were established for in 
the first place, by not providing the clinical specialists with accurate and completed 
data/information required to make an informed decision. Data required to service the 
MDT decision-making process originate at various points along the patient's cancer 
journey. Table 6.1 summarises the origin of the data.  The primary contributors to these 
data items are secondary care and tertiary care. Vital information required for the MDT 
is the histology report along with staging information. 
 
Primary care provides the basic demographic information along with co-morbidity and 
lifestyle information. The difficulties stem from the way the data journeys, most of the 
time following the patients, flow across the health system. This is further complicated 
by the factor that not all the data items are captured and held by one sector or 
professional group.  Following the introduction of the MDT into operational service, 
there has been very limited concerted effort to streamline and standardise data 
collection from many disparate systems across the health community. The cancer 
registries collated the data from all NHS primary care organisations and hospitals on a 
regular basis, producing valuable annual reports following analysis of the data 
presented to them. Lung management data, both administrative and clinical, are also 
sent to the LUng CAncer DAta database called LUCADA. 
On the whole, under the present configuration data-management, availability, 
completeness and quality are very big issues. This is fraught with logistic nightmares 
for data collection as not all service providers have deployed an electronic repository 
for capture and data sharing. The Cancer Registries are then tasked with the data 
clean up, as they are required to hold a single instance of the patient records on their 
system. All parties involved in the data management and servicing of the MDT spend a 
lot of time preparing for these meetings, followed by keeping the database up-to-date.  
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Data 
Cancer Registry 
MDT Data set 
Data Source 
NHS Number  A 
Hospital number  B/C 
Organisation Code  A/B/C 
MDT Tumour group  B/C 
Surname  A 
Forenames  A 
Patient address at diagnosis  A 
Postcode of address at diag(Area lives now-MDT)  A 
Sex  A 
Birth date  A 
Diagnosis date  A 
Primary diagnosis  B 
Tumour laterality  B 
Histology / Type of cancer  B 
MDT Discussion indicator  B/C 
MDT Discussion date  B 
Care plan agreed date  B/C 
Recurrence Indicator  B/C 
Cancer care plan intent  C 
No cancer treatment reason  C 
Co-morbidity indicator description  A/B/C 
Co-morbidity indicator value  A/B/C 
Performance status  B/C 
Stage T  B 
Stage N  B 
Stage M  B 
Stage - site specific staging classification  B 
Grade of differentiation  B 
Cancer vascular or lymphatic invasion  B 
Excision margin  B 
Nodes examined number  B 
Nodes positive number  B 
Consultant  B/C 
1st appointment date  B/C 
Key worker  B/C 
Hospital (MDT use referring Hospital)  B 
Pre / Post treatment  B/C 
DTT date - days remaining  B/C 
View referral symptoms  B/C 
Investigations  B/C 
Treatment - date of surgery (link to op note)  B/C 
Treatment - procedure  B/C 
Treatment - treatment intent  B/C 
Clinical Trial status  B/C 
Pathology - report date  B 
Photographs obtained  B/C 
Table 6.1 MDT data set and organisation generating the data. 
A= Primary Care, B= Secondary care (cancer Units) and C= Tertiary (Cancer Centre) Hospitals 
 
6.2.6 Key findings from the MDT Review  
The two main objectives of the Multidisciplinary Team are to improve clinical outcomes 
for patients and improve the patient's experience of cancer care. 
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MDT working provides a framework that allows all relevant patients to be reviewed by 
the representatives of the respective tumour site-specific professional team, with all 
pertinent information to ensure that the patients receive the most appropriate care. As 
discussed in Chapter 4, prior to MDT review, lung cancer patients on average make 
contact with about 20 health professionals217 including the consultant they are under, 
but usually it is only the consultant who discussed the diagnosis and treatment options 
with the patient, without any contribution from the other professionals that the patient 
was likely to come across during their treatment. 
It was important to define some key terminology/concepts/processes to establish clarity 
to help understand the problem situation during SSM1, as the word Multi-Professional 
Team had differing interpretations. So the following questions were discussed at the 
workshop. 
 Is the multidisciplinary team a real team or a select group of professionals 
with specific skill-mix coming together to jointly review the patient? 
 Who led this team? 
 Does anyone lead the MDT? This is an interesting situation, given that the 
world of medicine or health care is strictly hierarchical.  
 Does the team evaluate its effectiveness? Carry out formal review? 
 If not, should it evaluate its effectiveness? 
 If yes, against what criterion? 
 How are conflicts of opinion addressed?  Are these recorded anywhere? 
 How are professional differences addressed? 
 Do the representatives in the team retain their professional and personal 
identity, to be able to work and contribute on equal terms, i.e. is the team 
equitable? 
 Does every one participate and contribute to the discussion? 
 What mechanism is there to assess the decision made by the team? 
 Are there any standard operating procedures? 
 If there are any negative consequences arising as a result of the MDT 
decision, how are these assessed, addressed and managed? 
 Can MDT get it wrong? 
 How are the decisions communicated to the patient? 
It was not easy to obtain clear and straight forward answers to most of the questions 
because the concept of MDT has more or less mandated upon the professional groups 
as good practice rather than the professional groups arriving at this conclusion hence 
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had no opportunity to assess these questions themselves. Like in any professional 
group, human behaviour has a huge bearing on the delivery of stated objectives. Group 
dynamics218 come into play in any setting and what works in one need not work in the 
other, irrespective of how grounded the objectives are.  
 
6.2.7 Pre-requisites for an MDT service  
The following were defined to be essential pre-requisites for operating the MDT service 
 Suitable meeting facility 
 Equipment to view pathology slides 
 Image viewing equipment 
 Facility to record discussions, decisions and outcomes 
 Facility for communicating across-sites or between organisations – video 
conferencing systems 
 Administrative resource to schedule, co-ordinate and organise the meetings  
6.2.8 Development of Conceptual MDT service models 
Two conceptual models were developed a) one taking the approach on emerging 
technology of a portal and the other based more on a traditional relational database 
approach. Both the conceptual models (Fig 6.7 and 6.8) developed were designed to 
address the inefficiencies, whilst ensuring that the patient’s records are accessible, by 
following the users. There are two aspects of this design; the model can be deployed 
within an organisation, or across the cancer network or across a regional boundary. 
The first model was dropped owing to inter- and intra-organisational infrastructure 
sharing protocol issues. This was out on hold; the key attribute of this model was the 
inclusion of the patient to view their record via The Web. The major stumbling block 
was N3 connectivity as most patients and some intermediate agencies did not have 
access to N3 connectivity, a mandatory infrastructure framework for exchanging and 
sharing confidential data. 
 
The second conceptual model met all the key attributes mentioned in the root 
definition, facilitating easy, timely, accurate access to the information for MDT 
representatives to make an informed decision. The implementation proposal was for 
this model to be housed in the North West Cancer Intelligence (previous known North 
West Cancer Registry). The model is designed to act as a central repository for all 
Cancer MDTs and, if housed within a Cancer Registry, can provide access to all the 
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service users within its catchment area. Having the ability to be interfaced or linked to a 
neighbouring registry will allow a seamless transfer of data, releasing numerous hours 
of staff time and money spent on tracking relevant information, preparing the MDTs to 
ensure that a clinical decision could be made. 
 
 
Fig.6.7  First Conceptual MDT Data Sharing Model. 
 
 
The model was designed knowing pretty well the issues surrounding data transfer 
between organisations. In this way none of the individual organisations are the owners 
of the system.  
The individual organisation can only upload and update information relevant to that 
episode of care and will have just read-only assess to data uploaded by another 
organisation. This will allow the Cancer Registry to maintain a single instance of the 
patient record. 
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Fig.6.8 Second conceptual MDT Data Sharing Model. 
Cancer Registries too will have restricted access to data from patients of the individual 
Trust.  There are 8 Cancer Registries in England (Table 6.2)  
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Cancer Registries - UK / Ireland 
1 Eastern Cancer Registration and Information Centre - ECRIC 
2  North West Cancer Intelligence Service - NWCIS 
3 Northern and Yorkshire Cancer Registry and Information Service NYCRIS 
4 Oxford Cancer Intelligence Unit OCIU 
5 South West Cancer Intelligence Service SWCIS 
6 Trent Cancer Registry  
7 West Midlands Cancer Intelligence Unit WMCIU 
8 Thames Cancer Registry 
 Northern Ireland Cancer Registry NICR 
 Scottish Cancer Registry SCR 
 Welsh Cancer Intelligence & Surveillance Unit  WCISU 
Table 6.2: List of all cancer registries in England, Wales, Scotland and Northern Ireland. 
 
 
Installing a unified system in these eight Registries will not only allow easy exchange of 
data across the Regional boundaries, but bring about substantial saving on the money 
spent on procuring, interfacing and maintaining numerous systems, all aimed at 
achieving the same objectives. In addition to this it will also enable data changes to be 
introduced in a systematic and seamless manner. Data collated by the cancer 
registries are shared by other national and international organisations Fig 6.9 provides 
a schematic data flow across the various national organisations. 
 
 
 
 
 
 
 
 
 
 
 
Fig.6.9 The cancer registration system in England219 
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Cancer Registries Cancer Networks (CN) 
Eastern Cancer Registration and 
Information Centre 
Anglia Cancer Network  
 Essex Cancer Network  
 Mount Vernon Network 
 North London Cancer Network  
North West Cancer Intelligence Service  Greater Manchester & Cheshire CN 
 Lancashire & South Cumbria CN 
 Merseyside & Cheshire CN 
Northern and Yorkshire Cancer Registry 
and Information Service 
Humber and Yorkshire Coast CN 
 North of England CN 
 Yorkshire Cancer Network 
Oxford Cancer Intelligence Unit  Thames Valley Cancer Network 
 Central South Coast Cancer Network 
South West Cancer Intelligence Service Avon, Somerset & Wiltshire CN 
 Central South Coast CN 
 Peninsula Cancer Network 
 Three Counties CN 
 Dorset CN 
Trent Cancer Registry  Derby-Burton Local Cancer Network 
 Leicestershire, Northamptonshire and 
Rutland Local Cancer Network 
 Mid Trent Local Cancer Network 
 North Trent Cancer Network 
West Midlands Cancer Intelligence Unit Pan Birmingham Cancer Network 
Thames Cancer Registry Central South Coast CN 
 Kent and Medway CN 
 North London CN 
 North East London CN 
 North West London CN 
 South East London CN 
 South West London CN 
 Surrey, West Sussex and Hampshire CN 
 Sussex CN 
Table 6.3 List of the Cancer Networks in England. 
6.3 Summary 
This chapter has summarised the work undertaken to develop a service model and an 
MDT model. This has been based on the problems identified within the current 
configuration, whist taking into consideration the requirements and recommendations 
of the various cancer policy documents aimed at reforming the provision of cancer 
service by improving quality, access and communication. The key challenge was to 
design a solution that could be implemented within the current operational 
environment, not requiring additional funding or attracting additional overheads. The 
next chapter will detail the work done to validate the MDT model. 
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7 MODEL VALIDATION & MODEL BASED EXPERIMENTS 
7.1 Introduction 
This chapter summarises the approaches undertaken to verify and validate the service 
model and the Multidisciplinary Team (MDT) model to assess their fitness in the real 
world situation, how the models were realigned against the findings and subsequent re-
evaluation of the model prior to deployment in the real world. The expected outcome of 
the model verification and validation process is the quantified level of agreement 
between experimental data and model prediction as well as the predictive accuracy of 
the model. Verification and validation are the primary processes for quantifying and 
building confidence (or credibility) in the model, where verification is concerned with 
identifying and removing errors in the model and validation with quantifying the 
accuracy of the model by comparing the solution with experimental data. 
 Verification is the process of determining that the model accurately 
represents the conceptual description, i.e. verification ensures that the 
particular product has been built according to the requirements and design 
specification. 
 Validation is the process of determining the degree to which the model is an 
accurate representation of the real world from the perspective of the 
intended use of the model i.e. fit for purpose. 
7.2 Model Verification 
As described in Chapter 4 the root definition expresses the core or quintessential 
perception to be modelled220 and contains a transformation process T that transforms 
an input entity to an output entity. As the root definition, in addition to the CATWOE 
elements, also contains P by Q to achieve R, where 
P = what to do, Q = how to do it, R = why to do it 
Checkland states that by formulating the root definition with P,Q and R it makes the 
model building process richer.  The conceptual model is a structured set of linked 
activities which is necessary to carry out the transformation process supported by a 
monitoring system and the control system221. So in other words while the root definition 
is an account of what  the system is, the conceptual model can be seen as what the 
system must do, in order to be a system named in the definition222.  
7.3 Approach to model verification 
The SSM methodology adopted for this research has the following stages: SSM1 -  
Defining the problem situation, SSM2 – Expressing the problem, SSM3 – Development 
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of root definition, SSM4 - Model development, SSM5 – Model validation, SSM6 – 
Model based experiments and SSM 7- Model deployment phase relying on stakeholder 
participation to understand the problem situation and establish purposeful activities, 
based on declared world-views. These led to cogent questions that stimulated 
questions about the real situation and the required changes. Hence it can be said that 
models formulated in SSM are relevant to debating about the situation perceived as 
problematical. These models are primarily developed to stimulate, aid support and 
structure the debates. SSM models cannot be tested by checking how well they 
represent a situation in the world, because this is not what they are supposed to do221. 
Fig 7.1 illustrates the approach adopted for reviewing the model's accuracy by 
engaging the relevant stakeholders who were responsible for delivering the business 
objectives and who contributed during the problem definition SSM1 stage. This also 
illustrates the synergy between business processes and technology. Multiple 
stakeholder teams were established with appropriate representation from all relevant 
professional groups and sectors. This partnership approach was well received by all 
stakeholders and all played an active part during the life cycle of this research. 
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Fig. 7.1  An integrated approach for successful system deployment. 
 
7.3.1 Presentation of the conceptual MDT model 
Representatives from each professional group and sector were first presented with 
summary of the key finding Fig 7.2 along the schematics of the current state (Fig.7.3) 
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and the patient pathway schematic 4.10a in Chapter 4. The group reviewed the root 
definition which included the three Es (Efficacy, Efficiency and Effectiveness) and the 
PQR. In SSM the conceptual model should be defensible, i.e. under a particular world-
view a statement is made that specific activities will transform an input into an output 
(efficacy). However the primary purpose of building models of purposeful activities is to 
coherently interrogate the actual problem situation, hence once models are built, SSM 
proceeds by comparing these models with of the real-world problem situation, 
facilitating, defining and implementing desirable and feasible changes. The conceptual 
model Fig 7.4 which illustrated the integration of the purposeful activities supporting the 
stated transformation along with key enablers was presented to the stakeholders who 
reviewed and commented upon the accuracy of the model, reflecting the complex 
problem situation. This highlighted the key issues, constraints, bottlenecks, risks and 
good practices. The conceptual model enabled the users to visualise and understand 
the interdependencies for the various processes and the significant impact of poor 
practice on the overall delivery of patient care.  
 
Fig. 7.2 MDT Pathway review ( Yellow = Process; Pink = Issues and Green = solutions). 
 
Most of the representatives were able to trace all associated inter-related pathways 
identified and captured during the various one-to-one and group interviews.  Those 
who had attended the process review workshops held during the SSM1 and SSM2 
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stages also concurred that the schema had captured the essence of the overall level of 
integration. 
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Fig 7.3 Schematic representation of the interactions between primary, Secondary, Tertiary 
and Palliative care. 
All relevant detailed workflow process maps (Appendix J) were then presented that 
helped to scrutinise the high level pathways in greater detail. The review covered all 
aspects of the patients’ journey within the Trust in greater detail discussing issues, 
concerns and bottlenecks identified during the review process. 
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Fig 7.4 Conceptual model incorporating all components of the Root Definition.
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It provided a good opportunity to re-iterate the need for effective communication, 
before, during and after effecting changes to operational processes, procedures and 
policies.  
This was then followed by presenting the conceptual model for data sharing (Fig 7.5), 
drafted to address the key issues established along the MDT pathway. The future state 
was presented to the groups with all the key dependencies and risks along with 
relevant mitigations. The proposal took into account that other organisations may not 
be willing partners to this proposal, but until such time the solution will be able to 
operate within the Trust, interacting and co-existing with all the other information and 
clinical systems on site. The users on the whole agreed with the concept, but there was 
a high degree of scepticism for hosting the data repository outside the organisation. 
They also questioned the control element of this situation, ending up in a number of 
'what if' questions and possibilities. 
This resulted in employing aspects of Discrete Event Simulation to enable the group to 
evaluate the model using real life simulation, reviewing a series of scenarios, and 
exploring how the design would handle exceptions and evolve over a period of time as 
the MDT service matures or is reconfigured. A dry run of the model was undertaken at 
the workshop that resulted in fine-tuning of the model, reviewing the various options 
and prioritising the work streams. The workshop also facilitated an in-depth discussion 
that enabled the question to be asked regarding established current work processes, 
procedures and polices: “Why do we do what we are doing?” “Should we continue to 
do what we are doing?” Is there anything we ought to be doing differently that would 
help deliver improved patient care? Discussion focused on all the six key themes used 
in defining the future state; i.e.  
 High quality best practice care for patients 
 Improving the patient experience 
 Ensuring patient safety 
 Efficiency and effectiveness 
 Seamless delivery of care 
 Access to full information on patients’ care 
Delineating improvement for patients, care providers, cash and non-cash releasing 
benefits. Some key changes were identified during the course of this review and the 
resulting discussion, especially to look beyond organisational boundaries when 
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formulating MDT teams, as this would, in addition to building in resilience, also pave 
the way to resolve a number of operational boundaries. 
 
Conceptual Model for Data Sharing  
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 Fig 7.5 Schematic representation of the draft MDT model.  
It would also definitely improve communication between professionals and with 
patients, allowing the tracking of patients and designing the pathway around the 
patients. It would also provide an opportunity for General Practitioners with a special 
interest in oncology to become part of the MDT, thus redefining the role of MDTs. The 
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MDT data sharing model (Fig 7.5) was reviewed in conjunction with the Purposeful 
Activity Model and elements of the data sharing proposal were challenged by the users 
for being impracticable, often owing to the abstract nature of the organisational model 
of the National Health Service and the historic issues with data sharing. In addition to 
this, the case review exercise provided valuable suggestions to counter-balance some 
of the unanticipated expectations from service users. Based on the feedback received, 
the model was revised prior to formal model validation. 
7.4 Model Validation 
Contrary to the prevailing notion in hard Operations Research (OR), in Soft System 
Methodology (SSM), validity seems to play a minor role223. The primary reason for this 
is that SSM models are of a different type; they are not would-be descriptions of real-
world situations. The question of validity has to satisfy two criteria 1) whether a model 
is ‘relevant’ or not and b) whether a model is competently built224.  SSM facilitates 
learning along the SSM cycle thereby addressing the question of relevance by ensuring 
an in depth understanding of the problem situation is gained and the desired 
transformation explicitly defined in the root definition. The second criterion regarding 
competence is assessed by comparing the root definition and the model to evaluate if 
the model is defensible. Checkland states that each phrase in the root definition should 
lead to activities in the model, each activity in the model should be traceable back to 
the word or concept in the root definition and the measures of performance for efficacy, 
efficiency, and effectiveness of the model must be linked to the words of the root 
definition and the Weltanschauung (transformation) it expresses224 Checkland 
continues to state that in SSM there are four ways of comparing: informal discussion, 
formal questioning, scenario writing based on ‘operating’ the model and trying to model 
the real word in the same structure as the conceptual models (method-overlay-
method)225. 
7.4.1 Validation of the MDT Model 
Validation of the model shown in Fig 7.5 involved comparing the root definition and the 
model. The model addressed the issues of improving consistency; continuity; co-
ordination and cost-effectiveness, by standardising structured data sets, 
streamlining data collection, including real-time data capture solutions and sharing 
these data across the pathway. Thus improving cost and data quality by eliminating or 
minimising missing data, with the need for chasing missing data enabled timely 
availability of information for review at the MDT. As the revised process is structured 
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around the patient journey i.e. is patient centric, there is significant confidence of 
achieving patient satisfaction.    
The relative ease with which the model was validated is owed to the life cycle of SSM. 
As mentioned earlier, a number of iterations were performed in conjunction with 
customers. A number of issues were raised, although not directly relating to or 
impacting upon the MDT model, that were quite relevant to the overall model 
development and its fit within the organisation's data flow. Hence these issues were 
heard and acknowledged during this workshop. 
Validating models developed using SSM exposed some limitations. These are 
addressed in chapter nine. 
7.4.2 Issues that impacted upon ingredients of the MDT model 
7.4.2.1 Referral pathway and data flow 
A very good example of this was illustrated when attempting to standardise the format 
for exchanging clinical information between primary care and secondary care when 
referring a patient for further investigation prior to treatment.  The Department of Health 
had defined the requirement, in the form of a minimum data set, for exchanging data 
between the two sectors, but did not mandate how this exchange should be effected. 
There was no one formal template or standardised forms for data exchange, thus 
resulting in each secondary and tertiary care provider defining individual referral 
templates. This created an immense burden for the primary care team who had to 
complete the appropriate referral forms, depending upon which secondary care or 
tertiary care organisation they were referring their patients to. 
In addition to this, there were multiple referral pathways, some adopted by primary care 
representatives, some designed and dictated by the secondary care sector. Some 
organisations required all the referring primary care teams to adhere to a specific 
format, while some organisations adopted more that one pathway, frequently defined 
by the receiving secondary clinical teams.  The primary care doctor would send the 
referral in the form of a “Dear Dr.” letter, which often ended up at the booking office, for 
the administrative staff to screen and identify the most appropriate Doctor or clinic that 
was best placed to review the patient based on the information provided. On other 
occasions the primary care doctor would address the referral to a specific secondary 
care doctor, again in the form of letter that ended up with the doctor or his/her secretary 
directly, by-passing the booking office only for it to be rerouted to the booking office by 
the clinician’s secretary. The booking office would then make the booking and write to 
the patient confirming their outpatient appointment. 
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These variations introduced referral delays owing to re-routing, loss of referral 
correspondence, and lack of data compliance due to the individual clinician adopting 
different styles of presentation which required the secondary care team to chase further 
information from the referrer etc. The secondary and tertiary care organisations spend 
an inordinate amount of time tracking referrals, with individual secondary care 
organisations re-engineering the most effective referral pathways that best suited that 
organisation. However, this often did not take into account the impact on the primary 
care organisations that have to service these differing referral pathways. The cancer 
service collaborative programme helped to streamline some of the issues with the 
formation of a cancer network, by merging and unifying the various referral pathways 
into, where possible, a single pathway. These revisions have made a significant impact 
on the referral turn around times, but have not eliminated the issues altogether. 
The representatives were able to realign and reformat the approach presented in the 
model by identifying the controllable and uncontrollable components due to 
organisational boundaries, financial and clinical freedom/practice.  Another good 
example of the workshop validating the feasibility of the model is purely based on 
heuristic knowledge of the representatives. In an attempt to resolve an issue identified 
as creating a bottleneck during the work flow review, the model proposed a simple but 
effective solution to alleviate the problem, under the assumptions that all the required 
variables were quantified and captured.  
7.4.2.2 Dependency identified – Multiple hospital visits 
The specific problem identified was the delay experienced by patients in receiving 
chemotherapy. The work flow analysis revealed that all patients required to undergo 
chemotherapy were given an outpatient appointment to be seen by the doctor or the 
nurse (depending on the cycle) prior to treatment. This was to ensure their fitness to 
receive the medication, usually assessed by reviewing the latest blood report. To 
ensure the latest blood report was available to the reviewing clinician, patients were 
asked to come an hour earlier than their appointment time to have their bloods drawn 
and tested. This format, often called a one visit schedule, resulted in the laboratories 
experiencing peaks and troughs, with their capacity stretched during the peak 
outpatient periods, calling for very tight turnaround times for outpatient blood requests, 
to ensure results are available prior to the consultation time. 
The laboratories had in place an effective system, but this was dependent on the 
following: a) the patient arriving an hour earlier than their appointment time, and b) 
samples reaching the laboratories with adequate sample volume in the designated 
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vials. Not meeting any one of these resulted in a delay. The issue with this design was 
firstly that the system was reliant on all the patients arriving an hour early, which the 
system had no control over. Secondly there was no wriggle room to accommodate 
delays within the consultation schedule arising from delays in receiving blood reports 
other than to place the patient further behind in the queue. This delay is then cascaded 
down to the treatment areas where treatments are usually planned based on the type 
and duration of the treatments and the shelf life of the medication required to be 
administered.  To reduce these delays the model suggested the adoption of a two visit 
schedule, whereby the patient visits the hospital for bloods the day prior to their 
appointment, thus allowing the laboratories to have the time to ensure reports are 
available for the clinical team for review and for treatment to proceed on schedule. In 
fact this model has been adopted in some organisations such as the St James’ Cancer 
Centre Leeds, as their patient survey indicated that an overwhelming majority of 
patients supported the two visit schedule as opposed to just one visit.  
7.4.2.3 Dependency identified – Car park 
 When this was presented to the team at the workshop, it was accepted that this would 
solve the operational problem, but could not be implemented because patients were 
reluctant to come for two visits, mainly because of car parking issues. Hence solving 
the car parking issue would enable the issue of treatment delays to be solved. The 
issue and dependency of car parking was not identified as a dependency before this 
workshop. 
The workshop also helped to review the implementation of the model following 
validation. One of the recommendations from the workshop representatives was to 
break the model into multiple components to allow prioritisation of resources and 
testing of aspects of the model that would deliver the single biggest benefit and 
significantly improve service delivery that would in turn improve patient delivery. The 
suggestion was valuable and quite important when making changes to a dynamic 
system that cannot be halted, yet requires changes to be introduced. 
7.5 Revalidation of the MDT Model 
The divisional leads and representatives for professional groups were presented the 
current state data flow (Fig 7.6), before the revised MDT model was presented to give 
the group the scale of efficiency the MDT model was to deliver. The current data flow 
required to feed the MDT and other processes relied on multiple source systems, some 
of which were used to capture and process data required for MDT meetings and to 
define the treatment pathway and the reporting requirements to the various external 
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bodies. The group were then presented with the revised MDT model (Fig 7.7). The 
group raised the control issue again, but approved the model as a practical solution as 
parts of the solution could be implemented within the Trust. However, they said that 
they regarded the overall deployment to be too futuristic, with dependencies that rested 
on other organisations also when data sharing is still being debated across most 
organisations. 
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8* = use of eight different tumour and proformas employed to capture data.  
Fig 7.6 Schematic overview of the current data flow within a secondary / tertiary unit. 
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Fig 7.7  Conceptual MDT Model. 
 
The group recommended that the approach should be revised and that the model 
should be first deployed into individual organisations, allowing them to have some 
control in managing internal dependencies, before they can start collaborating with 
other organisations to achieve the final configuration. The representatives highlighted 
the fact that although there was a minimum data set defined for MDT data collection 
and exchange of data between primary / secondary and tertiary care, there was no 
standard data collection template defined by the NHS. This has led to a range of 
interim solutions being put in place by various organisations, programmes and 
initiatives, such as Cancer Networks, Modernisation Teams, and Cancer Collaborative 
Teams etc. that are likely to impact on establishing a standardised operational 
procedure as suggested by the model.  The interim solutions in some cases involved 
individual local tumour groups designing their own template to record the specified 
MDT data item on paper and then transcribing these onto to spreadsheets in Microsoft 
Excel. In other cases there was the developing and deploying of organisation-specific 
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stand-alone databases using Microsoft Access, or implementing databases developed 
in Microsoft Access by national tumour specific groups such as LUCADA (Lung CAncer 
DAtaset Project), DAHNO (Data for Head and Neck Oncology) and BASO (British 
Association of Surgical Oncologist) etc. These national databases are used to record, 
collate, collect, exchange, monitor and analyse tumour specific data across the patient 
journey, with special attention being paid to clinical outcomes, e.g. that took a broader 
view that just that of the MDT. 
A few others procured off the shelf networked products such as the Somerset Cancer 
Register System with tumour-specific data collection templates, to collate, analyse and 
report the findings, rolling it out across the local cancer network.  This also allows 
electronic exchange of data with cancer registries. Whilst all these systems provided a 
means to an end solution for individual tumour groups, they did not provide an effective 
mechanism for organisations to manage operational inefficiencies. These were largely 
retrospective data repositories, often populated with data from various health 
information systems, such as the Electronic Patient Record (EPR) systems in primary, 
secondary and tertiary care organisations, along with numerous legacy systems such 
as those for pathology, radiology, radiotherapy etc. None of these systems has 
addressed the issue of real-time patient information capture and presentation of data at 
the time of treatment planning/ decision-making.  
 
Based on the work done to identify the work flow, a future state data flow configuration, 
Fig 7.8,  was presented to the representatives, one that would deliver both cash 
releasing and operational efficiency gain once operational even with the deployment of 
a scaled down version the model. The cost of interfacing all the relevant systems was 
identified as having a better return on investment; however, data cannot be shared 
here due to commercial sensitivity that has no bearing on this research, relating to 
facilitating a seamless flow of data from all the interconnected systems.  This was to be 
tested and deployed as part of the operational process and was taken out of the pilot. 
7.5.1 Piloting the Model 
The model was revised following the series of workshops to maximise efficiency and 
with a review of Standard Operating Procedures before model-based experiments were 
designed and executed. The model-based experiments were largely confined to new 
ways of working and exploring solutions introduced by the model to examine the 
accuracy of the model and the effectiveness of the solutions proposed to address 
critical issues. 
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Fig 7.8  Future state of data flow. 
 
Model validation involved piloting the MDT data proformas, as shown in Fig 7.9. [A 
point to note here, Lung MDTs were hosted by Wythenshawe Hospital, a District 
General Hospital, as the thoracic surgeons was based there. They were supported by 
the local clinical teams, including, both pathologist and radiologist; consultants from the 
Christie attended these meetings regularly. Lung patients were referred to the Christie 
for chemotherapy and radiotherapy].  This process was initially paper-based to 
evaluate the appropriateness of design and content. Table 7.1 shows the schedule that 
piloted the new system. The data items in the proforma required both the referring 
team's population data items that they had dealt with, allowing the reviewing team to 
make an informed decision, followed by the reviewing team populating the remainder of 
the data items. 
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Fig 7.9 Proforma for Lung Cancer MDT 
7.5.2 Review of the Pilot 
The pilot established that the concept would work for MDT meetings that had support 
of the MDT co-ordinators who played a key role, whose skills are vital to the efficient 
running of these meetings. Some of the key tasks they provide are: 
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 arranging meetings. 
 preparing lists of patients to be discussed. 
 co-ordinating case notes, all diagnostic results, histopathology, radiology, 
including some from other hospitals. 
 recording attendance, discussions, diagnosis, decisions and treatment plan. 
 collecting data on the prescribed proforma. 
 booking and tracking patients' future appointments. 
 co-ordinating and communicating with related teams in the cancer network 
and with referring Primary Care organisations. 
 
Where there is no administrative cover, the medical secretaries provided limited cover. 
Usually the peer reviewed MDTs are provided MDT cover, as these MDTs are 
subjected to external assessment by the NHS Peer Review team. The aim of peer 
review of MDTs is to support the development of effective, safe and well planned care 
for cancer patients by reviewing MDT compliance with the measures contained within 
the Manual of Cancer Services; and to identify issues related to the achievement of the 
measures and to identify and share good practice.   To summarise the aims are: 
 
 to ensure services are as safe as possible.   
 to improve the quality and effectiveness of care.   
 to improve the patient and carer experience of care.  
 to provide development and learning for everyone involved.   
 to encourage the sharing of good practice . 
 
Table 7.1 provides details on the number of MDT meetings held by each tumour group, 
the time and frequency of the meetings, and the maximum number of patients that can 
be reviewed at each of these meetings by the Radiologist and Pathologist. Thus the 
clinical teams’ capacity is defined indicating the dependencies of the availability of 
appropriate diagnostic results and other information required at each meeting. In Table 
7.1 the column heading MDT Cover indicated whether the MDTs had a co-ordinator 
cover. Where there is a question mark, this is indicative of limited cover at the time this 
document was prepared. In addition to this, the peer reviewed MDTs are also colour 
coded in green, the yellows are a combination of non-peer reviewed MDTs hosted by 
Christie's and those that are hosted by others and so did not require co-ordinator cover, 
such as the Lung MDT. The effectiveness of the proforma was assessed by using 
wireless laptop devices in place of paper to record data without using the proforma. 
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MDT Meeting Day Time Frequency 
Max cases for 
Radiology 
Max cases 
for Pathology 
MDT 
Cover 
Colorectal / PMP Monday 8am Weekly 8 n/a Yes 
Head & Neck 
(South) 
Tuesday 8.15am Weekly 8 No max Yes 
Lymphoma - 
Radiology 
Tuesday 8.15am Monthly 6 n/a No 
Joint Endocrine 
Tuesday / Weds 
(alternate) 
9.30am Quarterly ? ? No 
Palliative Care Tuesday 12.30pm Weekly n/a n/a Yes 
ALU Tuesday 12.30pm Weekly ? ? No 
Neurology Tuesday 1pm Weekly 5 n/a No 
Endocrine Tuesday 1.15pm 1 every 2m 5 n/a No 
Melanoma Tuesday 4pm Monthly 5 5 No 
GU Weds 8.15am Fortnightly 6 ? No 
HPB Weds 9am Weekly tbc tbc Y 
GU Weds 12.30pm Weekly 6 ? Yes - ?  
Haematology Weds 3pm Weekly n/a No max Yes 
GIST Weds 4pm Quarterly 3   No 
Sarcoma Weds 3.30pm 3 p/m     From MRI 
Head & Neck 
(Central) 
Thurs 8am Weekly 8 + 8 No max Yes 
Breast Thurs 8.15am Fortnightly     No 
Gynae Thurs 12.30pm Weekly 7 No max Yes 
Lymphoma - 
Pathology 
Thurs 1pm 
Fortnightly 
n/a ? No 
Thyroid Thurs 5pm Fortnightly n/a No max Yes 
GI Friday 8am Fortnightly 8 n/a No 
Lung Friday 8.15am Fortnightly 5 ? No 
Endocrine Friday 8.15am 1 every 2m 5 n/a No 
Teenage cancers Friday 8.30am Weekly n/a n/a Yes -  
Oesophageal Friday 9am Weekly 6 6 Yes  
Surgical 
Pathology 
Friday 1pm Monthly n/a 6 Yes 
Anal Friday 1pm Quarterly 8 No max Yes 
Lymphoma Friday 2pm Weekly 10 No max Yes 
Table 7.1 MDT Meeting Schedule. 
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This proved inadequate as the task of data capture was assigned to the MDT co-
ordinator who was also responsible for managing the case notes, They also had to 
ensure that when one case was completed, the next set of case notes was handed to 
the clinician, making it difficult for the MDT co-ordinator to manage real time data 
capture. 
The use of the proforma confirmed that a structured instrument enhanced data capture. 
Moreover it reduced transcribing time and errors, as it was a lot easier for data input 
clerks to sequentially key in the data without having to search for the information 
hidden within a referral letter, thereby speeding up data entry. It also proved useful 
when summarising the information. Although there were some positive findings, it 
demonstrated that the reliance on staff from the referring organisation completing data 
items in the proforma was largely left to chance. There was very little control, with no 
mechanism for enforcing stricter adherence to standards. As a consequence, the MDT 
co-ordinators were called upon to follow-up the missing data items prior to the MDT 
meetings (see Fig 7.2).  
As mentioned earlier, there were clear indications that organisations were evolving 
independent systems to capture MDT referral data; some using an Access database, 
some using an Excel spread sheet, others were investing in specialised MDT 
applications such as eMDT, patient MDT solutions, etc. Irrespective of what systems 
organisations deployed, the issue of data exchange between organisations persists. 
For example, tertiary unit clinicians were repeating diagnostic tests such as 
histopathology, CT and MRI studies just to progress treatment, while MDT co-
ordinators were following up with referring units seeking missing information.  
The other aspect of the validation exercise involved testing the ability of the model to 
help clinicians manage MDT meetings that are often held in other organisations, for 
example in secondary care settings, with relevant specialists from tertiary care in 
attendance. Studies as referenced earlier in Chapter 4 indicated that attendance of 
specialists from other organisations was often a limiting factor, especially in relation to 
thoracic surgeons, radiologists and medical oncologists. To address this issue the 
model looks towards an efficient way of participating in the MDT meeting using 
appropriate communications technology.  
Options from video conferencing to web conference calls were reviewed with 
representatives. There were issues with the sharing of networks and access to data for 
non-organisation staff. Although all were part of the wider NHS, individual sites had 
their own approaches with regards to the enforcing of policies for data sharing. 
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Following successful negotiations with video conference suppliers, this technology was 
piloted in two MDT meetings. This was supported by a detailed benefit realisation plan 
on the use of video conferencing solutions. The pilot and benefit realisation plan 
demonstrated that this option would enable the clinical team to meet and review case 
notes on time, thereby improving patient care whilst also providing excellent value for 
money in terms of utilisation of clinical time.  
The outcome of this work highlighted the dependency on numerous healthcare 
professionals investing their time, to organise the meetings, making sure there is an 
appropriate number of patients and case mix and that all the relevant tasks are 
completed and ready for the specialist team to review and formulate the most 
appropriate treatment plans. The effort spent in organising the weekly or fortnightly 
MDT meeting as agreed by the tumour groups was not an efficient use of staff time. It 
was not sufficiently productive to warrant continuation of this system.  The cancer 
registries were mandated to collate the MDT minimum data set as part of the Cancer 
Data Set and were constantly following up with all the contributory primary, secondary 
and tertiary organisations within their catchment area for incomplete data items that 
were not captured along the cancer pathway. In doing so, data for the same patient 
from all the organisations the patient was either referred to or was seen at, including 
from those operating the satellite sites for cancer centres, were being received by the 
cancer registries with a significant amount of duplication. They then employed staff to 
clean these data, merging and filing missing data items. In doing so their reports were 
almost two years behind at any given time.  
The next phase of model validation critically reviewed the ability of the MDT model to fit 
within the overall patient pathway. The service review and work flow assessment 
identified numerous issues, mainly relating to communications, scheduling of 
appointments, processing issues that created a bottleneck at certain point of the 
pathway and the flexibility required to accommodate varying patient/ carer/provider and 
staff requirements. 
As most of the organisations were embarking on the introduction of a Level three 
Electronic Patient Record system, it provided an excellent opportunity to assess the 
ability of the model not only to address some of the issues described above, but also to 
test possible solutions prior to operational deployment.  
The pilot study highlighted that organisations employed very tedious, effort driven but 
nevertheless essential processes starting from those which generate the data, right 
through to the cancer registries who collate, analyse and report on behalf of the 
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organisation to the DoH.  In doing this, a large number of databases and computer 
systems are procured and deployed, along with the numerous staff employed to 
capture, clean, update, validate, maintain and manage these data.  
The conceptual MDT model proposed here is for the cancer registries to procure an 
application such as the Somerset Cancer Register System. This would be funded 
jointly by the various organisations that capture the data and rely on these data for the 
management of their patients, along with an on-going yearly maintenance cost paid to 
the registries. This will allow all appropriate staff from primary, secondary, tertiary, 
palliative, community, hospice and private care sectors, within the catchment area of 
the registry, access to a single system, sharing a single data base with strict access 
control. 
Access control would enable staff to contribute their data whilst having view/read only 
access to other care providers’ data. This would reduce numerous data exchanges, 
replication, the transcribing of data from paper to e-systems and would result in having 
a single body monitoring data quality with regular data quality reports forwarded to 
relevant organisations for timely action. This would also enable the Registry to produce 
timely reports and facilitate a central shared repository of data. This could then be 
accessed by different professional groups for managing their patients, for service 
planning, and for reviewing clinical performance and outcomes.  
7.6 Summary 
This chapter has summarised the methodology undertaken to validate the proposed 
model, the process employed to refine the model from an ideal state bringing it closer 
to the real work, to enable the model to be viable in a live operational environment. The 
examples detailed demonstrated the viability of the model, thereby testing the 
hypothesis of this research as described in Chapter 1. The next chapter will describe 
further testing of the model in real life situations and show how elements of the model 
were integrated into the business domain. 
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8 MODELLING WITHIN AN E-HEALTH ENVIRONMENT 
8.1 Introduction 
Having, in the previous chapter demonstrated the validity of the MDT model, this 
chapter provides highlights of some of the additional work undertaken to test the 
integration of the MDT model within the operational environment. The work undertaken 
had to incorporate integrated solutions evolved by combining solutions identified by this 
research and those developed by other operational work streams, to resolve and /or 
introduce new ways of working to enable the service to perform more effectively and 
deliver a better quality of service. Following the dry run at the workshops to confirm 
current practice and agree the future business processes, a series of pilot studies were 
initiated to test proof of concept of the solutions for both technological and non-
technological dimensions. 
Chapters 4, 6 and 7 detailed the dependencies of the MDT model that needed to be 
supported by the operational systems to enable in order to enable the model to deliver 
the objectives identified in the root definition. Hence it became evident that to evaluate 
the integrated MDT model adequately it was essential to put in place the necessary 
building blocks that would enable testing of the internal data interchange as proposed 
in the model.  Some of the technological functionalities planned for deployment, such 
as clinical documentation, order communication and result reporting and e-prescribing 
and scheduling, were designed based on the specification developed by the Trust to 
replace the current paper based systems. Hence, they required evaluation in controlled 
pilot studies. 
The author has attempted to retain the focus of this thesis to the research objectives as 
much as possible, but as mentioned earlier the nature of this research was such that it 
was extremely difficult and at times impossible not to effect changes to the key 
operational processes that were contributory to ensuring that the MDT model could 
become operationally effective. 
These pilot studies helped not only to test the functionalities, but also the workflow 
suggested by the model (influenced by the knowledge gathered during the SSM1 and 
SS2 stages of this research) in realigning the business processes. This also helped to 
gauge the degree of resistance to change; moving away from the old tried and tested 
ways of working and adopting new ones, often working with unproven systems.  
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 The deployment of various aspects of the service and MDT model into the operational 
platform was accelerated both by the convergence of the organisation’s need to bring 
about efficiency and improve service delivery and also to meet the timescale to 
implement Level 3 EPR as mandated by the government. To facilitate this, the 
organisation drafted a service-based output specification that formed the framework 
against which to test the model. The scale of testing the MDT model was again 
confined to tertiary care owing to cross boundary issues and management of differing 
operational priorities. 
8.2 Implementation of the EPR  
The implementation of the Electronic Patient Record afforded the opportunity, not only 
to test the validity and scalability of the MDT model, but also deploy many aspects of 
the service model either in full or in part, following a successful pilot.  Although 
deployment of the service model was governed by factors such as timescale, 
operational priorities, the degree of change, resource availability, clinical resistance 
and/or implication of external initiatives, it enabled the embedding of some of the basic 
framework required to deploy the MDT model. 
The assessment period also provided an opportunity to rationalise aspects of the two 
models against the degree of resistance to change, and to examine the cost of service 
realignment against likely benefits. A good example of this is summarised below.  
8.2.1 Real life example 
The workflow analysis revealed that some patients experienced long waits at various 
points, mainly awaiting diagnostic reports, especially haematology and biochemistry. 
The non-availability of results delayed the outpatient consultation appointment as the 
clinicians could not approve treatment without seeing the patients’ results. This also 
delayed administration of chemotherapy for protocol patients, i.e. patients who did not 
have to be seen by the doctor prior to the start of treatment, but whose results were 
reviewed by specialist nurses. Root and branch review of the process identified a 
number of reasons for these delays, as itemised below, some of which were avoidable. 
 Phlebotomy staff send blood samples via the internal POD system (Pneumatic 
air tube system), but they wait to fill the POD before they send the samples to 
the lab. The labs have specific rules governing use of the POD as listed in 
Table 8.1. 
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All samples must be placed in a sealed bag and accompanied by a form. The plastic 
bag must be sealed, so that fluid is contained in the event of leakage. 
Place samples in the pod and ensure that the lid is firmly closed. Open pods sent 
through the system are the main cause for the system failure and breakdown. 
Key in the destination addresses, e.g. the pathology department's address (100). 
Place the pod in the system. If there is a delay this may mean that the system is 
already in use. Each pod takes approximately two minutes to reach its destination. 
Each pod goes in turn. 
If the system is out of action, make alternative arrangements for transportation of 
samples, eg, use the porter service or take the samples to the laboratory yourself. 
If the system fails, inform the pathology general office at xxxx so that they can 
report the fault and arrange for an engineer to visit to repair the fault. This cover is 
only available during normal working hours. There is no maintenance cover for out 
of hours’ repairs. 
Do not overfill the pods, as samples are difficult to remove from the pod and may 
break. 
Do not put any other samples in the pod with blood culture bottles. 
Do not overfill the pods so that the lid cannot close properly. 
Do not try to send any samples via the air-tube system without putting them in a 
leak proof pod first. 
Do not send any irreplaceable/ unrepeatable samples in the pod 
 
Table 8.1 Transportation of samples using the pneumatic air tube system (internal staff use 
only) 
 The labs have service level agreements with the outpatient department and 
wards on the turnaround time, but this is effected only after the sample is 
received in the lab, hence any delay en-route has no accountability. The labs 
can only process samples that are delivered to them undamaged and in a good 
state. 
 The labs delivered results back only to the location of request origin. Patients 
are at times asked to go to another location by staff in the outpatient 
department or ward, but their results did not follow them. Patients and staff did 
tell the review team of their experience of lost results in this process and having 
to provide another sample for retesting. 
 The forms accompanying the samples were not properly completed, most often 
with the diagnosis field left empty or with illegible hand writing and often with 
just the first name of the patient. 
 The pre-printed forms designed to speed up the process of requesting the most 
common tests offer very little opportunity to notify other specific tests, resulting 
in clinical staff writing the required test on the back of the form. Lab staff who 
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process the orders are not trained to turn over the pre-printed form to check for 
special requests; hence these samples are left as queries. Queries are initially 
handled by the receptionist, by contacting the staff who placed the order, for 
further information. This then escalates to the senior staffs for approval, who 
are often involved in managing operational duties and verifying results.   
These inherent delays had a knock-on effect across the day to day operations at 
various points, starting from the treatment unit, at the dispensary, where short life 
expensive chemotherapy medications are manufactured only after the patients are 
given the approval to have treatment. The preparations can take up to three hours 
adding to further delays, right through to transport, where the patient may have to wait 
for a revised booking. 
To resolve the issues of poor data quality, managing capacity to the demand, 
facilitating pre-ordering and tracking of the progress of requests, implementation of an 
electronic order communication system along with result reporting was identified as the 
best option to help the labs process the orders alongside the sample management 
pathway. 
 In terms of practical implementation, the model was developed with the following key 
objectives in mind:  
a) providing the labs with all the necessary information required for the lab staff to 
make an informed decision on the appropriateness of the request with the ability to 
suggest other first best tests; 
b) enabling the clinical teams to place the order well in advance of the patient arriving 
for the test; 
c) providing phlebotomy staff with access to information relating to the types for request 
for patients who were on the list and expected to arrive; and 
d) enabling clinical staff to have access to a real time status update on their requests, 
thereby reducing the number of calls they have to make to the labs chasing the result 
or to find out if the results were available. Although staff had access to the lab system 
across most locations, the lab system did not have a status update and hence clinical 
staff repeatedly checked the system for results prior to calling the labs.  
When the solution was piloted, it became very apparent that it took the requesters 
considerable time to place each order, as the labs made the key fields that provided 
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the relevant information to process the request mandatory. Whist this enriched the 
information received by the labs and enabled them to perform the most effective test, 
reducing substantially inappropriate tests and hence saving money in the process, two 
key issues halted the implementation. 
 The labs were not willing to change their internal workflow starting from the time 
they received the order, as the four labs (haematology, blood transfusion, 
biochemistry and histopathology) had differing sample processing procedures and 
insisted that the system conformed to their current way of working which was very 
heavily effort driven.  
 Senior clinicians found the ordering process time consuming as previously the 
nursing staff or junior doctors would fill the form and all they did was to sign. Now 
they had to complete the request form online. However, unlike in other specialities, 
the requester could place the orders away from the clinic as almost 90% of the 
requests were pre-orders, with the patient coming for the test only during the next 
outpatient appointment or treatment.  
On the other hand, junior and middle grade doctors who place the bulk of the orders 
found the system very useful as it allowed them to manage their time and workload 
effectively. The initial decision to deploy order requesting followed by result reporting 
was reviewed as a result of this finding. In the end it was decided to implement result 
reporting without order placement, to allow the clinicians to see the benefits of 
receiving results in real time hoping this would encourage them to start using the 
system for order placement. This compromise in the event led to partial 
implementation.  
8.2.2 Implementation of the schedule 
The body of work as described as part of this research contributed substantially to 
understanding the end-to-end patient pathway, identifying key bottlenecks, defining and 
proposing feasible solutions. The model validation exercises helped and provided the 
opportunity to review, examine and question current work practice in detail and enabled 
the development of a preliminary future state workflow. 
It also provided valuable insight into the users’ willingness to adopt new ways of 
working and embrace new solutions for old problems, while questioning whether the 
new solution would bring new problems. This enabled the service to introduce change 
identified by the model and to integrate this into everyday workflow.  
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The work also helped develop the implementation framework and prioritise the 
implementation schedule as shown in Fig 8.1, prioritising those functionalities that 
would a) deliver like for like functionalities, which the users have used and depend 
upon to deliver operational service; b) resolve or alleviate operational bottlenecks; and 
c) deliver and realise bigger benefits to the end users and the organisation.  
 
 Fig 8.1 – Implementation Schedule 
 Replacement of current patient administrative systems (PAS) 
 Interfaces to legacy system 
 Radiology 
 Radiotherapy 
 Pathology 
 Theatres 
 Finance 
 Pharmacy 
 Bed management – with real-time   Admissions, Discharge and Transfer (ADT 
functionality (part of PAS) 
 Clinical (Annotation) Noting and Proforma  
 Result reporting  
 Order Communication 
 Electronic prescribing (outpatients) 
 Theatres 
 Radiotherapy 
Bala Sridhar, ICIS Project Manager
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 External Clinics 
 Electronic Prescribing (Inpatients) 
Figs 8.2 and 8.3 summarise the step by step approach taken to interface to legacy 
systems with the EPR system making the EPR system a repository for vital clinical 
data, allowing users to access and view data from within a single system. The EPR 
system was the master system for recording patients’ demographics, which was then 
automatically rolled out into all the other systems connected to the EPR using the 
international standard of Health Language226 (HL7) defined for efficient data exchange 
facilitating interoperability across system suppliers. 
This allowed data from the legacy system to be analysed alongside the data generated 
within the EPR system. Integration of the EPR system with the existing system was 
vital to maintain optimal patient caseload as these changes were introduction into a live 
environment. However, some of these legacy systems were scheduled to be replaced 
as part this implementation. To support business operations these were interfaced in 
such a way that the replacement system would be re-interfaced with minimal 
modifications.  
 
 
 
Fig 8.2 Schematic of interfaces to legacy system 
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Fig 8.3 Schematic of interfaces to legacy system (cont) 
 
Fig 8.4 provides an overview of the Electronic Patient Records functional schematic 
showing the various modules that would enable the service to operate and deliver high 
quality care, by allowing staff to have access to patient-related information at the point 
of care. The research carried out provided valuable information for:  
 understanding the gaps, bottlenecks and base-lining of the current service 
provision 
 providing a knowledge source to customise and design the functional 
modules, with the researcher playing an active part in influencing the design 
on behalf of the organisation 
 enabling the research to be communicated and conveying the user 
requirements to various authorities  
 validating the model in an electronic environment. 
 planning and co-ordinating the implementation schedule based on the 
findings of the review to enable the service to deliver better patient-centric 
care 
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 allowing the researcher to modify the model from lessons learnt as part of 
the implementation. 
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Electronic Case Note
Patient details
Clinical history
Contact history
Security/
Confidentiality
Filter
Security/
Confidentiality
Filter
Security/
Confidentiality
Filter
Security/
Confidentiality
Filter
Level 3 Level 5Level 4 Level 6Key (EPR): Level 2
PACS
5
Knowledge-
bases 5
Clinical
alerts 1
Embedded 
Clinical 
guidelines 4
Order Comms
4
Results 
Reporting
3
E-Prescribing
5
GP eBooking
Bed 
Management
ADT 2 
Casenote
Tracking
1
Outpatients
1
Commiss-
ioning
2
Clinical
Encoder
3
Statistics, 
Reports
Clinical Noting
3
Theatres
1
Waiting List
1
Inpatients
1
Master  Patient 
Index 1
Clinical Proformas 
& Letters 
2
INTERFACE  ENGINE1
LEGACY  SYSTEMS 1- 3
Bayer
Laboratory 
System 3
Radiology
3
Blood 
Transfusion 
System 3
Radioisotope 
System
3
Histopathology  
System
3
Finance 
System
1
Microbiology 
System
3
Patient  
Diagnosis
Information  
4
Fig 8.4 Schematic of the Electronic Patient Records functionalities and their interrelationship.  
 
The implementation of the various EPR modules facilitated the realisation of the 
primary objective of the model by enabling a framework to be secured to record, 
exchange and present data/information at the point of care. The single biggest issue 
that faced the service delivery team was the number of disparate legacy systems that 
were used to capture and store data. Some of these offered limited opportunities for 
integration, whilst others were not able to be integrated with the upgraded platforms. As 
a result, staff were forced to replicate data from one to the other, often transcribing 
from an electronic medium to paper to maintain a record at a single place, which took 
the form of paper-based medical case notes. This acted as one of the biggest barriers 
for the implementation of an integrated MDT model. 
The ability to exchange data and access information between and from various 
systems enabled staff to redesign many of the operational procedures, thereby 
releasing valuable clinical time just by not re-entering and recapturing data multiple 
times. This also allowed the operational team to review their demand versus capacity 
model in order to align it with service configuration.  
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There are many good examples where these changes have directly benefited patients 
and their care, including the following: 
Clinical Annotation: providing instant access to patient care notes and care plans, not 
having to track the paper case notes. 
Real-time bed management: providing managers with an update on bed availability, 
prospective discharge, allowing staff to pre-plan and co-ordinate discharge planning, 
also allowing the receptionists to inform patients’ visitors as to the correct location of 
the patients.  
E-prescribing: eradicating illegible scripts, lost prescriptions, thus reducing  medication 
errors227,228 and delivering quicker service at the pharmacy counter; also allowing the 
delivery of the medications to the correct location within the hospital. Fig 8.5 and 8.6 
provides two very good examples that highlight the everyday risks that exist within the 
healthcare system. These errors are prevented from becoming a reality purely because 
of the many stringent operational policies put in place within the pharmacy, as a result 
of which there are always queues outside the dispensary. 
 The deployment of e-prescribing not only helps eradicate illegible writing, reducing 
some of the errors illustrated here, but more importantly provided the MDT team with 
valuable data for measuring the effectiveness of their treatment decision when it comes 
selecting a chemotherapy cause for first, second or third line treatment. 
 
Fig 8.5 Example of an illegible prescription. 
 
The prescription in Fig 8.6, if dispensed would have not only killed the patient but also 
cost the £340,000,000 for the 95kg of cisplatin.   
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Fig 8.6.  Second example of an illegible prescription; a very expensive prescription. 
Fig 8.7 and 8.8 illustrate the potential that technology offered to plan and monitor 
service quality and performance. 
 
Fig 8.7 Use of data obtained from the EPR system. 
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Fig 8.8 Use of data obtained from the pharmacy system. 
8.3 Summary 
This chapter has summarised the contribution made by the programme of research 
towards the implementation of the EPR system, thereby demonstrating the validity and 
scalability of the model in an e-environment and the integration between process and 
technology to address and resolve operational bottlenecks. It has demonstrated how 
the technology as an enabler can bring about significant benefits to patient care and 
allow professional staff the freedom to adhere to good practice. 
The project implementation team were very complimentary, as such an implantation 
could not have been achieved without substantial documentation and understanding of 
current business processes, which in turn enabled the development of the model as 
described in this thesis. The pilot studies undertaken prior to implementation benefitted 
from use of the model to plan, schedule and co-ordinate appropriate resources. 
The following chapter will go on to discuss and review some of the major issues that 
have arisen during the course of undertaking this research. 
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9 DISCUSSION 
The aim of this study was to question whether the current service configuration allowed 
every cancer patient to be reviewed by a multidisciplinary team (MDT) prior to 
treatment decision; and whether such review of all cancer patients by the MDT would 
improve survival rates, clinical outcome, improve access to care, facilitate professional 
communication and improve quality of care provided to cancer patients given the 
variations in current service organisation. 
The rationale behind these questions is based on the published evidence that the 
current cancer service organisation and provision across the country was variable. The 
Calman Hine Report recommended changes that called for a root and branch 
reorganisation of the current cancer service configuration. This posed an interesting 
challenge as the recommendations, described in Chapter 4, whilst proposing a revised 
service configuration to improve delivery of cancer care, provided little guidance or 
information to local service providers on how to carry out the service assessment, the 
resource implications required to undertake such a task and on how to bring about the 
recommended changes and manage their impact on service reorganisation. 
At the time of the publication of this report the NHS was operating a Purchaser – 
Provider Model, where the Health Authorities and Fund Holding General Practitioners 
formed the purchasers of health on behalf of their catchment population and the acute 
and community hospitals were the service providers. Some of the changes proposed 
were quite complex. As a result the service providers had to undertake detailed review 
of their service configuration, either by employing external consultants or by bringing 
together a group of staff with relevant skills to undertake this review to understand and 
evaluate the magnitude of the task. 
It was notable that as some of the information required to make the decisions and 
assess the impact on current service configuration did not form part of the operational 
requirements; it was not recorded and hence was unavailable. A special team of staff 
were deployed to collate this information, investigating a number of source systems 
and conducting dedicated audits to gather these data.  
Chapters 4 and 5 described the work that was required to be undertaken to define the 
baseline, before providers could work with one another and with purchasers to redefine 
service configuration. Providers in the same catchment area were competing with each 
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other, as they were all trying to achieve Cancer Centre status as this would attract both 
higher funding and skilled staff to their organisation. 
Service evaluation revealed the extent of service disparity even within the health foot 
print of a given health authority. This led to service commissioners and finance 
directors demanding large sums of funding from the Regional Authorities (soon to be 
rationalised into Strategic Health Authorities) to bridge the gap and develop the service. 
This provided the author with an excellent opportunity to understand, to examine the 
current cancer service configuration, and identify issues, bottlenecks and constraints of 
the real world, before defining an idealised model of service delivery by employing Soft 
Systems Methodology. The reasons for choosing this methodology are discussed 
below. 
It was then possible to define how services could be realigned with limited resources in 
contrast to identifying what was dependent on both internal and external factors such 
as equipment, staff and skill shortage.  This study also helped to identify the good, poor 
and outdated practices and processes in the delivery of cancer care, prompting 
questions such as “Are we getting value for money from the National Health Service?” 
“Can we get more for the current level of investment?” “Will the service perform better 
with additional investment, whist retaining the current management practice and 
standards?” 
9.1 Development of a Service Model 
The author started this research with the intention of developing a toolkit, a 
mathematical model to enable NHS managers to define, design and evaluate a service 
model for oncology. This would then enable them to deploy a service model that they 
knew would work or at least give managers great visibility as to the issues, gaps and 
changes required. As soon as data collection and investigation for data sources was 
started, two key issues became apparent. The first was access to data from various 
organisations, as detailed in Chapter 5; the second was all existing data repository 
systems in the organisations approached that were largely designed to collect 
administrative data with a small sub-set of clinical data. Developing a mathematical 
model to address clinical work flow, without clinical data, proved challenging and had to 
be abandoned. 
This critical issue forced the author to re-evaluate the modelling approach and 
understand and define the problem prior to identifying which modelling techniques 
should be employed. Review of local service configuration presented a complex, 
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messy operational problem situation. It became clear that problem definition for this 
research was not straight forward, but in itself problematic, in that those different 
professional groups had different perceptions of the issues and requirements and there 
were differences within the same professional group in defining the problems. Hence 
as detailed in Chapter 4, Soft Systems Methodology (SSM) was chosen to help define 
the problem prior to model development as it had the capability and a proven track 
record for handling groups with diverse starting points and differing mind sets. There is 
an assumption that homogeneity exists amongst stakeholders when they come 
together to review, address and create/construct solutions for the problem situation, but 
this assumption can be highly misleading. In addition to differing opinions and 
perceptions, other constraints such as time and resource availability also influence the 
dynamics of the group. This approach does not take the organisations for granted, 
always assuming that staff working in these organisations have differing views and 
perceptions rather than subscribing to some overarching objectives and priorities. 
This approach also enabled the author to deconstruct some of the misconceptions the 
author had about soft methods. In mathematical approaches or in operations research 
it is typically assumed that a model is a proper representation, a simplification or an 
abstraction of the real world. In this view it is vital to ensure that the model is truly 
representational and its operations thoroughly validated against the part of the real 
world being modelled. In contrast such assumptions are unnecessary in soft 
approaches, where models are developed, with the developer of the model interacting 
and involving people, staff or users in debate about possible actions, discussing cause 
and effect of those actions. This is carried out prior to developing the model that is to 
be tested, shown to be relevant and most importantly owned by the people of that 
organisation. 
Hence the focus of the research was diverted to developing a model using SSM that 
would also contribute towards the development of systems that would facilitate the 
establishment of a robust repository for clinical data, thereby enabling review of clinical 
outcomes, efficacy of treatment etc. Research in healthcare modelling aimed at 
developing mathematical toolkits is under way in a number of other universities, e.g. 
researchers at the University of Southampton, School of Mathematics are working on a 
project titled “"RIGHT" (Research into Global Healthcare Tools) – creating a toolkit of 
techniques for NHS service delivery”, an EPSRC-funded project. 
Soft models not only help to identify and express the interrelationships and 
dependencies of the various processes, but also identify and bring to the surface 
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hidden issues, at times the critical components of the service that are often invisible. 
Resolving these is often very important, prior to addressing the visible issues, to ensure 
safe delivery of the service.  This research allowed the author to appreciate the 
importance of soft models, their practicality, and significantly the ability to engage 
service users along the modelling process. 
Employing Soft Systems Methodology for conducting service review helped to identify 
and define a number of issues that would otherwise have been missed. The use of the 
Rich Picture to encapsulate the real-situation, constructed in a participatory manner, 
allowed the various representatives in the group to contribute their individual process 
components that merged into the larger picture. This visualisation of the process 
evoked creative thinking, enabled to surface arcane and at times cryptic issues 
contributing to exemplify those issues that are difficult to express as words, but which 
are easier as pictures. 
The Rich Picture provided the opportunity to capture the day-to-day processes freely in 
a way that allowed the users to contribute without any rigid constraint and enabled the 
author to note down almost all of the processes. Moreover, it helped to bring out a 
number of inter/intra professional misunderstandings, the complex nature of the 
processes that were followed, which the other groups were not aware off and also the 
constraints under which some of the professionals delivered their work. Most of these 
processes were not explained explicitly during the workshop, but it was quite evident 
that other professional colleagues had not fully comprehended the intricacies of the 
processes they came to rely on. 
It became evident that most users were aware of the service issues and often had a 
practical solution for some of the routine issues they faced, but were unable to 
implement these, either because they were not able to voice their opinion or that these 
solutions were not paid due attention by the immediate managers.  
Joining up or sequencing the processes was done later on in the workshop. The impact 
of these question and answer sessions was revealed during the presentation of the 
preliminary service model as the users were questioning aspects of processes and 
procedures in situ that were otherwise taken for granted. The interactive sessions had 
sent a subliminal message that came into fruition during the presentation of the 
preliminary model.  
The review undertaken as detailed in Chapter 4 identified a series of complex issues 
along the cancer patient’s pathway. 
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9.2 Communications 
Inter/intra professional and sector communication was identified as a major issue, both 
along the vertical and horizontal hierarchy of the organisational structure.  It was 
compounded further by the fact that each organisation often had different service 
delivery pathways and modes for exchanging patient related data/information. The 
method of communicating and adoption of technology to support these data exchanges 
also varied, often dictated by the availability of technology, skilled staff to implement it 
and infrastructure to use such technology.   At times technologies that were 
implemented to facilitate communication and exchange of vital clinical data introduced 
new issues that were not previously present. A good example that illustrates this point 
is the way the oncologist reviewed results prior to approval of chemotherapy treatment. 
The laboratories always published interim results for both biochemistry and 
haematology requests. The interim results were often communicated over the 
telephone followed by mailing the paper copy to the relevant clinical staff.  The 
laboratories then validated the results and the final report was subsequently mailed. If 
any variations were identified, then the labs contacted the relevant clinical staff by 
phone to communicate these changes. This process had many weaknesses, but 
principally the following two:  
 The first was not being able to contact the clinical staff on time, staff who had 
made the request and who reviewed the interim result and actioned 
treatment, to notify the changes. 
 The laboratory policy was to mail the result to the original location from 
where the request was made, but often when the patient was moved to 
another ward or location the paper copy did not follow them. This led to 
clinical staff not receiving the result and repeating the test again, 
inconveniencing the patient and wasting resources. 
Electronic results were introduced to resolve these issues, allowing the clinical 
staff/team to look up the results, removing the need for the clinical staff to ring the labs 
to obtain results or vice versa. However the printing of paper results continued along 
with the policy of mailing results to the original location from where the request was 
made. Access to the e-result was limited by the availability of computers. The staff to 
computer ratio was far too low with more than 10 staff sharing one machine in certain 
areas. With the advent of electronic patient records (EPR) the laboratory systems were 
interfaced to the clinical information system that supported the EPR, with an agreement 
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for interim results to be over-written by the final result. This was done in order to 
economise on data storage as this was expensive, adding further capital and revenue 
cost.  
The reasoning behind this decision was also based on the fact that the source system 
contained a record of both the interim and final report. Operationally this caused clinical 
risk at the user’s end, as staff approved treatments based on interim results. However, 
when staff came to administer the medication and checked the results, they saw the 
final result that had been revised following laboratory validation, indicating that the 
patient was not fit to receive the medication. Since the interim result had been over-
written by the final one, there was no way to confirm if this was a mistake or poor 
clinical judgement. The only way to resolve this was to check these results on the 
source system to which the end users did not have access. Such cases are recorded in 
the incident form as near misses and time and effort is spent in trying to understand 
why this had been caused in the first place and what appropriate mitigating actions 
should be put in place.  
The system implemented to eliminate and ease such communication issues at times 
was forced to make compromises due to limited funds, thus creating new issues that 
could have been avoided. 
Looking across the patient journey, many such examples were identified and the model 
developed attempted to address some of the key issues that either could be addressed 
within the resources available when supported by management or else had a direct 
dependency on the Multidisciplinary Team model.   
9.3 Referral delays 
Professional staff in the NHS have always said that standardisation kills innovation and 
creativity, but in the case of the referral process standardisation was essential to 
resolve referral delays. Delays in referral often were due to the referring organisation 
not adopting the pre-specified format for requesting outpatient appointments. The 
patient is being managed by multiple clinical teams and professional groups and this 
information is often not communicated back to the surgeries or to the secondary unit. 
Non-compliance of staff to adopt and embed new technologies effectively into the 
operational process was not the only factor however as the data required to complete 
the referral forms were often not available to the front line staff at the time of 
completion.  
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9.4 Dichotomy of professional standards and requirements  
The health care workforce could largely be divided into clinical and non-clinical staff 
groups. The clinical group undergo a strenuous scrutiny and assessment prior to being 
certified fit to practice and this was followed by an on-going programme of professional 
development that consists of tiered periodic evaluation and assessment that enabled 
weak/ poor performing clinical staff to be identified, thus enabling them to obtain 
appropriate help to address these issues.  
On the other hand non-clinical staffs were assessed against the job description at the 
time of their interview prior to their appointment and from then on there was very limited 
assessment on an on-going basis, apart from a yearly formal review and informal 
personal development plans. However these are not rigorously monitored and thus do 
not have the same rigour as applies in the case of the clinical staff. Also continuous 
professional development is discretionary, being decided by the line mangers who 
often have only very limited funds to support their staff's development. Management 
staff training is arranged on an ad hoc basis and new skills are often limited to dealing 
with new initiatives.  
Management staff's experiences moulds them to be able to discharge their duties, 
meeting and delivering the directives defined by the Department of Heath, regional 
authorities, senior management etc. It also helps them become well versed in dealing 
with local issues and customising solutions to fit specific problems, with very little 
opportunity to share these across the wider NHS network, although this situation is 
changing fast with the advent of the NHS Institute for Innovations and Improvements.  
The impact of this is that there are now some extremely talented, highly skilled and 
motivated clinical staff who expect to be supported by equally talented, skilled and 
motivated administrative and management staff. To a large extent this is the case, but 
the pace and numbers of initiatives, targets and directives does not allow these staff to 
flourish within the current service configuration. 
9.5 Dealing with change 
The findings of this study demonstrated many justifiable reasons as to why the delivery 
of heath care varies and does not meet expected standards at times.  Changes 
introduced into the system are often poorly tested and their impact on current service 
patterns, demand and skill requirements are either not fully understood and 
appreciated or else are considered not to be relevant. Too many directives aimed at 
improving the quality of the care delivered, the safety of the care and the introduction of 
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new treatments and methods of care are initiated independently in close succession, 
either as a result of an investigation, or as a direct consequence of clinical and 
technological advancement. This causes the health care delivery system to lurch from 
one initiative to another leading to partial implementation, with too little time being 
available to properly embed such changes into the operational process. Programmes 
are often aimed at one professional group, but the impact and dependencies on other 
professional groups is not well defined or not properly communicated. This only 
becomes apparent during the implementation process, calling for additional resources 
in the form of funds, staff, skills mix, infrastructure development and the reprioritising of 
existing work programmes. 
Other initiatives mandated by the Department of Health, such as target monitoring, 
performance, waiting lists etc., impact significantly on organisations as a whole, as 
these initiatives require the organisation to start collecting new data items that are not 
part of the normal data gathering process. The organisation then spends much time 
and effort gathering data and employing staff dedicated to monitoring and ensuring that 
the organisation meets these new requirements. They also spend time in upgrading 
their data collection system to meet these new requirements, some of which are 
discarded when another new initiative is introduced the replace the earlier initiative.  
The constant reorganisation of the NHS has necessitated the organisation to rebrand 
and merge229 services on a periodic basis. The rationale of these constant reforms has 
often been questioned by many think tanks and researchers230. The dependencies 
between policy and economic logic in terms of the control of total costs, the equitable 
distribution of hospital services, and efficiency in delivery have been subjected to 
detailed study. In the 1970s policies were introduced to achieve equity, but not 
efficiency. In the 1980s the Thatcher government introduced an efficiency drive through 
a budgetary squeeze that resulted in the NHS funding crisis in 1987-88.  This led to the 
creation of the NHS internal market with its purchaser-provider split, mentioned earlier 
in this thesis, with the belief that money would follow the patients, thereby justifying the 
injection of additional funds for three years. In the 1990s the Labour government 
abolished competition, but maintained the internal market that sustained the 
constraints. This resulted in the funding crisis of 1998-1999. 
9.6 Resource utilisation 
Resources referred to in this discussion constitute finance, workforce, infrastructure, 
estate, equipment and information. Although this study was focused on ascertaining 
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service configuration of the cancer service and issues associated with it, it enabled the 
author to obtain a close look at the impact of initiatives, including programmes that 
were mandated for various health professionals such as the pharmacists, laboratory 
staff, health informaticians etc. What became evident was that although these were 
targeted at specific professional groups, when they had to be implemented there was a 
dependency on other professional groups. This dependency was either not fully 
understood or made explicit, thereby calling for unplanned realignment of services to fit 
the requirements either for safety or changes to service needs. 
There was an opportunity to understand the scale of under-utilisation of resources right 
across the board including equipment, staff, consumables, space, energy and time. 
These were mainly due to the way the services were organised delivering care from 
8am to 6pm for five days a week; leaving the service handling only emergency and 
inpatient care between 6pm to 8am during the week and with skeletal staff cover over 
weekends, Bank and National holidays.  Organisations need to review their operational 
service as the present configuration lends itself to creating a bottleneck whereby 
patients have to wait longer then normal during weekends and holidays for getting their 
results, and being seen by appropriate care professionals. Patients categorised as 
critically ill are well served, but the service offered to the medium to minor emergencies 
are significantly affected. 
Major issues exist in communication as highlighted earlier in this chapter. These exist 
between the health care professionals themselves, be it during handover, exchange of 
significant clinical data or when communicating to patients about their diagnosis, 
prognosis or in relation to care. This is constantly attributed to lack of time and demand 
on the service, whereby the professionals have very limited time to spend with each 
patient. This issue at times is a reflection on the way the service is structured and 
supported with staff and equipment, driven mainly by the financial envelope rather than 
by demand. In addition to these pressures, the service managers and administrators of 
the system have to deliver year-on-year cash improvement (savings) programmes 
(CIPs) of up to 3%.  
The inability to procure new technology to deliver these improvements results, most of 
the time, in loss of lower order administrative staff. They were mainly responsible for 
managing and maintaining the routine tasks such as filing of results, letters, clinical 
documentation, updating demographic information, adding additional note sheets in the 
patients’ notes, preparing the case notes for medical review etc. Thus this loss results 
in disorganised case notes, with the reviewing clinicians not able to find important 
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information in the notes. Electronic case notes are extensively deployed, but limited 
funding to such projects necessitates the maintenance of paper case notes when the 
patients are seen in locations outside the hospital. 
9.7 Deployment of Technology  
Concerns about the escalating cost of health care are reflected in the investment and 
pace of introduction of health technology. Numerous economic studies evaluating the 
cost effectiveness and cost benefit of technology have been published231,232. The 
Department of Health placed a higher value on the formulation of systems to support 
service delivery within the NHS, but soon recognised the need for standardisation of 
these technologies. Over the years primary, secondary and tertiary care have seen a 
steady increase in the growth of electronic patient record (EPR) systems. 
Electronic systems have their own issues as these systems are only good if they are 
specified and designed correctly. In the NHS system specification is predominantly 
done in three ways:  
 Approach 1) Identifying a group of key staff from amongst the various 
professional groups who are then delegated the task of writing the specification. 
They in turn host series of workshops, meetings and discussion groups before 
finalising the requirements.  
 Approach 2) The second option is to ask other organisations who have recently 
deployed such systems for a copy of their specification and to customise them 
to meet local requirements.  
 Approach 3) A combination of the above two. 
Approach 1 requires a long lead time, good planning, stakeholder engagement and co-
ordination, something that organisations with short time scales to define requirements 
cannot undertake. The down side of this approach is that from the time this work gets 
started, the signing off of specifications and the procuring of systems can take anything 
between three to five years, which at times can render some of the requirements 
obsolete as some aspects of the health care system are very dynamic; this includes 
realigning services to meet nationally imposed changes. 
 Approach two usually has a quick turn around, but with limited stakeholder 
engagement and consultations. On implementation this meets with a lot of resistance 
and many aspects of the systems do not find a natural home, with the implementation 
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team tasked with revising and realigning the way people work around the system, 
rather than the other way around. 
For these systems to be successful in meeting their stated objectives and benefits, 
managers using these systems need to understand their full potential and how they fit 
into the business process of the service. Deploying technology in an organisation, 
because they can afford technology or because that is what all the other organisations 
are doing, without proper consideration of the technology often results in these systems 
being used more or less like a glorified database service;  their main purpose being 
only to capture data that meet the reporting requirements of the organisation. It is also 
a common experience in organisations when the relevance of these systems is not 
clarified within an organisation. These systems are directly reliant on good data 
collection processes and periodic data quality checks to ensure data quality and 
completeness. Lack of data can become a limiting factor and as such can negate the 
cost-benefit values of these systems. 
Deploying new technology enables the organisations to realise the hidden potential of 
the system, with models helping to integrate these systems into operational work flow 
with the co-operation of the end users. This is a major factor that is often cited for the 
poor uptake of technology in healthcare233 and in other sectors. This is also one of the 
main reasons for the failure of IT projects. 
9.8 Development of MDT Model 
The work flow study undertaken to understand the requirements for developing a 
Multidisciplinary Team (MDT) model highlighted the dependencies of numerous 
precursor factors and variables that had to be available before an MDT service could 
be effectively operated. The main requirement for the MDT service was the availability 
of relevant vital clinical data items and information from referring organisations and 
clinical teams to enable the MDT team to make an informed treatment decision. Lack of 
these data made this process fail the core purpose of the MDT service objective. 
9.8.1 Capacity versus Demand 
The first significant challenge for the service was to deal with capacity versus demand 
issues, i.e. how to process every patient with a diagnosis of lung cancer so that they 
might be reviewed by the respective MDTs. The study identified that accommodating 
all the patients into the tumour-specific MDT was an enormous challenge. If any 
patients already had an MDT at the referring organisation, this meant that a treatment 
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decision was already made and the referral was part of that decision. As this primary 
MDT decision was significant for a lung patient, the Lung MDT was unusually hosted at 
the Cancer unit or at a District General Hospital (DGH). 
9.8.2 Availability and access to data relevant to MDT 
The core data requirement for all the MDTs, irrespective of tumour groups, apart from 
some limited variations, was common. This also meant that the issues they faced were 
also largely the same, particularly access to data from the referring clinical team, be it 
primary care or secondary care. The NHS cancer plan and other cancer strategies 
advocated the need of data and defined the data items, but provided little guidelines or 
funds to secure systems that could be deployed to capture these data. Hence it fell on 
the organisations to come up with the most appropriate system that would allow them 
to collect these data. Solutions ranged from organisations using Microsoft Excel and 
Access database applications to organisations procuring bespoke MDT applications, 
such as eMDT and the Somerset Cancer Register Systems that facilitated data 
capture. 
The interoperability of a system was considered, but did not feature as a priority and 
was often compromised to keep the cost of the system down, as long as there was a 
way of extracting the data in an electronic format.   This impacted on the seamless 
electronic transfer of data across the cancer pathway.  
In addition to funding for data systems and setting them up, the organisation had to find 
a way and the necessary staff to collect, manage and co-ordinate all the MDT meetings 
to facilitate review of patients' case notes. This too was done in different ways 
depending on the financial position of the organisation. Servicing of the MDT meeting 
became dependent on the availability of MDT co-ordinators, who were often very 
scarce, hence able to service only a few MDT at any given time. This meant that only 
peer reviewed MDTs were serviced by MDT Co-ordinators. Peer reviewed MDTs are 
those that are scrutinised by an external body as compared to non-peer reviewed 
MDTs. Hence non-peer reviewed MDTs are seldom staffed or are only serviced when 
there were no competing demands from the peer reviewed MDTs. 
9.8.3  Local versus National solutions 
When it came to implementing the MDT model, apart from local organisational 
differences, deployment was further compounded by the fact that there was already a 
programme of work progressed by the NHS Modernisation Agency via the Cancer 
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Services Collaboration to address these issues and which had the national mandate to 
implement their solution. These solutions were developed by health professionals 
submitting their ideas/concept for a prospective solution to the agency, which in turn 
selected the most promising, substantiated with evidence, and funded these initiatives 
for pilot studies. If they were proven to be successful locally, then they were 
recommended to the other health communities. The issues with these recommended 
solutions were that they might have worked for the specific health community where 
they had been developed and piloted to resolve particular issues that affected that 
health community. It is only when other health communities try to adopt these 
recommendations that they identified issues that were not witnessed during the pilot 
studies. 
Local solutions often have to compete for funding alongside all other equally important 
priorities, but the cancer collaborative programmes were often backed up with separate 
funding streams, encouraging local managers to prefer a national solution over the 
local. This resulted in only the part implantation of the MDT model at the level of the 
local health economy. 
9.9 Contributions to knowledge 
This research project enabled the author to experience service developments from 
within the health service and question some of the current practices. This research 
provided the researcher with an opportunity to combine principles of SSM, LEAN, (also 
referred as the Toyota Production system, is a management system refined by Eiji 
Totoda of Toyota Motor company, for problem solving, leadership, focused on 
improving production {efficiency by eliminating waste}, operations, supplier 
collaboration, product and process development  and customer support) and aspects of 
Discrete Event Simulation (DES) within a complex, critical and dynamic environment to 
forge a new way of working, contributing to improved patient care and in the process 
testing the flexibility and accommodativeness of the modelling approaches adopted for 
this research. This research enabled the author to contribute and influence the 
development of date utilisation with in the operational environment, assisting in the 
establishment of clinical business intelligence repository Fig 9.1. 
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Fig 9.1  Model of clinical business intelligence development dimensions. 
 
9.9.1 Modelling Methodology 
Through his research the author has demonstrated the applicability of soft models in 
the health care domain, most importantly to define problem situations by facilitating the 
involvement of relevant stakeholders (professional groups) as partners. This process 
enabled the voices of the stakeholders to be heard, and in turn they had a heightened 
sense of willingness to participate and contribute, as they felt empowered to envision 
the transformation required and construct practical solutions to resolve the (uni- or 
multi-professional) problem situation. 
Modelling techniques helped the service managers and users to review and assess 
options with more certainty and clarity. Models helped to crystallise the cause and 
effects of proposed changes and the impact on valuable resources. Without the aid of 
modelling the service would have adopted a trial and error method to test options that 
were formally selected following an options appraisal exercise on paper. Adopting soft 
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models is the best approach when dealing with a dynamic, complex, process rich, 
multi-professional team dependent, protocol and guideline driven health care domain. 
This research using Soft Systems Methodology was able to delineate the various 
pathways that would have otherwise been impossible to differentiate, to deal with what 
looked very complex issues to resolve prior to employing this modelling approach. The 
weakness of deconstructing a complex system is that it is easy to miss the whole 
picture in the process. The strength of SSM has been to help the researcher 
concentrate on the research question, whilst retaining the context of the wider system 
within which the researcher is operating, helping to preserve the relationship between 
the two.    
9.9.2 Clinical Domain 
Applying a model-based framework to define the clinical service problems enabled the 
author to reconfirm to the various professional staff responsible for delivering cancer 
services the innate intertwining of service pathways and their dependencies on each 
other. It might be argued that the complex nature of health care pathways is a well-
known fact to staff working in this domain or even staff in the health care services more 
generally. At times it is assumed that they are aware of these relationships. However, 
dissecting the various pathways followed by the patients and/or data with 
representatives of the multi-professional staff enables the staff to gain an in-depth 
understanding of these relationships and at times openly admit that they never realised 
the full nature of the complex processes that were involved. A good example was when 
the group was reviewing the requesting of a pathology lab test, discussing the 
importance of completing the request forms in full, with details of diagnosis and other 
clinical data, apart from what test was requested and by whom. The consultants 
involved in the review were more interested to know about delays in obtaining results 
and asking the lab staff to explain.   
The world view of the requesters of tests was that samples were collected and received 
by the labs, and that these were then processed in analysers that generated the results 
at the end. Now what the lab staff were to do was to review these results and inform 
the clinicians. It was only when the lab staff explained all the additional tests that they 
did (for example,  reflux testing based on the diagnosis to ensure that the clinical team 
got the full picture of the patient's biochemical profile, the governance and safety rules 
they had to adhere to as part of the validation routine prior to releasing a result and the 
sample management process) that the consultants and other professional staff in the 
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group understood for the first time the complex and investigative nature of the activity 
of the lab staff who work purely on the information they glean from the request forms. 
On hearing the steps and procedures that the labs follow when handling each sample, 
the consultants in the group acknowledged the speed at which these results were 
delivered to them for progressing treatments, especially chemotherapy. Haematology 
results on average were turned around in eight minutes and biochemistry in twelve 
minutes. In addition to facilitating transfer of operational knowledge, the modelling 
process also enabled the staff to question both intra- and inter-professional practice, a 
self-appraisal process that ended with a more streamlined process, and helped achieve 
a LEAN outcome without the group realising that this is what they were doing. The 
biggest benefit of this process was realised at the time of implementation as large parts 
of the changes were well received, with the staff feeling that they owned these revised 
processes. There were still some outstanding issues as not all that had been agreed 
within the group was approved for deployment by the management. 
 The use of modelling allowed the author to propose a two tier service model to fast 
track early stage patients. Although this was not part of the original research, it was 
something that had emerged as a result of the work carried out to understand the 
system configuration. It was not accepted, however, due to the ethical ramifications of 
a system that is funded by tax payers. Many of the lessons learnt from the service 
review were used in customising and implementing the EPR system at the Trust. 
Another of the key issues that was identified as part of the research via modelling was 
the lack of good quality clinical data and systems to capture them. This was also 
addressed via the EPR implementation. A further outcome was that the Trust were 
recommended to appoint two clinical information analysts to support and prioritise 
services based on clinical performance. 
The value of using modelling as an integral part of health care planning at local level 
cannot be overlooked.  
9.10 Summary 
This chapter summarised the observations, challenges, issues experienced and the 
contributions to knowledge made by the author during the course of this research, 
some directly impinging on the research subject and others affecting the services as 
whole. The remit of this research did not extend to addressing all the issues observed 
along the cancer pathway, but provided an opportunity to reflect on complex inter-
relationships between the various pathways that interact with the patient's journey. It 
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also provided insight as to the missed opportunity of not capitalising on the unique 
strength of an organisation such as the NHS; something that other healthcare systems 
do not have and cannot match, namely access to a consolidated wealth of population 
health data waiting to be harnessed through a network of health information systems.  
The final chapter which follows will summarise the conclusions of this research, the 
extent to which the objectives have been achieved, together with suggestions for future 
research. 
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10 CONCLUSIONS 
10.1 Introduction 
As mentioned in Chapter 9, the author started this research with a firm commitment to 
contribute to developing practical solutions to everyday issues that could be 
implemented and used within the life of this research. The initial vision of developing a 
mathematical toolkit for NHS managers to manage and deliver services in the most 
effective way was not achievable due to the complexity of organisational bureaucracy 
as detailed in Chapter 5, affecting access to data and the availability of relevant data 
within the health community. The time and effort expended was not wasted, however, 
as it provided a valuable insight into some of the core issues that researchers needed 
to be aware of and prepare for to enable similar work to be undertaken in the future. 
This experience in essence proved the point quoted by Adam Savage of MythBusters, 
“Failure is always an option” in scientific methods.  
An initial perception of the author was also proved wrong. This was that only 
mathematical models could provide more accurate and much valued operational 
solutions that were precise, replicable and scalable rather than soft models. However, 
following the work carried out for this research and presented in this thesis, this view 
has been completely altered, with the author realising the true potential and strength of 
such modelling approaches, their significant value and importance in dealing with any 
operational situation, not just for addressing problem situations.  
10.2 Meeting the objectives 
Chapter one stated nine specific objectives, let us now return to each of them in turn 
and consider the extent to which they have been achieved.  
 To critically review published evidence for an existing or in-
development integrated multidisciplinary service delivery model for 
lung cancer.  
 To critically review published evidence to see if there similar models 
developed in other health disciplines or other sectors/ industries.  
An in depth review of published literature, not just at the beginning of the research, but 
on an ongoing basis, has demonstrated that although other health researchers and 
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teams within the NHS were working to address the issues surrounding the MDT 
pathway, there was no work replicating the objectives of this research. 
 To review current service configuration and identify the key issues, the 
bottlenecks along the cancer journey. 
The details documented in Chapter 4 provide a synthesis of objectively studying the 
system from within, by being able to establish the cause and effect relationships of the 
various inter-connecting processes and pathways; differentiating those that are core to 
the delivery of cancer care and those required to facilitate the multidisciplinary team 
service. The unplanned changes to clinical bases (locations) provided an excellent 
opportunity to study different cancer service configurations that were all set up to serve 
differing populations with different health profiles and social deprivation indexes. This 
also provided the opportunity to test the validity of the study framework developed to 
review cancer service configuration at the first clinical base (location); to define issues, 
bottlenecks and constraints across the health boundaries. This strengthened the 
author’s knowledge of current cancer service configurations, identifying service issues 
that were common to the different services and the salient issues affecting the 
particular health community. 
 To review supportive evidence by performing data collection and analysis 
The data collection and analysis undertaken during the course of this research 
established objectively not only the existence of issues impacting on clinical delivery, 
but also substantiated their extent and quantified the size of the problems. This work 
also enabled the author to identify the gaps in provision and to differentiate simple and 
complex issues related to data and data collection methods.  
 Understand the data collection process and requirements to support MDT 
meetings 
Having gained an overall understanding of data flow along the patient's cancer journey, 
the specific data requirements for MDT service were established along with the issues 
surrounding these. The limitation of such local service reviews often highlighted the fact 
that what could be identified as a problem for one cancer network need not be the 
same for another; but when it came to the MDT service model various national reports 
established that issues identified by this research were common across the range of 
other cancer networks. 
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 To develop a MDT model that will enable the service to review patients 
efficiently and is integrated into the service model.   
This research met the objective of developing an MDT service model, by constructing a 
conceptual MDT model that could support and address the issues identified during this 
research and also those documented in various publications specific to MDTs. 
However, given the limited remit of this research, testing across the local network was 
not possible.  
 To develop a pathway to facilitate rapid, safe, efficient, effective referral 
communication and data capture system. 
The author was able to incorporate much of the lessons learnt form this research into 
the operational design of the local Electronic Patient Record system with a view to 
facilitating and delivering the above stated objective. However these are again confined 
to organisational boundaries as other organisations went with the national solution for 
patient referral, namely Choose and Book. However, in the context of the Christie,  as a 
tertiary hospital, this system did not address the referrals between secondary and 
tertiary care, which is paper driven.  
 To validate the MDT model, by undertaking model-based experiments   
Model-based experiments and discussion with local cancer registry managers validated 
the proposed model, but implementation was limited by the current service 
configuration where, increasingly, clinical data and activities are seen as commercially 
sensitive. Adoption of the proposed model calls for major changes to current views on 
ownership and management of data. 
Restructuring of cancer registries should facilitate the housing of a regional cancer data 
repository as there is already a requirement for all organisations to submit their data to 
their respective registries.  
 To integrate the MDT model into operational workflow 
The organisation (The Christie Hospital) procured the Somerset Cancer Register 
System as this was offered to the Trust, funded by the Greater Manchester Strategic 
Health Authority in collaboration with Greater Manchester Cancer Network. The author 
was made responsible for the implementation of this system and it provided an 
opportunity to incorporate the concepts of the model wherever possible into the 
operational framework. 
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10.3 Contributions to knowledge 
This work further strengthens the evidence and value of SSM within the healthcare 
domain whilst highlighting the need for a comprehensive clinical data repository that is 
accessible, secure, economical (value for money), scalable and adaptable to promote 
and contribute to the improvement of clinical outcomes. 
Based on the limited number of published studies of the effectiveness of an MDT234 on 
clinical outcome and survival and review of local audits, it can be said that MDTs have 
been remarkably instrumental in changing patient care plans by channelling patients 
into more effective treatment pathways. The system should review patients at earlier 
stages of the disease to achieve further improvement in clinical outcomes, survival and 
quality of care. This outcome from the research has irrefutably demonstrated the 
benefits and the need for the employing of appropriate techniques and methodology to 
understand the requirements arising from the problem situation, prior to developing a 
solution. This applies whether it is a specialist or nontechnical issue so as to ensure the 
resources deployed deliver solutions that are durable and fit for purpose. 
This work has elucidated the importance of technology as a critical driver to achieve a 
significant reduction in the unit cost of health, improving the quality of data captured, 
and improving access to critical, clinical information while ensuring security and 
availability of data at the point of care. 
10.4 Further Research 
On the basis of evidence gained from this research, the author believes that a 
combination of both hard and soft modelling techniques has a vital role to play to 
facilitate healthcare to meet the challenges of the future. Significantly as the unit cost of 
delivering health is increasing exponentially, modelling will ensure that the service 
planner can develop services that will meet the needs and expectation of both patients 
and staff. By harnessing the rich data, the NHS has already generated and is 
generating developing of modelling solutions will support customisation and tailoring of 
patient- and staff-centric services based on clinical needs.  
Further research is needed into the use of SSM as modelling approach within health 
care. Literature review undertaken for this research established SSM as a well-
grounded and reasonable approach for understanding problem situations; however 
there are fundamental questions about the effectiveness of this methodology. The key 
strength of this methodology is also its weakness. Conceptual models developed in 
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SSM are constructed on the basis of the root definitions; hence these models are not 
models of real situations and cannot be tested to represent the real world, but only the 
specific problem situation. In this method defining problem situation is based on 
perception - either that of an individual, or of a group or groups, and perception can be 
distorted or these distortions can be persistent, thus rendering the evaluation of the 
effectiveness of this approach rather subjective.  SSM is said to be a learning system, 
as taking action is not the end point, as action taken to change the problem situation 
can give raise to new problems, hence there a learning cycle. 
Two key questions arise from this, first relates to SSM as a learning system, ‘To what 
extent does SSM enables users to learn about a real-world situation and whether the 
situation has improved or not?’  
The second relates to the assessment of effectiveness, ‘To what extent is SSM useful 
in distinguishing potentially beneficial actions from potentially weak ones?  
More work needs be done to address the assessments and evaluation of pursuing this 
methodology as there is a growing need within health care for combining the use of soft 
methodology and hard (OR) models in a way that lends itself to replicating the real 
world situation. 
 The NHS as an umbrella organisation should consider establishing a dedicated 
modelling unit to test and evaluate the effectiveness of policies and service changes 
before recommending or mandating the appropriate organisations.  This will support 
the delivery of cost effective and high quality care within the NHS whilst harnessing the 
wealth of national patient health data for the betterment of care in England and Wales. 
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Appendix A Patients Attitude Questionnaire 
Introduction: 
The questionnaire presented in this Appendix was used to obtain the patients’ experience and opinion 
of the local cancer service provision and help build a clear understanding, eliminating assumptions and 
distorted perspectives gathered through anecdotal evidence. 
This analysis of the data collected enabled the Health Authority comprehend the true extent of the 
quality, range and utilisation of the local cancer services including the good and bad service delivery 
experienced by the users. 
Table A.1 IN-DEPTH INTERVIEW QUESTIONNAIRE 
Category/ Question numbers Questions 
INTRODUCE SUBJECT:  
 
Thank you for agreeing to the interview. We wish to look at your attitudes 
towards cancer service provision in your health authority. in terms of how 
you feel your condition has been managed to date and any improvements 
you would like to see which will aid patients’ going through this process in 
the future. 
Ask patient to complete patient consent form. 
1) DIAGNOSIS  
Q1a  What is your diagnosis: 
Q1 b  Length of time since diagnosis: 
02   Did your condition come to light through a visit to the GP or via a hospital 
visit? 
 If  via GP visit go to Q3; if via Hospital visit go to  Q6 
Q3  Reasons for consulting the GP in first instance? 
Q4 How was the initial meeting handled by the GP/degree of 
sensitivity/information/explanation provided? 
Q5 What action did the GP take on this first visit?  
 If condition discovered via Hospital visit ask Q6. Otherwise go to Q7 
Q6 How did your condition come to light? 
1 a) DIAGNOSTIC TESTS 
CONDUCTED   
Ask All 
Q7  What diagnostic tests were conducted? 
Q8a Where /at which hospital were these conducted?  
Q8b  
 
How quickly were you referred on for tests following the initial GP visit? 
How satisfied were you with this waiting time? 
Q9  
 
How much explanation was given regarding the tests/procedures being 
conducted?  
What would you have like to have been told? 
Q10 How long did it take before a firm diagnosis was provided? 
 speed of provision of test results 
 how were you informed 
 completeness of diagnosis provided (i.e. initial diagnosis vs 
confirmation / exclusion of secondaries ) 
Q11 What counselling, if any, was offered? Was it adequate? 
Q12 How much information was provided at diagnosis about: 
a) the condition 
b) treatment options/protocols 
Q13 What questions did you want answered at this stage? How well did your 
GP/hospital staff address your needs? 
Q14 How important do you think it is for the GP/hospital to provide support/an 
explanation for your partner/ family /carer? Did they get the support they 
needed? 
Q15 Thinking about the care you received, from the point where you first visited 
the GP/found there was a problem at the hospital, until you had a firm 
diagnosis, what improvements would you like to see for patients in the 
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Category/ Question numbers Questions 
future? 
2) HOSPITAL  MANAGEMENT Ask Q16 if initially seen by GP, otherwise go to Q18a 
Q 16a How soon after your first visit to the GP were your first referred to hospital? 
Q16b Why were you referred? 
Q 16c Which hospital?  
Q16d   How long did you have to wait for your first hospital out patient visit 
following referral from the GP? 
Q17 How much choice were you given regarding where you were going to be 
treated? 
 awareness of variation in facilities at local vs specialist centre/unit 
 extent to which any patient preferences taken into account 
Ask all:  
Q18a 
How far do you have to travel to get to hospital? How much of a problem is 
it for you to get there? 
Q18b When thinking about hospital choice, what would you say is more 
important: 
 distance to the hospital i.e. that it is local to you? 
 or   that it is the specialist unit? 
Q19 Who were you first referred to at the hospital? 
 oncologist     1 go to  Q20 
 general surgeon   2 
 radiotherapist    3  go to Q22a 
 other specialist (specify)   4 
Q20 How much did the oncologist explain to you about how your condition could 
or should be treated at this visit? 
Did you have any say in how you were going to be treated? 
Q21 What happened next? 
Degree of follow up at the hospital: 
Q22a How often do you have to visit the hospital?  
Q22b Who do you see on these visits?  
Q22c Do you see the same person at each visit? 
 Yes   1 
 No   2 
Q22d How important do you think it is to see the same person or team of people 
at a hospital visit, is it: (READ OUT:) 
 Very important     1 
 Quite important     2 
 Neither important nor unimportant  3 
 Fairly unimportant    4 
 Very unimportant     5 
Experiences of surgical procedures 
Q23 Have you had to have any surgery as part of the treatment for your 
condition? 
 Yes    1 go to Q24 
 No     2 go to Q27 
Q24 How long did you have to wait for the surgery?  
Q25a Did you feel you were told enough about why the procedure was being 
conducted and any possible after effects? 
 Yes    1 
 No    2  go to Q25b 
Q25b What else would you like to have been told? 
Q26 Overall, how satisfied were you with how your surgery was managed, in 
terms of: 
a)  information provided before surgery 
b)  support and counselling offered by staff 
c)  waiting time before surgery 
d)  after care by staff 
Were you: 
 a b c d 
Very satisfied 1 1 1 1 
Quite satisfied  2 2 2 2 
Neither satisfied nor 
dissatisfied 
3 3 3 3 
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Category/ Question numbers Questions 
Fairly dissatisfied 4 4 4 4 
Very dissatisfied 5 5 5 5 
 
Q27 What could the hospital do to improve the service for future patients 
undergoing surgery? 
Experiences of 
chemotherapy/ radiotherapy 
Q28 
Have you had to have any chemotherapy/radiotherapy as part of the 
treatment for your condition? 
 Yes   1 go to Q29 
 No   2 go to Q43 
Q29 Which type of treatment have you had or are you receiving at present? 
 Chemotherapy  1  Q30 
 Radiotherapy   2  Q37 
 Both   3  Q30 
Q 30 Thinking about your chemotherapy, how long did you have to wait before 
your first session? 
Q31 a Did you feel you were told enough about why the procedure was being 
conducted? And any possible after effects? 
 Yes   1 
 No    2 
Q31b Did you feel you were told enough about any possible side-effects? 
 Yes   1 go to Q32a 
 No    2 go to Q31c 
Q31c What else would you like to have been told, either about the procedure or 
possible side-effects? 
 Procedure - 
 side-effects - 
Q32 Did you have any side-effects from treatment? 
Yes   1 go to  Q33 
No   2 go to 034 
Q33 How well were these managed by hospital staff? 
Q34 What, if anything were you told about how long you would have to have 
chemotherapy? 
Q35  
 
Overall, how satisfied are you with how your chemotherapy was or is being 
managed, in terms of: 
a) information provided before course of therapy 
b) support and counselling offered by staff 
c) waiting time before therapy 
d) after care by staff 
Were you: 
 a b c d 
Very satisfied 1 1 1 1 
Quite satisfied  2 2 2 2 
Neither satisfied nor 
dissatisfied 
3 3 3 3 
Fairly dissatisfied 4 4 4 4 
Very dissatisfied 5 5 5 5 
 
Q36 What could the hospital do to improve the chemotherapy service for you 
and future patients? 
If have had or are currently undergoing radiotherapy, ask Q37. Otherwise go to Q43 
Q37 Thinking about your radiotherapy I how long did you have to wait before 
your first session? 
Q38a Did you feel you were told enough about why the procedure was being 
conducted? 
 Yes     1 
 No     2 
Q38b Did you feel you were told enough about any possible side-effects? 
 Yes     1 go to  039a 
 No     2 go to 038c 
Q38c What else would you like to have been told, either about the procedure or 
possible side-effects? 
procedure: 
side-effects:  
Q39a Did you have any side-effects from treatment? 
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Category/ Question numbers Questions 
Yes    1 go to 039b 
No    2 go to 040 
Q39b How well were these managed by hospital staff? 
Q40 What, if anything were you told about how long you would have to have 
radiotherapy? 
Q41 Overall, how satisfied are you with how your radiotherapy was or is being 
managed, in terms of: 
a) information provided before course of therapy 
b) support and counselling offered by staff 
c) waiting time before therapy 
d) after care by staff, 
 a b c d 
Very satisfied 1 1 1 1 
Quite satisfied  2 2 2 2 
Neither satisfied nor 
dissatisfied 
3 3 3 3 
Fairly dissatisfied 4 4 4 4 
Very dissatisfied 5 5 5 5 
 
Q42 What could the hospital do to improve the radiotherapy service for you and 
future patients? 
Q43a Are you aware of any support services at the hospital which provide advice 
and support to patients such as yourself? 
 Yes     1 go to Q43b 
 No     2 go to Q44 
Q43b Which support services at the hospital, to provide advice and support are 
you aware of? 
 Support group   1   
 Macmillan Nurses  2   
 Other(specify)   3 
Q43c Which of these support services, if any, have you been in touch with? 
 Support group   1   
 Macmillan Nurses  2   
 Other(specify)   3 
Q44 Would you like to be put in touch with a support group? 
 Yes     1 
 No     2 
Thank you very much for your valuable comments. 
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Appendix B – Summary of Patients’ Attitudes to Local Cancer Service  
Introduction: 
This appendix presents the summary report of the patients’ attitude to local cancer service provision. 
The report presents the key findings of the patient survey captured using the questionnaire attached in 
Appendix A and series of focus groups held to understand the experiences of patients, carers and their 
relatives to help the local evaluation team gain a better perspective of the current service configuration 
by identifying the good, fair and bad aspects of care provided locally. This report is referenced in 
Chapter 1 and Chapter 4. 
 
Overview:  
 This report provided the documented evidence of the patients’ views in relation to local cancer service 
experience and care provision, identifying the local practices, attitudes and approaches of local care 
providers across primary, secondary, tertiary and community health care settings. It highlighted the 
communications issues, staff insensitiveness to patients’ needs and expectations, schedules and 
workflow that was devised primarily to serve the staff rather than patients.  
It was evidence from this report that enabled the local organisation to focus on specific aspects of the 
care pathway by undertaking root cause analysis and/or prompted further detailed work, audits, 
pathway analysis, review of guidelines, protocol reviews and standard operational procedures. A 
number of user involvement workshops were also held. 
Key findings 
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Fig B.2 Patient went to their GP/Hospital 
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Fig B.3 Reason for consultation 
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Fig B.4 Action taken by GP 
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Fig B.5 Test performed 
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Fig B.6 Patient was referred to  
Did you see the same person
n=83
59
24
0
10
20
30
40
50
60
70
No Yes
No
 O
f p
at
ien
ts
 
Fig B.8 Did you see the same person? 
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Fig B.7 Length of time taken from referral to 1
st
 Outpatient appointment – Decision to treat – Treatment 
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Fig B.9 Patients view on the importance of seeing the same person at each visit. 
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Fig B.10 Number of visit made by the patient 
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Fig B.11 Number of visit made by the patient 
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Appendix B (cont) –Report of Patients’ Attitudes to Local Cancer Service Provision 
RESEARCH METHOD 
Face-to-face interview using a semi-structured questionnaire (Appendix A) 
 
Patients were interviewed as they attended the oncology clinic, either prior to, or immediately following 
their appointment.  Patients were approached randomly so as to avoid any bias in the sample, with the 
only proviso being that they had to have been undergoing treatment for a minimum of 6 months 
(although this timescale was dependent on the prognosis of the cancer).  Nursing staff at each of the 
clinics attended assisted in ensuring that this criterion was met. The types of cancer patients who took 
part in the research included those with: bowel, bladder, lung and pancreatic cancers. 
Interviews took between 15-35 minutes to complete.  All patients were given assurances as to the 
confidentiality and anonymity of the research, to assist in getting patients to speak openly and freely, 
without fear that their participation may have an effect on how they were subsequently treated.  
Patients were also asked to sign a consent form, to confirm that they understood what their 
involvement entailed and agreed to take part in the research. 
 
A total of 80 interviews were conducted, with patients attending oncology clinics at the hospitals.  The 
interviews were subsequently analysed to produce the report which follows. The names of the hospitals 
and details have been removed for these reports to ensure commercial confidentiality. 
 
HOSPITAL 1  
 Patients initially had difficulty trying to locate the clinics. It was also said that it was far from the 
main entrance, and if it were not possible to get the lift, then it would be very difficult for those 
with walking aids or the infirm. 
 The clinic’s waiting area looked as if it had not been decorated for some time, as the paint was 
cracking in certain places and it looked an off colour. For some patients, this gave the room a 
degree of dullness. 
 The nursing and medical staffs were generally seen as being helpful, caring and sympathetic to 
patients’ needs. Some had built up a good relationship with the healthcare professionals that 
were caring for them. 
HOSPITAL 2 
 Clinics were easily accessible from the main entrance. Good directions given by hospital 
reception/information staff. 
 Refurbished waiting room, air-conditioned, bright, airy and fairly comfortable. Room/space to 
accommodate a large number of people. Most patients felt it was a pleasant waiting room. 
 Very helpful and “cheerful” staff. Patients warmly welcomed by reception staff. Booking in staff 
knowledgeable about patients’ e.g.  Next appointments, type of cancer/condition etc.  Patients 
liked the sense of not just being “another patient”. 
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 All patients like attending Hospital 2. A few admit that it’s too far to travel. However, most 
appear to have access to their own transport. Slightly less likely to use public transport to get to 
Hospital 2 than patients at the Hospital 1. 
HOSPITAL 3 
 Easy and straight forward access to the clinic from the main entrance. 
 The clinic area appears spacious, although it is not particularly comfortable and some patients 
expressed annoyance in the early stages of attendance that they were unsure exactly where to 
go or sit once in the clinic area. 
 General indifference to the reception staff. Perceived as “satisfactory” although a few felt some 
staff appear to be unsure or displaying poor communication between nursing, clinician and 
administrative staff. 
 Although there were “grumbles” most patients were happy to continue with attending Hospital 
3, the main reason being that it is convenient to their home. There were a few who said they 
had some difficulty getting to the hospital by public transport. 1-2 expressed difficulty in 
parking. 
 
CANCER SERVICES 
For the majority of the patients that took part in the research, diagnosis of their cancer had been made 
by tests and examinations at a hospital. These patients claimed that they were sent to hospital by their 
GP either because their symptoms had persisted despite treatment initiated by the GP or because their 
GP expressed concern about the symptoms they were displaying. Only a few patients claimed their GP 
had told or diagnosed them as having cancer. In some of these cases, the patients had questioned the 
doctor specifically on the possibility of them having cancer. Many of these patients felt if they had not 
asked, their GP would not have told them, indeed, some of these patients felt their GP appeared 
uncomfortable giving them the news about their cancer. Many patients claimed they had their 
symptoms for some time i.e. months before they presented to their doctor. Only a few patients said 
that they went to their GP immediately after they noticed the first symptoms. 
 
In the majority of instances patients felt that their GPs had acted appropriately, however, some patients 
felt that with hindsight, they would have liked their diagnosis to have been made quicker. Many of the 
patients spoken to had not expected to have cancer. For some it was not until their GP appeared to 
show concern did they begin to consider there was more to their condition than they first thought? The 
majority of patients claimed to have presented at least twice before their GP had recommended them 
to go to the hospital for further investigations or examinations; in many cases it was three visits to the 
GP before referral. 
 
In terms of the examinations undertaken by GPs, most patients could not recall the GP performing any 
complex or invasive procedure. For the majority, a physical examination was the extent of the GP’s role 
at this point. Only a minority of patients expressed dissatisfaction with their GP’s handling of the early 
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stages of their condition involving the assessment of their symptoms and the confirmation of a 
diagnosis. The most common areas of dissatisfaction centred around the length of time it took to refer 
them once they thought there was something  seriously wrong with them. A general lack of concern or 
urgency was how some patients perceived it. Another common issue was the view by a few respondents 
that their GP did not show any sympathy towards the patient during not only the time they were 
undiagnosed but also once their cancer had been confirmed. 
 
It is nevertheless fair to say that these patients represented the minority of the patients who took part 
in this research, however many expressed their views of dissatisfaction very strongly. Many of the 
patients who were unhappy with their GP said they had subsequently found it difficult to “get on” with 
their GP following their eventual diagnosis, even though prior to that point they had a good relationship.  
There were a few cases of patients whose GP had genuinely misdiagnosed and subsequently wrongly 
treated a condition which later turned out to be cancer. In these cases, patients did not appear to be as 
bitter/angry with their GP as those patients whose GP had not diagnosed anything specifically and had 
not referred the patient earlier. In cases where patients are being referred to hospital for tests, most 
appear not to be given many details regarding which tests are being conducted and what they are 
specifically intending to establish. However, for most patients it was enough for them to know if these 
tests will determine exactly what is wrong. Therefore, many are unwilling to ask what the tests do 
specifically. If the tests were to involve a complicated procedure, patients just want to know what they 
have to expect (i.e. X-ray, biopsy, endoscopy, barium meal etc.,) It was considered unacceptable to be 
just told they are to be sent for “tests” although it is claimed some GPs do this, without telling the 
patient anything else. 
 
Many patients who had their condition diagnosed some time ago (more than 18 months) could not 
remember what examinations or investigation had been carried out. Some patients said that the 
concern and anxiety at the time overshadowed the procedural aspect of the condition. The referral 
times for tests/examinations following the initial GP visit varied widely not only across the three 
different hospitals, but also for each patient within the three hospitals. Overall, Hospital 2 in particular, 
but also Hospital 1 were seen as having an acceptable waiting period for referrals. The waiting time 
varied from less than a week (the next clinic) for one patient with cancer of the bowel to 3 -4 weeks for 
one patient with prostate/bladder cancer. One patient claimed she was told by her GP that she may 
have to wait up to 6 weeks before she could be seen in hospital. For a few patients the time it took to 
get a firm diagnosis from the time they first presented with symptoms was as long as 5 months. 
Therefore they were untreated for that period. 
 
Hospital 3 was not specifically seen as having a long waiting time, but it did not receive the same 
number of compliments as the other two hospitals. The choice of which hospital to attend was not a 
particular issue for most patients. Generally most did not know how the hospital they attended 
compared with others. Convenience appears to be much more important than attending a specialist 
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centre for many patients. Most patients claimed to be sent to the general surgeon when first referred to 
the hospital. However, there were many patients who were unsure of the speciality of the doctor. These 
patients said their GP did not specify nor did they ask the specialist when they arrived at the hospital. In 
essence, information given to the patients by the hospital focused on the type of cancer the patient had, 
on the options for treatment and some commented on prognosis. Patients visit hospital typically every 
4-6 weeks. In most cases the patient will see the same team of doctors (i.e. headed by the same 
consultants on each visit). This procedure was well liked overall as patients “liked” all the members of 
that clinical team. Most patients had received some form of either chemotherapy or radiotherapy. 
There appeared to be equal satisfaction with the oncology departments as with the surgical 
department/team. 
 
For most patients radiotherapy and chemotherapy was an option of treatment that would have been 
mentioned at some time after confirmation of their cancer.   Many said chemotherapy or radiotherapy 
was often discussed or initially raised when first being told about the treatment that was available for 
them. Knowledge of why chemotherapy or radiotherapy was being used was said to be vague by many. 
The oncologists were generally seen as caring, communicative and sensitive, but patients admit certain 
parts of the treatment are confusing and not all of what is said is taken in. Information on side-effects 
was given to all those who would need to have chemotherapy. For many patients this aspect of their 
treatment was the most difficult as it required frequent visits in which transport had to be arranged 
and/or time off work or other activity was required. Patients also said that they often felt as bad with 
the condition as they did when they had received radiotherapy or chemotherapy. 
 
The nursing staffs were singled out by many patients for providing valuable sympathetic and caring 
nursing for patients. It was said that the nurses did not only look after their medical needs but many 
issues where patients had emotional needs. Questions patients were too frightened to ask doctors 
would be asked of the nurse. Again, in Hospital 2 and Hospital 3 nurses were felt to be particularly 
encouraging/ supportive. In most cases patients felt their relatives were adequately informed by the 
medical staff. However, it was often prompted by the patient themselves or an obvious observation by 
the medical staff that a friend/relative is anxious or very concerned. The desire or need to belong to a 
support group appeared not to be very strong. Most felt there had not been much direct 
encouragement from their hospital staff or needed to be to join these groups. However, a few felt that 
their view might change in the later stages of the condition. 
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Appendix C – SERVICE DESCRIPTIONS 
Introduction:  
The service description document is a summarised version of the framework suggested by the Calman-
Hine Report. This was used by the local service review team to evaluate the current service provision 
and estimated the variation from the recommendations. 
Overview:  
The attached service criteria were used to establish current service configuration, to assess the local 
organisation’s service levels i.e. if they meet the criteria for Cancer Centre or Cancer Units, overall 
organisational readiness and fitness for the delivery of cancer care. The finding from this assessment 
provided the motivation for the research. The findings from this were used to define the current and 
future service specifications The service criteria checklist attached facilitated the Health Authority and 
local organisations conduct a valuable, in-depth service review and objectively gain an insight and 
evidence of the care provision and formulate the ideal/ optimal care based on the needs of the local 
population whilst conforming to the recommendations of the Calman-Hine report. The main reason for 
offering this information was to provide evidence for the detailed background work carried out by the 
author and the findings that motivated this research. 
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Table C.1  Proforma used to assess the local acute hospitals against the criteria recommended 
in Calman-Hine report. 
 
CANCER UNITS 
a) Part of an Acute hospital with full range of specialties on site.  
b) Lead cancer clinician for whole hospital. Specific sessions for leading and coordinating the 
development of services for all cancers. 
 * Lead Cancer Clinician 
- organises and co-ordinates the whole range of cancer care provided by Unit 
  - well established interest in cancer 
  - specific dedicated sessions (minimum 5 sessions) 
  - ensures non-surgical support 
  - ensures audit and CME (Continuous Medical Education) 
  - ensures regular meetings between primary care, Unit and Centre to develop and 
implement uniform standards and protocols 
  - ensures multi-disciplinary working between surgeons and non-surgeons 
 
 
c) Site specific cancer services/general standards.  
*  Classification of cancer sites: 
A. Very common sites:  
  Breast, Lung, Skin (non-melanoma). 
 B. Common sites:  
  Stomach, Pancreas, Rectum, Colon, 
  Bladder, Prostate, Lymphomas. 
 C. Less common sites:  
  Ovary, Uterus, Cervix, Kidney, Oesophagus, Brain, Melanoma of Skin, Leukaemia. 
 D. Rare sites: 
  All other cancers 
 * Lead subspecialist surgeons 
  - Major commitment to subspeciality 
  - Leading service development 
  - Second designated surgeon 
  - Extensive role 
 
  - Overall volume of specialist work adequate  
d) Multidisciplinary team working effectively 
 * Multi-disciplinary team includes: 
  - oncologist 
  - nursing 
- histopathology 
  - radiology 
  - pharmacy 
 * Functions as a team 
 * Clinical meeting weekly 
 * Managerial meeting quarterly 
 * Joint working between surgeon, physician and oncologist 
 * Close relationship with primary care, including fund-holders. 
  - good pre-referral access 
  - agreed guidelines 
* Screening and prevention practised 
 
e) Referral arrangements - adequate 
 * Pre-referral telephone access to GPs. 
 * Agreed guidelines 
 * All specialty problems referred to the specialist service 
 * Consultant prioritisation in few days permitting rapid referral 
 * Appointment letter sent within 1 week - agreed format for layout and contents 
 * First appointment: urgent within 2 weeks non-urgent within 4 weeks 
 * More than 1 clinic per week 
* Second out-patient appointment within 2 weeks of first 
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 * System in place for monitoring these response rates 
 * Out-patient facilities: 
  generally satisfactory standard 
 * Treatment plan sent to GP within 2 weeks of second out-patient appointment 
 - ‘key’ symptomatology pathways in place 
 - ‘others’ firmly planned 
 * GP referral pathways for specific common symptomatology 
 
f) Admission/discharge, operations/treatment arrangements - effective 
 * Within hospital referrals 
  - majority new cancer patients referred to lead surgeon/support surgeon 
  - arrangements to encourage: guidelines 
 * Emergency admissions 
  - most major surgery by lead surgeon 
  - arrangements to achieve this: guidelines across surgical firms. 
  - emergency theatre available 
 * Elective operations 
  - majority carried out by lead/rest support surgeon 
  - arrangements to achieve: guidelines/protocols and demonstrate usage in practice 
  - operative issues 
 * Discharge arrangements 
  - information for GP sent out with patient (shared patient held record) 
  - more detailed report sent within 2 weeks 
 * Oncology 
  - oncologist 
  - sessions for site-specialties 
  - sessions elsewhere 
  - joint working arrangements 
  - local chemotherapy: 
   specialised site for administration 
  - radiotherapy access 
 
g) Patient information/communication – high quality 
 * Public information and education led by specialist service 
 * Patient and carer information (written and verbal) 
 * Voluntary organisations and self-help groups: 
  - facilitated by the service 
 
h) Follow-up arrangements - adequate 
 * Out-patient follow-up 
  - jointly with oncologist 
 * Formal links with hospice/palliative care 
 * Highly-specialised referrals made elsewhere 
 
i) Audit/Protocols/Outcomes reporting  arrangements - effective 
 * Progress with guidelines and protocols 
 * Progress with clinical audit 
  - within specialist surgical firm 
  - with oncology 
  - with comparable services in other hospitals 
  - across primary care 
  - including palliative care 
  - links with guidelines 
  - links with continuing education 
 - reflecting TCR data usage 
 - nursing audit 
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* Agree minimum clinical outcomes dataset. 
  - survival rates 
  - recurrence rates 
  - restoration of function 
  - response to treatment: 
    wanted effects; unwanted effects 
  - relief of symptoms 
  - quality of life 
  - infection rates/management policies 
  - pressure sore rates/management policies 
- reflecting TCR data usage 
 
j) Information Systems/R&D/Education - adequate 
 * Information 
  - development of monitoring systems 
  - input to TCR 
 - links with clinical audit 
 * R&D 
  - patients entered into clinical trials 
  - implementation of new good practice 
 
 * Professional development across all  
  disciplines 
  - how needs identified 
  - learning strategy and its implementation: 
   specialist education centre 
  - integration with audit 
 
k) Investigations - general arrangements adequate 
 * Histopathology high quality  
  assessment within 1 week 
  - cytology 
 * Haematology 
  -  integrated with any haematological oncology 
 * Imaging 
  - routine radiology within 1 week 
  - CT scanning - waiting time adequate 
  - NMR - waiting time adequate 
  - ultrasound within 1 week 
  - nuclear medicine 
 * Endoscopy within 1 week. 
 
l) Bed utilisation - effective 
 * Adequacy to avoid: 
  - dispersal of patients 
  - deferment of operations relative to seasonal bed utilisation pressures 
 
m) Oncology generally. 
 * Radiotherapy access with at least 5 sessions of oncologists working also at a specialist 
centre with radiotherapy 
 * Cancer site specialisation of oncologists 
 * Local chemotherapy at a specified location in line with Joint Council for Clinical Oncology 
Guidelines. 
 
 * Waiting times should be: 
  Good Max 
Urgent 24 hrs 48 hrs 
Palliative radiotherapy 48 hrs 2 wks 
Radical complex radio. 2 wks 4 wks 
Intensive chemotherapy        1 wk      4 wks 
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n) Clinical support staff, their training and organisation (nos, qualifications) 
 * Breast nurse 
 * Stoma nurse 
 * Oncology nurses (inc. Macmillan) 
 * Chemotherapy nurses 
 * Prosthetics 
 * Pharmacists 
 * Psychologists 
 * Counselling 
 * Social services 
 
o) Palliative Care. 
 * Patient choice between home, hospice and hospital (written guidance) 
 * Palliative care consultant 
  - sessions 
  - base 
 * Palliative care team 
  - 24 hrs? 
 
 * Hospice provision - respite care 
 * Hospital provision - respite care 
 * Special pain control 
 * Palliative care team 
  - membership 
  - method of working and meetings 
 * Chaplaincy 
 * Complementary therapies 
 
p) Terminal care (as for palliative care plus): 
 * Care of the dying policy - when last revised 
 * Guidance on living wills 
 
q) General aspects of service: 
 * Ethos reflecting patient centred care/respect for patient 
 * Public information and education 
 * Patient and carer information/communications 
 * Psychosocial aspects of care 
 * Voluntary organisations 
 * Guidelines and protocol development - demonstrate usage in practice 
 * Clinical audit/entry into trials 
 * Information 
 * Research and the development of good practice 
 * Professional development (multi-disciplinary) 
 * Accessibility for patients and relatives 
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CANCER CENTRES 
Criteria and standards additional to those required for a Unit. 
a) Part of large acute hospital or network of hospitals with catchment population of ideally 
more than 1 million, and a minimum of 700,000.  New cases per annum 3000 - 4500 (2500 
minimum).  Capable of treating all cancers to a high standard except a small number of very 
rare cancers e.g. choriocarcinoma. 
 
b) Oncologist staffing - adequate 
 * At least 8 non-surgical oncologists 
 * Site specialisation 
 * Includes both medical and clinical oncologists 
 
c) Specialist surgery including plastics and reconstructive surgery available.  
d) Sophisticated diagnostic services and support services - delivering good quality service to 
patients from equipment maintained to recommended standards. 
 * Pathology 
 * Haematology - BMT and PBSC 
 * Radiology 
 * Imaging 
 
e) Radiotherapy - high quality services. 
 * Supervision by clinical oncologist 
 * Sufficient workload 
 * Radiotherapy treatment machines.  Linear accelerators: 
  - single beam low energy x ray unit (4 to 6 MV) 
  - cobalt 
  - dual beam high energy x ray unit (9 to 18) 
  - 100DV X-ray machines 
  - 150DV superficial machines 
  - 300DV deep voltage machines 
    - electron therapy 
 
 * Simulation and treatment planning 
  - diagnostic x-ray 
  - high energy treatment 
  - optical magnification and screening 
  - dedicated planning computer compatible with CT scanner (MRI alternative to CT) 
 * Moulds  - 100% accuracy and reproducability 
 * Dosimetry  - 100% protection/shielding 
 
 * Ultrasound 
 * Implants 
  - remote after-loading systems with individualised gynaecological insertions and planar 
interstitial implants 
  - high dose equipment in shielded rooms - low dose equipment installed in modified 
wards or single rooms 
 * Reproductive aspects 
  - counselling 
  - semen storage 
  - preservation of reproductive function where practicable 
 * Minimises complications/side effects 
 
 * Waiting times 
 Good Max 
Urgent 24 hrs 48 hrs 
Palliative 48 hrs 2 wks 
Radical 2 wks 4 wks 
 * Staffing  - competent technical staff; - ongoing training 
 * Protocols/guidelines shared, demonstrate use in practice 
 * Quality assurance 
 
f) Chemotherapy (intensive chemotherapy with complex haematological support in line with 
Joint Council for Clinical Oncology Guidelines).   
 Designated chemotherapy unit, full complement of cancer chemotherapy staff, including 
clinical (radiological) oncologists, medical oncologists, haematologists and oncology 
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specialists. 
 * Clear guidelines on roles and responsibilities of various types of oncologists (medical, 
clinical and haematological) 
 * Workload 
  - supervision by accredited and experienced medical and clinical oncologists 
  - written policy for workload split with linked units 
 * Specialist facilities 
 * Waiting times: good 1 week, maximum 4 weeks 
 * Staffing  - chemotherapy nurses 
 * Protocols.  Use of defined protocols for: 
  - curative intent 
  - palliative intent 
  - adjuvant chemotherapy 
  - pre-surgery chemotherapy 
 * Quality assurance 
 * Specialist pharmacy support 
 * Options for chemotherapy in various care settings - IP, DC, OP, home etc. with skilled IV 
therapy teams - special attention to continuity of care for cyclical chemotherapy 
 * Complications/side effects minimised 
 
g) Specialist diagnostic and clinical support services. 
 * Imaging 
 * BMT and PBSC 
 
h) Adequate specialist cancer nurses with post registration qualifications on site: 
  - IV cytoxic chemotherapy 
  - palliative care 
  - breast care 
  - rehabilitation/psycho-social support 
  - lymphoedema management 
  - stoma care 
 - adult oncology 
 - paediatric oncology 
 
i) Pharmacy. 
 * Named co-ordinator 
 * Adequate, safe manufacturing facilities - aseptic compounding 
 * Safe dispensing 
 * Cytotoxic drug preparation for Inpatient, DC and home use 
 * Written guidelines for drug use in common medical problems 
 * Protocols in use 
 * Links with other disciplines 
 * Patient information/advice 
 * Total parenteral nutrition 
 * Drug use evaluation 
 
j) Non-surgical oncology beds. 
 * Dedicated 7-day ward beds 
 * Dedicated 5 day ward beds 
 
k) Rare cancers. 
 * Children and adolescents 
 * Brain (primary) 
 * Ophthalmic 
 * Choriocarcinoma 
 * Bone 
 * Plastic and reconstructive surgery 
 
l) Lead role with public.  
m) Lead role in clinical audit.  
n) Lead role in education and professional  development of staff. 
 * Specialist education centre  
 
o) Lead role in R&D including integration with unit activities e.g. trial entry, joint protocols and 
continuing education 
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Appendix D Rich Pictures 
Introduction: 
 
This appendix presents a series of Rich Pictures created to capture/define the problem situation. The 
following series of Rich Pictures were developed with the users at the workshops held to identify gaps 
and further enhance the understanding of the problem situation. These are holistic Rich Pictures that 
facilitated the capturing of the inter-relationships, interconnected pathways and their dependencies, 
current issues, bottlenecks and practices affecting the services as a whole, which also affected MDT 
service. 
Overview 
Rich Pictures are created within a participatory context with input from various stakeholders that often 
help to provide a pictorial representation of the problem situation as assembled in the time available. 
Using diagrams as a means to aid the thinking process is well established and used in other techniques 
such as mind maps, road maps and other visualisations or graphic presentation of thought processes.  
Rich Pictures were particularly developed as a part of Peter Checkland’s Soft System Methodology for 
gathering information about complex situations. 
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D.1- Rich picture generated at the workshop that captured the pathways, issues, bottlenecks and constrains. 
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The following series of rich pictures were developed with the users at the second workshop to identify gaps and further enhance the understanding of the problem situation. 
D.2a – Summary of the situation as established at the first workshop 
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D.2b Summary of the situation as established at the first workshop 
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D.3a – Defining the problem situation affecting the delivery of high quality care to patients  
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D.3b Defining the problem situation affecting the delivery of high quality care to patients 
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D.3c – Summary of the real world juxtaposed with ideal state, with identified enablers that will facilitate to narrow the gap and resolve the issues of the real 
world and deliver the vision. 
 
 
 
 
 
 
 
 
 
PhD Thesis                Bala Sridhar 
Page 208 
 
D.4a Defining the problem situation affecting improving patient experience 
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D.4b Defining the problem situation affecting improving patient experience 
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D.4c Summary of the real world juxtaposed with ideal state, with identified enablers that will facilitate to narrow the gap and resolve the issues of the real world 
and deliver the vision. 
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D5a Defining the problem situation affecting patient safety 
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D5b Defining the problem situation affecting patient safety 
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D5c Summary of the real world juxtaposed with ideal state, with identified enablers that will facilitate to narrow the gap and resolve the issues of the real world 
and deliver the vision. 
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D6a Defining the problem situation affecting efficiency and effectiveness 
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D6b Defining the problem situation affecting efficiency and effectiveness 
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D6c Summary of the real world juxtaposed with ideal state, with identified enablers that will facilitate to narrow the gap and resolve the issues of the real world 
and deliver the vision. 
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D7a Defining the problem situation affecting seamless delivery of care 
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D7b Defining the problem situation affecting seamless delivery of care 
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D7c Summary of the real world juxtaposed with ideal state, with identified enablers that will facilitate to narrow the gap and resolve the issues of the real world 
and deliver the vision. 
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D8a Defining the problem situation affecting access to full information on patients’ care 
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D8b Defining the problem situation affecting access to full information on patients’ care 
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D8c Summary of the real world juxtaposed with ideal state, with identified enablers that will facilitate to narrow the gap and resolve the issues of the real world 
and deliver the vision. 
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Fig D.9 Capturing the issues, bottlenecks, constrains to help define MDT problem situation 
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APPENDIX E – AUDIT DATA FORMS  
 
Introduction:  
To understand current service configuration and establish a baseline for the various aspects of the 
current service performance, a review of the service was performed using structured proforma or data 
collection forms. The purpose of these audits was 
 to track patients, data and information flow along the patients’ journey 
 establish referral pathway and pattern 
 assess treatment options  
 evaluate the performance against the expected standards and guidelines 
 
The following data collection forms/audit proformas were used to define the baseline, to establish and 
evaluate adherence to good practice within clinical and nonclinical settings in all three sites.
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Fig E.1 Data collection form used at North Middlesex Hospital 
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Fig E.2 Data collection form used at Whiston Hospital 
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Fig E.3 Data collection form used at Christie Hospital 
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Appendix F – Audit Results 
Introduction:  
This appendix presents audit results following the analysis of the data collected using the data 
collections forms presented in Appendix E. Detailed results are provided for the following audits: 
 Baseline Lung Cancer Service audit carried out in 1994 (Fig F.1 – F.22) 
 Re-audit of Lung Cancer Service carried out in 1999 (F.23 – F.65) 
 Audit of non-surgical management of Lung Cancer 2001 (F.66 – F.133) 
 Audit of outpatient Phlebotomy and Pathology 2005  (F.134- F.151) 
 The results of these audits were used as supportive evidence to evaluate current practice and narrow 
down the key issues that were initially identified during the workshop.  
 
Baseline Lung Cancer Service audit carried out in 1994 (Fig F.1 – F.24) 
FIG F.1 Age distribution 
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FIG F.2 Smoking History 
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FIG F.3 Smoking pattern 
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Fig F.4 – Referred by 
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Fig F.5 – Admitted under speciality  
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Fig F.6 – Diagnostic method  
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Fig F.7 – Treatment  
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 Fig F.8 – Histology 
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Audit of patient journey before the implementation of Calman-Hine recommendations in 1996 
 
Fig F.9 Length of Stay 
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Fig F.10 Gender Split 
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Fig F.11 Age Distribution 
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Fig F.12 Incidence of smoking 
Incidence of smoking 
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Fig F.13 Patient referral route 
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Fig F.14 Patient first seen by 
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Fig F.15 Method of Diagnosis 
Method of Diagnosis
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Fig F.16 Time taken from referral to first appointment 
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Fig F.17 Time taken for decision to treat 
Decision to Treatment
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Fig F.18 Time taken from first visit to decision to treat 
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Fig F.19 Survival for patients treated with Surgery 
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Fig F.20 Survival for patients treated with radiotherapy 
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Fig F.21 Overall survival 
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Fig F.22 Lung cancer survival – referral to death 
Lung cancer survival - Referral to death
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Re-audit of service following the introduction of Calman-Hine recommendations 1999. 
Table F.1, F.2 and F.3 ( Age, sex, and Ethnicity of patients) 
 
Table F.4 and F.5 (History and Years of Smoking) 
 
 
PhD Thesis         Bala Sridhar 
Page 243 
 
Table F.6 and F.7 (Risk factors and Type of referral) 
 
 
Table F.8 and F.9 Delay presenting to GP and reporting of x-rays 
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Table F.10 and F.11 – Delays in GP to referral and patient seen in chest clinic 
 
Table F.12 and F.13 Seen by and presenting symptoms 
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Table F.14 Time taken for Bronchoscopy to be performed 
 
 
Table F.15 and F.16 Time intervals 
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Table F.17 and F.18 Time intervals 
 
Table F.19 and F.20 Time intervals 
 
PhD Thesis         Bala Sridhar 
Page 247 
 
Table F.21 Time intervals 
 
Fig F.23a Diagnosis All; F.23b Diagnosis Lung Cancer only 
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Table F.22 Cancer Staging 
 
Table F.23 and F.24 Time intervals 
 
Table F.25 Time intervals  
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Table F.26 Type of operation performed 
 
Fig F.24 Treatment performed 
 
Table F.27 and F.28 Time intervals 
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Table F.29 and F.30 Time intervals 
 
Table F.31 and F.32 Time intervals 
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Table F.33 and F.34 Time intervals 
 
 
Fig F.25 Place of death 
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Fig F.26 Average time from referral to treatment 
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Fig F.27 Influence of MDT on Treatment decision 
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Lung cancer – an audit of non-surgical oncology management  
Patients referred to Medical and Clinical Oncology at a Cancer Centre and Cancer Unit January 2001 – 
March 2001 and September 2001 – Dec 2001 
Fig F.28  Where did the notes come from? 
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 Fig F.29 Gender of the Sample 
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Fig F.30 Age mix of the sample 
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Fig F.31 Source of referral 
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Fig F.32 Who did the patient see during their first appointment? 
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 Fig F.33 Where was the patient seen?  
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Fig F.34 How many patients were reviewed at the MDT (Cancer unit) 
10
MDT discussion 
(Cancer Unit Only)
Standard:
95% should be discussed at MDT
Results:
75 notes from Wythenshawe. (Information not recorded 
for 23 patients).
• 48% discussed at MDT.
• 52% not discussed at MDT.
 
Fig F.35 Histology Standard 
11
Histology standard
COIN*: 75% of all patients with a clinical 
diagnosis of lung cancer should have the 
diagnosis cytologically or histologically
confirmed
*COIN= Clinical Oncology Information Network
 
Fig F.36 Was the histological standard met? 
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Fig F. 37 Diagnostic test  
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Fig F. 38 Was there a confirmed diagnosis? 
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Fig F. 39 Was Performance Status/ Clinical Stage recorded? 
15
Record of clinical stage/performance status 
information
Before review After review
Stage 39% (79/203) 87% (177/203)
Performance status 49% (99/203) 88%* (179/203)
(KP or WHO)
COIN standard: 90% of patients with a WHO performance status of 0-2 
NSCLC should have the clinical stage recorded.
Results:  79% of patients with PS 0-2 NSCLC had stage recorded.
• General condition 
excellent / good = 0-1  Moderate = 2 Poor = 3-4
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Fig F. 40 Treatment modality 
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Fig F. 41 Reasons for no treatment  
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Fig F. 42 Who received chemotherapy? 
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 Fig F. 43 Number of cycles of chemotherapy administered. 
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 Fig F. 44  How many were recruited into trial? 
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Trials
• Entry into clinical trials only occurred in 
patients treated with chemotherapy
• Number of patients who had any chemo = 64 
• Number of patients entered into clinical trials 
= 28/64 (44%)
 
Fig F. 45 How many from the sample were entered into trial? 
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Fig F. 46 Standards for Palliative Radiotherapy 
25
Palliative radiotherapy for Nsclc
Standard:
The majority of patients treated with palliative 
radiotherapy for NSCLC should receive regimens of 1 or 
2 fractions. (COIN)
Results:
1 fraction 27 (45%)
2 fractions 4 (  7%)
8 fractions 29 (48%)
 Management of Non-Small-Cell Lung Cancer 
Fig F. 47 Staging Information  
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 Fig F. 48 Treatment Modality 
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Fig F. 49 Treatment by Stage 
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Fig F. 50 Comparison of Chemo standard against actual 
38
Chemotherapy for non small cell
Standard:
Death within 30 days of chemotherapy should be less 
than 10%.
Results:
Data available for 34 patients, 2 (6%) died within 30 
days.
Patient profile:
Pt 1 : PS = WHO 2 Stage = IV
Pt 2: PS = WHO 3 Stage = IIIB
 
Fig F. 51 Median Survival 
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 Fig F. 52 Total Survival 
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Fig F. 53 Survival for Radiotherapy 
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 Fig F. 54 Survival for Radical Radiotherapy 
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NSCLC survival for radical radiotherapy (n=16)
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Fig F. 55 Survival for Palliative Radiotherapy 
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Fig F. 56 Survival for Chemotherapy & Radiotherapy 
44
0.000
0.250
0.500
0.750
1.000
0.0 1.0 2.0 3.0 4.0
Survival Plot
Years
S
ur
vi
va
l
NSCLC survival with chemotherapy and radiotherapy (n=19)
Median = 0.39
 
Fig F. 57 Survival for Radical Radiotherapy 
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Fig F. 58 Survival with no active treatment 
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Fig F. 59 Survival with no active treatment 
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Fig F. 60 Survival with no active treatment 
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Fig F. 61 Survival for NSCLC Treatment 
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Fig F. 62 Survival with no active treatment 
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Fig F. 63 Survival by performance status 1 
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Fig F. 64 Survival by performance status 2 
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Fig F. 65 Survival by performance status 3 
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Fig F. 66 Survival by lung team 
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Fig F. 67 Survival by non-lung team 
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Management of Small-Cell Lung Cancer 
Fig F. 68 Staging Information 
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Staging – Small Cell (n=33)
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Fig F. 69 Treatment given 
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Fig F. 70 Treatment vs Std  
62
Small cell 
Standard:  90% of patients with small cell and a PS of 0-3 
should be offered chemotherapy.
Result:  25 with a PS 0-3, all (100%) were offered 
chemotherapy.
2 were not treated, both declined treatment.
Fig F. 71 Chemotherapy vs Std 
67
Chemotherapy for small cell
Standard:
Death within 30 days of chemotherapy should be less 
than 10%.
Results:
Data available for 26 patients, 4 (15%) died within 30 
days.
Patient profile:
Pts 1 to 3: PS = WHO 2 Stage = Extensive
Patient 4: PS = WHO 3 Stage = Limited
Fig F. 72 Median Survival 
68
Small cell median survivals (in years)
Overall survival (all samll cell) 0.20
Chemotherapy alone 0.08
Chemotherapy and radiotherapy 0.19
Limited stage 0.90
Extensive stage 0.06
(Performance status 0-1 not calculated only 3 patients)
Performance status 2 0.14
Performance status 3-4 0.14
 
Fig F. 73 Survival 
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Fig F. 74 Chemo Survival 
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Fig F. 75 Chemo Survival at 1 Year 
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Fig F. 76 Chemo Survival weeks 
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Fig F. 77 Chemo & Radio Survival 
73
Small cell survival with CT and XRT (n=11)
Median = 0.87
0.000
0.250
0.500
0.750
1.000
0.0 0.5 1.0 1.5 2.0
Survival Plot
Years
S
ur
vi
va
l
 
Fig F. 78 Chemo Survival 
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Fig F. 79 Limited stage Survival 
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Fig F. 80 Survival Extensive Stage 
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Fig F. 81 Survival by performance stage 2 
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Fig F. 82 Survival by performance stage 3-4 
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Fig F. 83 Wait for start of radical radiotherapy treatment  
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Fig F. 84 Wait for start of palliative radiotherapy treatment  
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 Fig F. 85 Waiting time to start of chemo treatment 
82
90%
5% 5%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
0-2 weeks 2-4 weeks 4-6 weeks
Pe
rc
en
t
Small Cell - Waiting time from clinic date to start of Chemo
Standard – within 2 weeks  for 100% patients
Mean = 9.76 days Median =  8 days
Min. 1 days Max = 37 days
(n=19)
(n=1) (n=1)
 
PhD Thesis         Bala Sridhar 
Page 272 
 
Fig F. 86 Waiting time to start of chemo treatment  
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All patients - Waiting time from clinic to start of treatment
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Fig F. 87 Standard against actual 
84
All patients –
Time from diagnosis to date first seen by Oncologist
Mean = 30 days Median =  16 days  
Min. = 1 day Max. = 288 days
Standard
80% patients to be seen within 1 week.
Results:
14% of patients (8 patients) seen within 1 week. 
(6 patients had histology done after first oncology clinic)
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Small cell  
 
Nonparametric Survival Analysis Report 
Page/Date/Time 1    15-Oct-04 10:54:18 AM 
Database  
Time Variable = Year  
Censor Variable = censored  
Confidence Limits Method = Linear (Greenwood).  
 
Data Summary Section 
Type Rows Count Minimum Maximum 
Failed 32 32 0.01 1.91  
Censored 2 2 3.63 3.75  
Total 34 34 0.01 3.75  
 
 
Product-Limit Survival Analysis 
 Cumulative Standard Lower Upper    
Event Survival Error 95% C.L. 95% C.L. At  Total 
Time (T) S(T) of S(T) for S(T) for S(T) Risk Count Events 
0.0 0.9706 0.0290 0.9138 1.0000 34 1 1 
0.0 0.9412 0.0404 0.8621 1.0000 33 1 2 
0.1 0.9118 0.0486 0.8164 1.0000 32 1 3 
0.1 0.8824 0.0553 0.7741 0.9907 31 1 4 
0.1 0.8529 0.0607 0.7339 0.9720 30 1 5 
0.1 0.8235 0.0654 0.6954 0.9517 29 1 6 
0.1 0.7941 0.0693 0.6582 0.9300 28 1 7 
0.2 0.7647 0.0727 0.6221 0.9073 27 1 8 
0.2 0.7353 0.0757 0.5870 0.8836 26 1 9 
0.2 0.7059 0.0781 0.5527 0.8590 25 1 10 
0.2 0.6765 0.0802 0.5192 0.8337 24 1 11 
0.3 0.6471 0.0820 0.4864 0.8077 23 1 12 
0.3 0.6176 0.0833 0.4543 0.7810 22 1 13 
0.3 0.5882 0.0844 0.4228 0.7537 21 1 14 
0.3 0.5588 0.0852 0.3919 0.7257 20 1 15 
0.4 0.5294 0.0856 0.3616 0.6972 19 1 16 
0.4 0.4706 0.0856 0.3028 0.6384 18 2 18 
0.4 0.4412 0.0852 0.2743 0.6081 16 1 19 
0.4 0.3824 0.0833 0.2190 0.5457 15 2 21 
0.5 0.3529 0.0820 0.1923 0.5136 13 1 22 
0.6 0.3235 0.0802 0.1663 0.4808 12 1 23 
0.7 0.2941 0.0781 0.1410 0.4473 11 1 24 
0.7 0.2647 0.0757 0.1164 0.4130 10 1 25 
1.0 0.2353 0.0727 0.0927 0.3779 9 1 26 
1.1 0.2059 0.0693 0.0700 0.3418 8 1 27 
1.2 0.1765 0.0654 0.0483 0.3046 7 1 28 
1.3 0.1471 0.0607 0.0280 0.2661 6 1 29 
1.5 0.1176 0.0553 0.0093 0.2259 5 1 30 
1.7 0.0882 0.0486 0.0000 0.1836 4 1 31 
1.9 0.0588 0.0404 0.0000 0.1379 3 1 32 
3.6+     2 1 32 
3.8+     1 1 32 
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Nonparametric Survival Analysis Report 
Page/Date/Time 2    15-Oct-04 10:54:18 AM 
Database  
Time Variable = Year  
Censor Variable = censored  
Confidence Limits Method = Linear (Greenwood).  
 
Plots Section 
Fig F. 88 Survival Plot 
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Fig F. 89 Survival Plot 
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Non-small cell 
 
Nonparametric Survival Analysis Report 
Page/Date/Time 1    15-Oct-04 11:41:54 AM 
Database  
Time Variable = year  
Censor Variable = censored  
Confidence Limits Method = Linear (Greenwood).  
 
Data Summary Section 
Type Rows Count Minimum Maximum 
Failed 90 90 0.02 1.16  
Censored 10 10 3.03 3.84  
Total 100 100 0.02 3.84  
 
 
Product-Limit Survival Analysis 
 Cumulative Standard Lower Upper    
Event Survival Error 95% C.L. 95% C.L. At  Total 
Time (T) S(T) of S(T) for S(T) for S(T) Risk Count Events 
0.0 0.9800 0.0140 0.9526 1.0000 100 2 2 
0.0 0.9700 0.0171 0.9366 1.0000 98 1 3 
0.0 0.9500 0.0218 0.9073 0.9927 97 2 5 
0.1 0.9300 0.0255 0.8800 0.9800 95 2 7 
0.1 0.9100 0.0286 0.8539 0.9661 93 2 9 
0.1 0.8800 0.0325 0.8163 0.9437 91 3 12 
0.1 0.8500 0.0357 0.7800 0.9200 88 3 15 
0.1 0.8400 0.0367 0.7681 0.9119 85 1 16 
0.1 0.8300 0.0376 0.7564 0.9036 84 1 17 
0.1 0.8200 0.0384 0.7447 0.8953 83 1 18 
0.2 0.8000 0.0400 0.7216 0.8784 82 2 20 
0.2 0.7900 0.0407 0.7102 0.8698 80 1 21 
0.2 0.7800 0.0414 0.6988 0.8612 79 1 22 
0.2 0.7600 0.0427 0.6763 0.8437 78 2 24 
0.2 0.7200 0.0449 0.6320 0.8080 76 4 28 
0.3 0.7000 0.0458 0.6102 0.7898 72 2 30 
0.3 0.6900 0.0462 0.5994 0.7806 70 1 31 
0.3 0.6700 0.0470 0.5778 0.7622 69 2 33 
0.3 0.6600 0.0474 0.5672 0.7528 67 1 34 
0.3 0.6300 0.0483 0.5354 0.7246 66 3 37 
0.3 0.6200 0.0485 0.5249 0.7151 63 1 38 
0.3 0.6100 0.0488 0.5144 0.7056 62 1 39 
0.3 0.6000 0.0490 0.5040 0.6960 61 1 40 
0.3 0.5900 0.0492 0.4936 0.6864 60 1 41 
0.3 0.5800 0.0494 0.4833 0.6767 59 1 42 
0.4 0.5700 0.0495 0.4730 0.6670 58 1 43 
0.4 0.5500 0.0497 0.4525 0.6475 57 2 45 
0.4 0.5200 0.0500 0.4221 0.6179 55 3 48 
0.4 0.5100 0.0500 0.4120 0.6080 52 1 49 
0.4 0.4900 0.0500 0.3920 0.5880 51 2 51 
0.4 0.4700 0.0499 0.3722 0.5678 49 2 53 
0.4 0.4600 0.0498 0.3623 0.5577 47 1 54 
0.4 0.4400 0.0496 0.3427 0.5373 46 2 56 
0.5 0.4200 0.0494 0.3233 0.5167 44 2 58 
0.5 0.3900 0.0488 0.2944 0.4856 42 3 61 
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Nonparametric Survival Analysis Report 
Page/Date/Time 2    15-Oct-04 11:41:54 AM 
Database  
Time Variable = year  
Censor Variable = censored  
Confidence Limits Method = Linear (Greenwood).  
 
Product-Limit Survival Analysis 
 Cumulative Standard Lower Upper    
Event Survival Error 95% C.L. 95% C.L. At  Total 
Time (T) S(T) of S(T) for S(T) for S(T) Risk Count Events 
0.5 0.3800 0.0485 0.2849 0.4751 39 1 62 
0.5 0.3500 0.0477 0.2565 0.4435 38 3 65 
0.5 0.3400 0.0474 0.2472 0.4328 35 1 66 
0.5 0.3300 0.0470 0.2378 0.4222 34 1 67 
0.5 0.3200 0.0466 0.2286 0.4114 33 1 68 
0.6 0.3100 0.0462 0.2194 0.4006 32 1 69 
0.6 0.3000 0.0458 0.2102 0.3898 31 1 70 
0.6 0.2900 0.0454 0.2011 0.3789 30 1 71 
0.6 0.2700 0.0444 0.1830 0.3570 29 2 73 
0.7 0.2600 0.0439 0.1740 0.3460 27 1 74 
0.7 0.2500 0.0433 0.1651 0.3349 26 1 75 
0.7 0.2400 0.0427 0.1563 0.3237 25 1 76 
0.7 0.2300 0.0421 0.1475 0.3125 24 1 77 
0.7 0.2200 0.0414 0.1388 0.3012 23 1 78 
0.8 0.2100 0.0407 0.1302 0.2898 22 1 79 
0.8 0.2000 0.0400 0.1216 0.2784 21 1 80 
0.8 0.1800 0.0384 0.1047 0.2553 20 2 82 
0.8 0.1700 0.0376 0.0964 0.2436 18 1 83 
0.9 0.1600 0.0367 0.0881 0.2319 17 1 84 
0.9 0.1500 0.0357 0.0800 0.2200 16 1 85 
0.9 0.1400 0.0347 0.0720 0.2080 15 1 86 
1.0 0.1300 0.0336 0.0641 0.1959 14 1 87 
1.0 0.1200 0.0325 0.0563 0.1837 13 1 88 
1.1 0.1100 0.0313 0.0487 0.1713 12 1 89 
1.2 0.1000 0.0300 0.0412 0.1588 11 1 90 
3.0+     10 1 90 
3.1+     9 1 90 
3.6+     8 1 90 
3.6+     7 2 90 
3.6+     5 1 90 
3.7+     4 1 90 
3.7+     3 1 90 
3.7+     2 1 90 
3.8+     1 1 90 
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Nonparametric Survival Analysis Report 
Page/Date/Time 3    15-Oct-04 11:41:54 AM 
Database  
Time Variable = year  
Censor Variable = censored  
Confidence Limits Method = Linear (Greenwood).  
 
Plots Section 
Fig F. 90 Survival Plot 
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NSCLC without 10 patients alive at 14 Oct 04 (today) 
 
Fig F. 91 Survival Plot 
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Outpatient Audit: Phlebotomy, Clinics and Pathology 
 
Fig F.92 Scope 
BNS
Audit Scope
• AIM
– To analyse the activity and waiting periods throughout 
the patient journey from arrival at reception to 
consultation.
• Method 
– One week snapshot 13th – 17th June 2005 of all 
outpatients at the Cancer Centre 
– Developed and completed pro-formas for nursing and 
modernisation staff
– Analysed information from completed pro-formas, LABO 
and Medway
 
Fig F.93 Overview 
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Fig F.94 Appointment Overview 
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Fig F.95 Consultation overview 
BNS
Audit Overview - Consultations
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Fig F.96 Process workflow 
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Fig F.97 Average waiting times 
BNS
Patient Journey – Average Waiting Times
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Fig F.98 Average waiting time in consulting room 
BNS
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Fig F.99 Time and motion 
BNS
SPC Thursday - Time Roomed to Time Seen
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Fig F.100 Biochemistry Algorithm 
BNS
Biochemistry Profile Process
Bloods received from wards via pod system and hand delivery
Samples/forms transferred to Biochemistry
Request forms go for entry on computer 
Request forms placed in “entered” box Samples transferred to numbered storage blocks
Samples checked against entered request form,
de-capped and placed in appropriate analyser rack
Primary Analyser
(Christie Profile)
Samples debagged and patient and request data validated
Blood samples centrifuged (10 
min cycle max 36 samples)
Request form sent for filing
Samples and forms re-checked and bar coded
Results transmitted to Medway
Technical
Validation
 
PhD Thesis         Bala Sridhar 
Page 281 
 
 Fig F.101 Average time for Biochemistry 
BNS
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Fig F.102 Request time 
BNS
SPC Thursday - Time Request Logged to Time Result Ready 
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Fig F.103 FBC Algorithm 
BNSB S
Full Blood Count Process
Pod arrival
Validate patient information, barcode samples, take biochemistry
samples to biochemistry lab
Put forms face down in order corresponding to 
position in grey tube holder
10 phials per grey tube holder
Forms for test requesting put on LABO
Results – Compare with previous results
Put into Mildred and Louise Analyser   
(weekly maintenance on Tuesday and 
Friday takes 2 hrs starts 3pm)
Results transmitted to Medway
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Fig F.104 Average times for Haematology 
BNSB S
Blood Sample Journey – Averages for 
Haematology
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Fig F.105 Request time 
BNS
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Fig F.106 Sample received 
BNS
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Fig F. 107 Patient arrivals  
BNSB S
Queues Forming - Thursday
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Fig F. 108 At Phlebotomy 
BNS
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 Fig F. 109 Summary of findings 
BNS
Summary
• Peak Phlebotomy Day – Tuesday
• Highest Planned Service Hours – Monday
• Longest Cumulative Waiting – Thursday
• Shortest Cumulative Waiting –
Wednesday
• Waiting Time Increases During Morning 
Session
• Biochemistry Samples from OPD 42%
• Haematology Samples from OPD 38%
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Appendix G  SUMMARY OF OPERATIONAL DATA REVIEW 
Introduction: 
This appendix provides additional details of the analysis of the operational data reviewed to gain an 
understanding of the current service configuration at Christie Hospital NHS Trust, a tertiary cancer 
centre, based in Manchester serving 3.2 million people across Greater Manchester and Cheshire. The 
results from this analysis were used to validate the model developed and firm up the service re-
alignment plan.  
G 1.0 Background  
The Christie Hospital NHS Trust is a tertiary cancer centre, based in Manchester serving 3.2 million 
people across Greater Manchester and Cheshire. The local health economy includes 11 primary care 
trusts (PCTs) and 15 other acute and mental health trusts. The PCTs are mainly co-terminous with city 
and borough council boundaries across the Greater Manchester and Cheshire Cancer Network. The local 
health economy is part of the North West Strategic Health Authority which serves the health needs of 
6.7 million people.  
The NHS North West has three tertiary cancer centres: Clatterbridge Oncology Centre on the Wirral, the 
Rosemere Centre in Preston and the Christie Hospital, which is the largest. There is also a radiotherapy 
unit in Carlisle, run by the North Cumbria Acute Hospitals NHS Trust.Based on the estimated number of 
new cancers each year, the Christie’s share of the potential market is currently 77% of all new patients 
within the network, 43% of all new patients across the North West, and 5% of new patients nationally. 
G2.0 Current Activity (Operational data) 
Based on 2005/06 data Christie treated 9,830 new patients, provided 79,878 radiotherapy fractions 
(measured doses), 32,756 chemotherapy treatments and carried out 2,938 surgical operations.  85% of 
new patients were from within the Greater Manchester and Cheshire Cancer Network, 11% were from 
outside the network but within the North West and 4% were from other parts of the country and 
abroad. In the same year, Christie treated patients from 224 primary care trusts across the UK.  The 
main local commissioners were the 11 primary care trusts in Greater Manchester and the eastern part 
of Cheshire.  In addition to this, significant contracts are held with primary care trusts in other parts of 
Cheshire, Merseyside, Cumbria and Lancashire.  Christie also holds a contract with Healthcare 
Commission Wales.  Christie has 257 beds including six critical care beds and 49 patient chairs for 
inpatient, day case and outpatient treatments. There are seven wards and one day ward, three surgical 
theatres and one radiotherapy theatre. This includes a specialist adult leukaemia unit and young 
oncology unit, which is one of only eight dedicated teenage cancer units in the country. 
Christie provides services in three main categories Table G.1: 
 Radiotherapy – the use of fractions (measured doses) of radiation. Treatment is usually several 
small doses over a specified period of days or weeks, but can also be given in a single 
treatment. Treatment covers both radical (curative) and palliative radiotherapy. 
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 Chemotherapy – the use of drugs to treat cancer, usually delivered as several treatments over a 
number of weeks.  
 Surgery – highly complex surgical procedures, with a range of specialties covering colorectal, 
upper gastro intestinal, ear, nose and throat, urological/ pelvic and gynaecological cancers, 
together with plastic and reconstructive surgery.  
Treatment modality Inpatient 
spells 
Day case 
spells 
Outpatients 
treatments 
Outpatients new Outpatients 
follow ups 
Chemotherapy 4,664 1,711 24,497     
Radiotherapy 1,463 779 67,527     
Oncology / 
supportive work 
5,169 4,128   6,796 42,055 
Transplants 97         
Total oncology 11,393 6,618 92,024 6,796 42,055 
Surgery and critical 
care 
1,432 1,210   2,070 7,816 
Endocrinology 75 1,136   809 2,997 
Clinical genetics and  
mental health 
      399 647 
Grand total 12,900 8,964 92,024 10,074 53,515 
Table G.1 Actual and projected patient activity  
Clinical support services is provided by a radiology department with three CT and two MR scanners and 
pharmacy, pathology, psychological medicine and rehabilitation services. Christies also provide specialist 
endocrinology services and private patients. Christies currently have 1,177 patients entered into 368 
clinical trials. Figure G.1 provided a summary of the Inpatient activity, actual and projected, based on 
the 2005/06 data; similarly Fig G.2 provided the actual and projected day case activity and Fig G.3  gives 
an overview of the actual and projected activity. The majority of the care is provided as outpatient 
treatments.  7.9% of the outpatient treatments are delivered at other sites.  Table G.2 provided an 
excellent summary of the number of new patients treated at Christies’ along with the volume of activity 
the Trust picked up as a specialist cancer centre.  
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Figure G.1 Actual and projected Inpatient activity  
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Figure G.2 Actual and projected Day case activity  
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Figure G.3 Actual and projected Outpatient activity  
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Population Annual no. of 
patients with 
cancer 
Annual no. of patients 
requiring chemotherapy 
or radiotherapy 
Annual no. of 
patients treated at 
Christie 
Christie share of market 
Network 15,182 11,387 8,749 77% 
Northwest 30,300 22,725 9,732 43% 
National 283,300 212,475 9,830 5% 
Table G.2 Number of new cancer patients 2005/06 
Table G.3 throws open a very interesting face in relation to the incidence of lung cancer. It demonstrates 
that the number of new cases of lung cancer is predicted to fall from 2193 in 2005 to as low as 2161in 
2012. In comparison, almost all the other tumours are seen to be on the increase. These data are 
corroborated by the trends seen in Fig G.4. The impact of health warnings and the restriction of smoking 
in public places could be a factor.  
  2005 2006 2007 2008 2009 2010 2011 2012 
Bladder  965 978 999 1,021 1,043 1,065 1,091 1,117 
Breast  2,260 2,310 2,375 2,439 2,504 2,569 2,640 2,711 
Colorectal  1,778 1,790 1,815 1,839 1,863 1,887 1,918 1,948 
Head & Neck  504 511 522 533 545 556 568 581 
Lung  2,193 2,173 2,170 2,166 2,163 2,159 2,160 2,161 
Oesophagus  426 433 444 455 466 477 490 503 
Pancreas  297 293 292 291 289 288 287 287 
Prostate  1,753 1,834 1,972 2,111 2,249 2,387 2,562 2,737 
Skin  419 438 469 499 529 559 595 632 
Stomach  483 470 462 453 444 436 429 422 
Others 4,105 4,120 4,107 4,095 4,083 4,071 4,037 4,003 
All  15,182 15,351 15,627 15,902 16,178 16,453 16,777 17,101 
Table G.3 The predicted incidence of cancer in Greater Manchester and Cheshire  2005 – 2012;  
1. These figures exclude non melanoma skin cancers. 2. Data from the North-West Cancer Information 
Service. 
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Figure G.4 Incidence of Lung cancer and Smoking.  
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Planned Activity (Operational data) 
Tables G.4, G.5 and G.6 summarise the projected activity.  Figure G.5, which is based on the Regional 
figures from the Office of National Statistics’ Cancer Atlas include an uplift of 1% p.a. In the local health 
economy (LHE) based on the % of the regional population living in the area. Within the LHE only 75% of 
new registrations require treatment by a non-surgical oncologist. The number of new patients at the 
Christie is based on the activity data for 2005/6. The impact of this plan on existing activity will be to 
increase the total number of fractions delivered from a baseline of 79,878 in 2005/06 to 94,380 in 
2011/12.   
9,830
new 
patients
The 
Christie
15,182 new patients
Greater Manchester & 
Cheshire
30,300 new patients
North West Region
283,300 new patients
National
 
Figure G.5 Projected number of New patients  
Source: National figures - Cancer Research UK 2002 statistics uplifted for 1% p.a. increase in incidence of Cancer.] 
The implications of this activity on radiotherapy are shown in Table G.4, on chemotherapy in Table G.5, 
surgery in Table G.6 and on clinical trial in Table G.7.   
 05/06 06/07 07/08 08/09 09/10 10/11 11/12 
Total radiotherapy fractions   79,878 82,661 89,693 94,380 94,380 94,380 94,380 
Outpatient treatments 65,681 67,527 72,880 77,047 77,047 77,047 77,047 
Day case 731 731 731 731 731 731 731 
Elective inpatients 1,329 1,329 1,299 1,269 1,234 1,199 1,169 
Non-elective inpatients 114 114 114 114 114 114 114 
Table G.4 The predicted radiotherapy fractions  
 
 2006/07 2007/08 2008/09 2009/10 2010/11 2011/12 
Outpatient treatments       
Clinical oncology  12,557 12,583 12,842 13,111 13,390 13,669 
Haematology 886 887 887 887 887 887 
Medical oncology 11,054 11,066 11,287 11,517 11,754 11,991 
Total 24,497 24,536 25,016 25,515 26,031 26,547 
Day case treatments       
Clinical oncology  339 357 373 388 402 416 
Haematology 333 333 333 333 333 333 
Medical oncology 1,039 1,057 1,088 1,117 1,143 1,169 
Total 1,711 1,747 1,794 1,838 1,878 1,918 
Inpatient spells       
Clinical oncology  1,569 1,624 1,671 1,709 1,757 1,805 
Haematology 287 292 295 297 298 298 
Medical oncology 2,808 2,915 3,007 3,082 3,176 3,270 
Total 4,664 4,831 4,973 5,088 5,231 5,373 
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Table G.5 Summary of base case chemotherapy activity plan 
Patients Out turn 
2005/06 
2006/07 2007/08 2008/09 2009/10 2010/11 2011/12 
Inpatients 1,725 1,430 1,267 1,374 1,500 1,648 1,648 
Day cases 1,215 1,210 1,228 1,255 1,283 1,312 1,312 
Table G.6 Summary of planned changes to overall activity as a result of the surgical oncology service plan 
Clinical trials Number 
 Phase I trials 38 
 Phase II trials 129 
 Phase III trials 201 
Total clinical trials 368 
Related research activity  
 Laboratory research 28 
 Other patient related studies 147 
 Number of projects in total 543 
Table G.7 Clinical trials and related research activity in 2005/06 
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APPENDIX H Current State 
This appendix provides examples of the detailed process mapping undertaken to establish how the patient journeys across the cancer pathway, along with the sub-
set of data that flows along side this pathway. Charting the patients’ journey, from primary care to secondary and tertiary care - (Outpatients, inpatients, diagnostic 
i.e. labs, radiology, etc, treatment and palliative care pathway). The examples provided in this appendix were part of the larger detailed process mapping undertaken 
as discussed in Chapter 4. 
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Fig H.1 – Pathway from GP to Consultants 
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Fig H.2 Process Map – GP – Endoscopy / Bronchoscopy 
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Fig H.3 Inpatient workflow 
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Fig H.4 Outpatient Workflow 
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Fig H.5 Theatre Process Map 
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Fig H.6 Physio Clinic Patient Pathway 
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Fig H.7 Current patient referral pathway 
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Fig H.8 Current appointment pathway 
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Appendix I -  FUTURE STATE 
Introduction: This appendix presents examples of the future state defined following the ‘What Good Looks Like’ exercise. This is combined with the operational objectives to achieve the desired 
optimal service delivery pathway for receiving, processing and servicing new referrals, the radiotherapy process from receiving an order to delivering care and the management of electronic 
radiological images using the Picture Archiving and Communication System. 
Fig I.1 New patient referral pathway 
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Fig I.2a Radiotherapy Workflow 
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Fig I.2b Radiotherapy workflow 
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Fig I.2c Radiotherapy Workflow 
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Fig I.2d Radiotherapy Workflow 
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Fig I.3 Mapping the Future state of Picture Archiving Communication System 
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Appendix J –  North West Cancer Intelligence Service reports on MDT Data 
submission and format. 
 
 
The following four reports, Reports G1 to G4, are provided as evidence to demonstrate the variation in 
practice evidenced by cancer units and cancer centre within the Greater Manchester Cancer Network 
when submitting data to the cancer registry. These reports are provided to all organisations with a view 
to encourage them to adopt a unified format for data transfer. 
These reports also demonstrate that owing to the submission format, compounded by data quality, 
cancer registries are usually a year or two behind in reporting the results and findings on population 
health. 
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Report J.1 MDT Log Report demonstrating format used for data submission from April 2008. 
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Report J.2 MDT data log report from July 08 – April 09, still demonstrating use of paper and electronic media for data submission. 
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Report J.3 Supplier score care provided each organisation highlighting the status of the data provided to Cancer Registry. 
This report also demonstrated the quality of the data provided.   
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Report J.4 This report shows the significant progress made with regards to submitting data from the Patient Administrative system (all electronic submissions yet failing on 
data quality). 
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Appendix K – Audit of Pharmacy turn around time. 
Fig K.1 Value stream analysis. 
Patient 
number 
Time 
arrived 
@hospital 
 
Wait to 
have 
bloods 
done 
OPD 
appt 
time 
Seen 
by 
doctor 
/nurse 
Left 
clinic 
Attended 
pharmacy 
Attended 
chemo 
Started 
treatment 
Finished 
treatment 
Pick up 
from 
pharmacy 
Comments from patients 
1 09.20 0mins 10.00 10.10 10.20 10.30 10.35 13.50 2.25 12.30  
2 08.45 15mins 09.00 09.15 10.30 N/A 11.30 12.45 07.45 N/A Had x-ray @ 11am 
3 09.00 20mins 09.00 10.10 10.20 10.25 10.30 10.45 12.30 13.00 Pharmacy disorganised today 
4 10.20 15mins 11.20 12.40 12.55  13.25 15.10 16.40 16.40 Delay in clinic- unwell patients x2 Take home 
prescription supplied by ward 
5 09.40 10mins 10.00 11.05 11.15 11.20 11.25 13.00 17.40 17.40 Pharmacy disorganised today 
6 09.25 10mins 10.30 11.20 11.30 11.40 11.45 14.35 15.05 13.00 Accepting delays with service today- unwell pt.  
7 08.55 8mins 09.00 10.20 10.35 n/a 10.40 13.30 14.25 n/a No explanation of wait in chemo 
8 09.20 25mins 10.10 10.30 10.35 n/a 10.40 13.00 14.40 n/a Chemo was very busy today prepared to wait 
9 08.45 10mins 09.00 09.15 09.20 09.20 11.00 13.45 14.05 13.30 Treatment went ok today 
10 12.05 10mins 13.00 13.30 14.20 14.25 14.40 16.30 17.50 15.00 Did not know what delay was 
11 13.20 15mins 14.00 14.35 14.55 n/a 15.10 16.45 17.20 n/a Chemo very busy 
12 08.15 10mins 09.30 09.40 10.10 10.15 11.00 12.30 16.00 13.20 Prescription picked up by family no long wait today 
13 10.25 15mins 11.10 11.45 12.15 n/a 12.20 14.50 16.20 n/a Prescription picked up on chemo ward 
14 13.00 20mins 14.05 14.40 15.10 n/a 15.20 17.10 19.30 n/a Ward was very busy 
15 13.10 10mins 14.15 14.45 15.00 15.05    16.15 Oral chemo patient 
16 08.40 10mins 09.20 10.00 10.35 10.40    11.15 Oral chemo patient 
17 08.00 20mins 10.40 10.50 11.00 11.00    12.20 Oral chemo patient 
18 09.00 10mins 09.45 10.25 11.15 n/a 12.30 13.55 15.05 n/a Attended for scan after clinic pharmacy picked 
treatment up on ward 
19 12.20 15mins 13.30 14.20 14.40 n/a 14.55 16.05 18.30 n/a  
20 11.00 n/a 11.15 11.30 12.00 12.05 12.20 13.50 14.20 14.55 Had bloods done 2 days before 
Totals 
Avg waits 
N/A 12min N/A 37 
min 
21min N/A N/A 110 min N/A 61min  
 
Please note that pharmacy waits are not recorded for chemotherapy patients on IV treatments only those on oral treatment 3 patients in total.  
 
